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1A General introduction and aims of this thesis
In eukaryotic cells, the process of gene expression, which is the transformation of the
genetic information stored in the base sequence of DNA into protein synthesis, is controlled
by DNA-binding proteins (activators and repressors). These proteins bind via weak forces to
specific DNA sequences and regulate transcription by their effect on RNA polymerase, either
preventing or enhancing its binding to DNA.1
This observation has led to a high interest in the recognition of specific nucleic acid
sequences. The design of molecules that recognize specific sequences on the DNA double
helix would provide interesting tools to interfere with DNA information processing at an early
stage of gene expression with high potential impact on the treatment of various diseases,
including cancer, viral infections and AIDS.
In DNA, both the minor and the major grooves are sites for specific interactions. Small
molecules such as synthetic polyamides containing pyrrole, hydroxypyrrole and imidazole
groups recognize specific DNA base sequences from the minor groove. Some of these minor
groove binders possess a specificity and affinity for DNA which is comparable to naturally
occurring DNA binding proteins and are therefore successful reagents for gene regulation.2-4
Based on their unique formation of hydrogen bonds deoxyoligonucleotides possess a
considerable potential of sequence-specific recognition. Their use as regulators for gene
expression had already been demonstrated by Zamecnik und Stevenson in 1978.5,6
Theoretically, oligonucleotides can interfere with the process of gene expression both at the
level of transcription (antigene strategy) and translation (antisense strategy) (Figure 1). For
sequence-specific recognition of a unique target sequence an oligonucleotide length of 12-15
nucleobases is required for statistical reasons.7
Within double-stranded DNA a deoxyoligonucleotide can recognize a purine-rich target
sequence in the major groove through formation of Hoogsteen hydrogen bonds. The resulting
structure is a (partial) DNA triple helix. Two main classes of triple helix have been
characterized, which differ according to the orientation and base composition in the third
strand (Figure 2). Pyrimidine-rich strands bind in a parallel fashion with regard to the central
purine-rich strand, involving T•AT and C+•GC triplets and a low pH for protonation of the
cytosines is required (pym•pupym motif). Purine-rich oligonucleotides bind in an antiparallel
orientation, including G•GC and A•AT triplets (pu•pupym motif). Formation of this triplex
2motif is pH independent.8-10 Both triplex motifs are stongly stabilized by divalent metal ions,
which are necessary to screen the charge interactions between the three negatively charged
phosphodiester backbones.11,12
Antigene strategy Antisense strategy 
Proteins 
oligonucleotide
Cell
Transcription Translation 
DNA
mRNA
triplex-forming
oligonucleotide
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Aptamer strategy
oligonucleotide
Figure 1: Process of gene expression and ways to influence the process of gene expression.
Triplex mediated specific modulation of transcription (antigene strategy) is possible, as
demonstrated by an in vitro experiment by Cooney et al. already in 1988.13 The process of
transcription can be both inhibited and activated. E.g., triplex formation in a regulatory region
of a gene can block transcription initiation by inhibiting transcription-factor binding or by
interfering with formation of the initiation complex.14-16 Alternatively, triplex formation
within the transcribed region can inhibit transcription by arresting the transcription machinery
during the elongation phase.17,18 Even the activation of transcription is feasible. Recently, a
TFO-peptide conjugate with the peptide being a transcriptional activator domain has been
shown to activate the process of transcription.19
3A second triplex-based strategy for altering a gene´s function is to induce a permanent
change in its sequence by using TFOs to deliver site specific damage in order to generate a
localized mutation. To this end, chemical reagents such as the photo-activatable psoralen have
been covalently attached to TFOs. These modified TFOs have been used to direct mutations to
a specific gene in cells.20 Even in the absence of a tethered mutagen TFOs have the potential
to induce mutations in vivo.21-23
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Figure 2: Base triplets involved in triplex DNA.
The residence time of a TFO on its DNA target is a determinant parameter to observe a
biological response. Dissociation constants of some triple helices tend towards values
comparable to values measured for transcription factors, thus affording competition with
natural regulators of gene expression. Thus, the best way to obtain a long-lasting biological
effect consists of irreversible linkage of the TFO to its target. More problems associated with
this triplex-based approach are the pH dependence of the C+•GC triplet, the general
susceptibility of oligonucleotides towards enzymatic degradation and their poor cellular
uptake.
In order to overcome these problems and to increase the in vivo stability of triplex
structures, multiple approaches, involving base, sugar and backbone modifications as well as
4 attachment of intercalating agents, triplex-specific ligands and crosslinking agents, are
currently being pursued.24,25 Furthermore, as triplex formation is originally restricted to
oligopurine sequences, attempts are made to extend the repertoire of target sequences, for
example, to achieve recognition of an interrupting pyrimidine or the recognition of two
oligopurine motifs located on each of the DNA strands (alternate strand recognition).26
Backbone modifications serve to optimize triplex stability while keeping the sequence
specificity and to achieve resistance towards degradation by nucleases. Some backbone
modifications are depicted in Figure 3.
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Figure 3: Oligonucleotide analogues.
5For example, it has been found that the stability of triple helices involving 2´-O-alkyl
oligoribonucleotides is higher than that involving oligoribonucleotides.27,28 Furthermore,
triplex forming oligo-N3´→N5´phosphoramidates seem to have promising antigene
properties, both in vitro and in cells.29
A further very promising candidate in antigene strategy is the so-called peptide nucleic
acid (PNA), a nuclease-resistant oligonucleotide analogue in which the deoxyribose phosphate
backbone has been replaced by a homomorphous, achiral and uncharged backbone based on
N-(2-amino-ethyl)glycine30 (Figure 3). Hybridization of PNA to target deoxyoligonucleotides
proceeds according to the Watson-Crick base pairing rules and with more stringent sequence
selection as compared to hybridization of deoxyoligonucleotides.31 In addition, PNA /
deoxyoligonucleotide hybrids possess greater thermal stability as the electrostatic repulsion
between the DNA and the (uncharged) PNA strand is decreased31 and they are virtually
independent of ionic strength of the medium.32 Binding of homopyrimidine PNA to double-
stranded DNA (ds DNA) results in displacement of the non-targeted Watson-Crick paired
deoxyoligonucleotide strand and formation of a (PNA)2 / DNA triple helix (triplex invasion
complex)33-35. The resulting structure is a so-called P-loop in which two PNA oligomers form
a (PNA)2 / DNA triplex with one PNA strand binding via Watson-Crick hydrogen bonds in an
antiparallel fashion to the homopurine deoxyoligonucleotide target and with the second PNA
strand binding via Hoogsteen hydrogen bonds in a parallel fashion to the homopurine
deoxyoligonucleotide strand. The second DNA strand is displaced (Figure 4). Once formed,
these PNA / DNA-PNA triplexes are exceptionally stable.34,36
+2
PNA DNA
(PNA)2 / DNA
triplex invasion 
complex
Figure 4: Formation of a (PNA)2 / DNA triplex invasion complex by reaction of
homopyrimidine PNA with duplex DNA.
6In this way, homopurine regions of eight base pairs or more in length within double
stranded DNA can be efficiently targeted.33,35 Because two PNAs are required to form these
complexes, most often bis-PNAs, in which the two PNA parts are chemically linked, are
employed for targeting of ds DNA.37 The formed (PNA)2 / DNA triplex invasion complexes
occlude protein binding (transcription factors, restriction enzymes) to proximal or overlapping
DNA sites38,39 and / or have sufficient stability to arrest the elongating RNA polymerase40,41
or DNA polymerase.42 Thus, PNAs are promising candidates for use in antigene strategy
although several features like the poor cellular uptake of PNA43 need to be optimized for an
efficient in vivo application. E.g. covalent attachment of PNA to peptides that bind selectively
to cell surface receptors can increase the cellular uptake of PNA into specific cell types.44
Recently, it was reported that antigene effects in Burkitt´s lymphoma cells in culture were
effected by a PNA 17-mer which was linked to a basic nuclear localization signal (NLS)
peptide.45 The latter mediated the transfer of the PNA-peptide conjugate across the nuclear
membrane and thus afforded its nuclear penetration.45
Furthermore, triplex forming bis-PNAs have been employed to cause mutagenesis within
a chromosomal target site in mouse cells.46 It has been found that the majoritiy of the
mutations were located in the PNA binding site and consisted mostly of single base pair
insertions and deletions, suggesting that a high affinity PNA clamp constitutes a mutagenic
lesion that may provoke replication slippage errors.46 Very recently, it has been reported that
the single-stranded DNA loop within a (PNA)2 / DNA triplex invasion complex has the
capacity to initiate transcription of a specific gene in cells,47 which could provide a new
approach for gene therapy.
Oligonucleotides can additionally interfere with the process of gene expression at the
level of translation by sequence specific interaction with the messenger RNA (antisense
strategy, Figure 1). The resulting structure is a mRNA-oligonucleotide duplex according to the
Watson-Crick base pairing rules. The process of translation can be inhibited either by
degradation of the targeted mRNA through RNase H mediated cleavage or by steric blocking
of ribosomes or essential translation factors.48,49 In the former mechanism, mRNA within the
mRNA-oligonucleotide hybrid is cleaved by the enzyme RNase H. The antisense
oligonucleotide is released and subsequently again available to bind another mRNA molecule.
One major impediment associated with this mechanism is that for RNase H activation
deoxyoligonucleotides are required. In vivo, deoxyoligonucleotides are rapidly degraded by
nucleases and therefore their application in antisense strategy is quite limited. In order to
7overcome this drawback, a plethora of chemically modified nuclease-resistent
oligonucleotides has been designed but except for phosphorothioates, these are not substrates
for RNase H.48,50
The first generation of antisense oligonucleotides was based on backbone modifications
conserving the phosphorus atom present in the naturally occurring phosphodiester linkage but
replacing either one or both of the non-bridging or bridging oxygen atoms50 (e.g.
phosphorothioates, methylphosphonates, Figure 3). Such modifications served to increase the
stability towards enzymatic degradation. To date, phosphorothioate drugs are in various stages
of clinical trials and one antisense sequence (Vitravene or ISIS 2922) has recently been
approved by the FDA for treatment of CMV retinitis in AIDS patients.51 Furthermore,
oligonucleotides modified at the 2´position of the sugar52 and N3´→5´phosphoramidates29 are
encouraging antisense candidates. Although these oligonucleotide analogues are RNase H-
incompetent, they have been shown to be effective antisense reagents when targeted to the 5´-
untranslated region and to the translation inition region of mRNA, where they interfere with
the formation of the translation–initiation complex. Steric blockage within the coding region
of mRNA is less efficient because of the unwinding action by the ribosomal complex during
translation.53-55
PNA is a very promising candidate for use in antisense strategy due to its favourable
hybridization properties with oligonucleotides and its stability against enzymatic
degradation.30 However, PNA / RNA hybrids are not substrates for RNase H.40,56 Therefore,
PNA must exert its antisense effect by direct steric blocking of ribosomes or essential
translation factors. Several in vitro studies have shown that homopyrimidine PNAs targeted to
homopurine sequences in the coding region of mRNA can even interrupt ribosome elongation
at the target site by triplex formation with the mRNA target.40,56,57 Duplex-forming mixed
purine / pyrimidine PNAs were successful as antisense reagents when targeted to the AUG
start codon region but not when targeted to sites within the coding region, indicating that the
PNA was displaced by the moving ribosome.55-57 Furthermore, it was shown that PNAs
targeted to exon and intron sequences of RNA reduced gene expression,54 suggesting that
PNA may have even acted within the cell nucleus to inhibit RNA processing. Thus, based on
its propensity to form very stable triplexes with a mRNA target, PNA is superior to other
RNase H-incompetent antisense oligonucleotide analogues (e.g. 2´O-alkyl
oligoribonucleotides and N3´→N5´phosphoramidates) in that it causes antisense effects not
8only when targeted to the 5´- untranslated region but also when targeted to the coding region
of mRNA.
In order to overcome the problem of RNase H incompetence of RNA / PNA duplexes,
PNA-DNA chimeras have been synthesized.58-60 These have been shown to hybridize
efficiently with RNA. The DNA part within these chimeras suffices to activate the enzyme
RNase H. RNA cleavage occurs sequence-specifically at the ribonucleotides which base pair
with the DNA part of the PNA-DNA chimera.59 Furthermore, it is also possible to attach
reactive entities to PNA which effect destruction of a RNA target. Recently, a PNA-
diethylenetriamine conjugate has been synthesized and shown to cleave a hybridized RNA
target in a sequence-specific manner.61
Finally, oligonucleotides can interfere with the process of gene expression at the level of
the proteins By high affinity binding of the oligonucleotides to proteins, inhibition of vital
proteins, e.g. transcription factors or crucial enzymes, can be effected (aptamer strategy).62
These aptamers originate from in vitro selection experiments which, starting from random
sequence libraries, optimize the nucleic acids for high affinity binding to given ligands.62
In both the antigene and the antisense approach metal ions have been employed to effect
destruction of a target sequence either by redox chemistry or hydrolysis. E.g., redox-active
metal entities attached via a a linker to the 5´or 3´ terminus of an oligonucleotide, can be
directed to a specific site within DNA to induce sequenc-specific cleavage. To this end,
EDTA-Fe(II)63, o-phen-Cu(I)64 and cationic manganese porphyrin groups65,66 have been
attached to oligonucleotides and to PNA oligomers66. In vitro studies demonstrated that in the
presence of a coreactant these oligonucleotide(analogue) metal conjugates were able to cleave
double-stranded DNA in a sequence-specific manner.63-66
Similarly, RNA can be targeted (antisense strategy). A wide range of metal ions (e.g.
Mg(II), Ca(II), Fe(III), Ni(II), Cu(II), Zn(II), Pb(II), trivalent lanthanides) is known to catalyze
RNA transesterification and hydrolysis.67 Some of these metal ions have been attached via a
ligand to oligonucleotides and were shown to cleave RNA site-specifically and efficiently,
thereby acting as artificial ribonucleases.67
The idea to use metal ions in order to link an antigene / antisense oligonucleotide and its
target irreversibly in order to impair transcription or translation through hybridisational arrest
of the transcription and translation machinery, is comparatively new. For this purpose, non-
redox active metal species of suitable coordination geometry which are capable of forming
thermodynamically stable and at the same time kinetically inert crosslinks between
9oligonucleotide strands are required. Bifunctional Pt(II) compounds are well suited in this
respect as shown first by Vlassov et al. as well as Chu and Orgel.68-71
Both the antitumor agent Cisplatin and its therapeutically inactive geometric isomer
Transplatin are able to form bifunctional lesions (interstrand crosslinks) with DNA. In
contrast to Cisplatin, these interstrand crosslinks occur more frequently with Transplatin 72
and, very importantly, due to its linear coordination geometry, without major distortion of the
DNA double helix.73-79 The two-dimensional NMR high resolution structure of a DNA double
helix containing a trans-(NH3)2Pt(II) interstrand crosslink between a central G/C base pair
reveals that the helix is only slightly bent (20°) towards the major groove and that no large
unwinding occurs. The trans-(NH3)2Pt(II) interstrand crosslink causes minor distortion only,
which is spread out over two base pairs on the 5´and 3´sites.78
Pt
NH3
NH3
Cl ClPt NH3
NH3
Cl
Cl
Cisplatin Transplatin
Figure 5: Structures of Cisplatin and Transplatin.
These results had been predicted by model chemistry. It was demonstrated that a linear
trans-a2Pt(II) moiety (a = NH3, NH2CH3) can systematically replace a proton of a H bond
within Watson-Crick and Hoogsteen A/T80 and G/C81-83 base pairs (compounds a - d in Figure
6). The presence of a linear trans-a2Pt(II) moiety within these metal-modified base pairs does
not significantly alter the overall structural parameters (e.g. interglycosidic distances and
coplanarity of bases) compared to naturally occurring unmetallated base pairs in duplex or
triplex DNA. Thus, crosslinking of two or three oligonucleotide strands by a trans-a2Pt(II)
unit is sterically feasible. As for DNA triplex structures, in principle, both the trans-a2Pt(II)
crosslinked analogue of the pym•pupym and the pu•pupym motif can be realized as
demonstrated by the model nucleobase triplets d81 and e84 in Figure 6.
Indeed, the principle of crosslinking an oligonucleotide with its target sequence via a
trans-(NH3)2Pt(II) unit has recently successfully been applied in antisense strategy.
2´O-methyl-oligoribonucleotides, crosslinked via a trans-(NH3)2Pt(II) unit to the coding
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region of a mRNA target have been shown both in in vitro and ex vivo experiments to
effectively arrest translation only by steric hindrance.85-87 This result has a high impact with
regard to the fact that even high affinity duplex forming oligonucleotide analogues like the
N3´→N5´phosphoramidates and PNA do not arrest the elongating ribosome.53,56 It is in fact
the first example of inhibition of translation by duplex forming occupance only antisense
oligonucleotides which are directed to the coding region of mRNA. Obviously, the trans-
(NH3)2Pt(II) interstrand crosslink efficiently stabilizes an antisense oligonucleotide / mRNA
hybrid against the translation machinery. For antisense strategy in general this means that for
duplex forming RNase H incompetent antisense oligonucleotide analogues crosslinking via a
trans-(NH3)2Pt(II) unit is a powerful new alternative to block protein synthesis at sequences
downstream the AUG initiation codon.87
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For generation of a site-specific trans-a2Pt(II) crosslink between an oligonucleotide and
its target, in principle two strategies exist. The first one is based on the observation that in the
reaction of an oligonucleotide containing a 1,3 trans-[Pt(NH3)2(GXG)] intrastrand crosslink
(bifunctionally trans-Pt(II) modified oligonucleotide) with a complementary oligonucleotide
target a rearrangement from the 1,3 trans-[Pt(NH3)2(GXG)] intrastrand crosslink into a site-
specific interstrand crosslink takes place (strategy 1, Figure 7).88 In this way, complementary
single-stranded oligonucleotides have been sequence-specifically crosslinked leading to
formation of trans-a2Pt(II) bridged Watson-Crick duplexes.78,79 The second strategy (strategy
2, Figure 7) is based on the observation that in the reaction of a monofunctionally trans-Pt(II)
modified deoxyoligonucleotide with a complementary single-stranded target sequence both
strands are irreversibly linked at a defined site by a trans-Pt(II) interstrand crosslink (Figure 7,
strategy 2).89-91 This strategy allows both sequence-specific crosslinking of two89,90 and three91
oligonucleotide strands, leading to formation of trans-(NH3)2Pt(II) crosslinked DNA duplex
and triplex structures, respectively. An essential element of both strategy 1 and 2 is that
sequence-specific recognition of the mono- and bifunctionally trans-Pt(II) modified
oligonucleotide with the target strand takes place prior to formation of a trans-(NH3)2Pt(II)
interstrand crosslink.
It is evident that the application of this approach in antisense and antigene strategy
requires an efficient synthesis of site-specifically trans-Pt(II) modified deoxyoligonucleotides.
The synthesis of site-specifically mono- and bifunctionally trans-Pt(II) modified
oligonucleotides by direct platination of an oligonucleotide with Transplatin or its solvent
species is generally hampered by the occurrence of multiple unregiospecific platination
reactions, preferrably at the endocyclic N7 positions of the purine bases.92 As a consequence,
the desired platinated oligonucleotide can only be obtained in moderate yields. Moreover,
laborious purification procedures are often required to separate it from the reaction mixture.
Through fine-tuning of the pH during the platination reaction only an efficient synthesis of
regiospecifically monofunctionally trans-Pt(II) modified pyrimidine-rich oligonucleotides
containing a single guanine as the preferred Pt(II) coordination site is feasible (strategy 2,
Figure 7).89-91,93 However, also in this case, occasionally, the formation of bifunctional
adducts (long-range intrastrand crosslinks) is observed, by which further crosslinking
reactions with a target sequence are excluded (suicide reaction). This problem has been
adressed by a protecting group strategy.93 The complex trans-[Pt(NH3)2(1-MeT)Cl] exhibits
exclusive monofunctional coordination. The 1-Methylthyminate ligand (1-MeT) serves as an
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acid-labile protecting group, which can be subsequently substituted by a chloro ligand
(strategy 2b, Figure 7).94-98
The incorporation of preplatinated building blocks into an oligonucleotide by solid-phase
DNA synthesis appears to be more rewarding for site-specific and sequence-independent Pt(II)
modification.99,100 This approach requires the synthesis of preplatinated building blocks which
are compatible with the solid-phase DNA synthesis protocol.
Solid-phase synthesis has been extensively applied for the generation of metal-
functionalyzed oligonucleotides.101-110 In these cases, the metallated building blocks were
compatible with the synthesis protocol as the metal center was protected by stable ligands. By
contrast, solid-phase synthesis of metal-modified oligonucleotides with the metal center
allowing for post-synthetic ligand exchange reactions (e.g. crosslinking reactions) is much
more difficult since metallated building blocks that contain labile ligands (e.g. chloride) are
not compatible with the automated DNA synthesis protocol.99 Exchange of the labile chloro
ligand occurs which leads to the formation of a trans-Pt(II) modified oligonucleotide
incapable of undergoing further crosslinking reactions.99 The solid-phase synthesis of
sequence-independently monofunctionally trans-Pt(II) modified oligonucleotide (analogues)
is therefore a major challenge.
The central aim of this thesis is the development of a solid-phase synthesis method which
allows the facile preparation of sequence-independently and site-specifically
monofunctionally trans-Pt(II) modified oligonucleotides and oligonucleotide analogues. A
further aim is the investigation of the crosslinking reactions of these monofunctionally trans-
Pt(II) modified oligonucleotide(analogues) with target oligonucleotides in order to examine
their potential application for modulation of gene expression according to strategy 2 (Figure
7).
In Chapter I the crosslinking reaction of a monofunctionally trans-Pt(II) modified single-
stranded pyrimidine-rich oligonucleotide, obtained by post-synthetic trans-Pt(II) modification,
with double-stranded DNA is described. Chapters II and III describe novel solid-phase
synthesis approaches towards the synthesis of monofunctionally trans-Pt(II) modified
homopyrimidine deoxyoligonucleotides for potential use in antigene strategy and towards the
synthesis of monofunctionally trans-Pt(II) modified mixed purine / pyrimidine PNA
oligomers for potential use both in antisense and antigene strategy.
Chapter IV describes more subtle electronic effects like the alteration of hydrogen
bonding properties of nucleobases involved in a trans-a2Pt(II) interstrand crosslink.
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B Main Section
Chapter I Crosslinking reaction of a monofunctionally trans-Pt(II)
modified pyrimidine-rich deoxyoligonucleotide with duplex
DNA
1 Introduction
Recent results show that in the reaction of monofunctionally trans-Pt(II) modified
deoxyoligonucleotides with complementary deoxyoligonucleotides initially sequence-specific
recognition takes place before a trans-(NH3)2Pt(II) interstrand crosslink is formed at a defined
site.89,90 In this way, deoxyoligonucleotides have been crosslinked both in parallel and
antiparallel fashions.89,90 The thermal stability of the resulting trans-(NH3)2Pt(II) crosslinked
duplexes is significantly increased compared to the respective uncrosslinked duplexes.89,90
With respect to antisense strategy this increased thermal stability of the oligonucleotide /
target hybrid means an increase in steric blockage of a given RNA target sequence against
translation elongation.
Similarly, sequence-specific crosslinking of a single-stranded monofunctionally trans-
Pt(II) modified oligonucleotide to a target sequence within duplex DNA is possible.91 By
means of gel-electrophoretic studies it has been demonstrated that a monofunctionally trans-
Pt(II) modified pyrimidine-rich 19-mer oligonucleotide with the monofunctional trans-Pt(II)
unit located at the 5´guanine recognizes via formation of Hoogsteen hydrogen bonds a specific
homopurine sequence within a double-stranded DNA fragment consisting of two 25-mers.
Subsequently, a site-specific trans-(NH3)2Pt(II) interstrand crosslink is formed between the
third strand and the homopurine strand of the Watson-Crick duplex.91 The resulting structure
is a trans-(NH3)2Pt(II) crosslinked DNA triple helix of the pym•pupym motif. With respect to
antigene strategy this means that permanent and irreversible steric blockage of a specific
sequence within DNA should in principle be feasible.
In order to analyze the structural details of a DNA triple helix in which a Hoogsteen
strand is linked via a trans-(NH3)2Pt(II) unit to a Watson-Crick duplex, an appropriate model
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compound in sufficient amounts for NMR or X-ray analysis is required. One of the aims of
this thesis is the design and synthesis of such a model compound. The complete 3D structure
of this model will be determined by NMR spectroscopic methods in the group of Prof. E.
Sletten, Bergen, Norway.
2 Choice of the oligonucleotide sequence
2.1 General considerations
The design of an appropriate model requires careful considerations concerning the
oligonucleotide sequence and the length of the oligonucleotide. E.g. a monofunctionally
platinated homopyrimidine-rich strand has to be sufficiently long to ensure efficient sequence-
specific hybridization with a given homopurine tract in DNA. On the other hand, the
oligonucleotide strands must not be too long since otherwise severe overlap of the NMR
signals will trouble an assignment. Ideally, the crosslinking reaction should be carried out at a
temperature which is far below the melting point of the triplex (dissociation of the Hoogsteen
strand from the Watson-Crick duplex) but at which crosslink formation (ligand exchange
reaction at the Pt(II) center) is still reasonably rapid.
The stability of parallel DNA triple helix structures according to the pym•pupym motif is
not only largely dependent on the pH and the concentration of positively charged counter
ions.111 Rather the nucleobase sequence of the Hoogsteen strand is also quite important. It has
been found that below pH 7.0 C+•GC triples are much more stabilizing than T•AT triples and
that triplex structures are most stable if the Hoogsteen strand consists of CT repeats, whereas
adjacent C residues destabilize third strand binding.112,113
In crosslinking experiments, it has been found that efficient triplex formation of a
monofunctionally platinated Hoogsteen strand with a duplex target, a major prerequisite for
subsequent site-specific interstrand crosslink formation, takes place if the monofunctional
trans-Pt(II) unit is located at a 5´guanine of the Hoogsteen strand.91 If the monofunctionally
platinated guanine residue is in the middle of the Hoogsteen strand, hybridization with the
Watson-Crick duplex is less effective.91
Based on these considerations, the 9-mer 5´d(GT2CTC2TC)8- (1) has been chosen as
Hoogsteen strand (Scheme 1). It contains one terminal 5´G, which can be easily
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monofunctionally trans-Pt(II) modified.89,93 The sequence 1 consists furthermore of four
thymine and four cytosine nucleobases, which are expected to afford efficient sequence-
specific recognition of the target sequence.
As a model of double-stranded DNA the hairpin sequence
5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3) was chosen. Here, two Watson-Crick hydrogen-
bonded DNA strands are linked by a 5´CTTG loop, a structural motif which is known to
encourage folding of this sequence into a highly stable two-base hairpin-loop structure.114 The
loop serves to diminish dissociation of the Watson-Crick helix and thus facilitates purification
of a trans-(NH3)2Pt(II) crosslinked DNA triplex by HPLC under denaturing conditions.
The homopurine tract within 3 is not entirely complementary to 1 in that it contains a
5´guanine instead of a cytosine. This modification was chosen in order to increase the rate of
interstrand crosslink formation between the monofunctionally platinated oligonucleotide 2 and
3 as Pt(II) has a greater affinity for guanine than for cytosine.92
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Scheme 1: Route for the synthesis of a trans-(NH3)2Pt(II) crosslinked DNA triple helix;
r1: monofunctional platination of 1; r2 : hybridization of 2 with 3;
r3: crosslinking reaction of 2 with 3.
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2.2 UV spectroscopic analysis of the hairpin (3) and the unplatinated triplex (1•3)
The viability of the described approach was first assessed by an investigation of the
melting profiles of the hairpin (3) and the unplatinated triplex (1•3). Melting of highly ordered
duplex and triplex structures results in disruption of base stacking which is accompagnied by
an increase in UV absorption (hyperchromic effect). This feature can be exploited to
determine the melting temperature: The turning point of the temperature-dependent UV
absorption curve indicates the melting point.112
First the melting behaviour of the hairpin (3) and the unplatinated triplex (1•3) was
investigated at pH 5 in a solution containing 100 mM NaClO4 and 5 mM Mg(ClO4)2. Figure 1
shows the temperature-dependent UV absorption of 3 and the unplatinated triplex (1•3). For
the hairpin (3) a melting point of 352 K was derived from curve a (Figure 1).
Under the same conditions the unplatinated triplex (1•3) exhibits a biphasic melting
profile (Figure 1) with transitions at 308 K, representing dissociation of the Hoogsteen strand
from the Watson-Crick duplex and 348 K, representing dissociation of the Watson-Crick
duplex. Biphasic melting profiles are dependent on pH and have been observed earlier for
DNA triple helices.113,115-119 The value of 308 K for the triplex→hairpin transition compares
with a value of 314 K for the same transition observed for a related DNA triplex under
slightly different conditions.113 The value of 348 K for the duplex→coil transition compares
with a value of 336 K in a related hairpin sequence (containing, however, a C4-loop).113 The
hyperchromicity for the transition of the unplatinated triplex (1•3) to the coil amounts to
approximately 20 % (Figure 1).
The results suggest that at RT the unplatinated triplex (1•3) is intact. With respect to the
aimed synthesis of a trans-(NH3)2Pt(II) bridged triple helix it means that hybridization of the
monofunctionally trans-Pt(II) modified single strand 2 with the homopurine tract within 3
should also be efficient so that the crosslinking reaction of 2 with 3 at RT is expected to
proceed with sequence-specific formation of an interstrand crosslink according to Scheme 1.
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Figure 1: Melting curves of a) hairpin (3) and b) the unplatinated triplex (1•3).
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3 Synthesis of the trans-(NH3)2Pt(II) crosslinked DNA triple helix 4
3.1 Monofunctional platination of 5´d(GT2CTC2TC)8- (1)
5´d(GT2CTC2TC)8- (1) was reacted with one equivalent trans-[Pt(NH3)2(D2O)Cl]+ in D2O
at RT at pH* 3.2 (r1, Scheme 1). Under these conditions the thymine (pKa = 9.9)121 and
cytosine (pKa = 4.4)121 nucleobases are protonated so that coordination of trans-
[Pt(NH3)2(D2O)Cl]+ is expected to occur primarily at the G-N7 position. The reaction was
found to be complete within 48 h as monitored by 1H NMR as well as ion-exchange FPLC,
yielding trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2) (Scheme 1) as the major product.
1H NMR analysis of the monofunctional platination primarily shows the appearance of
one new G-H8 signal in the aromatic region at 8.58 ppm (Figure 2). In addition, further
downfield a single minor signal appears at 8.73 ppm (Figure 2). In comparison with literature
data the former signal is assigned to a G-H8 proton originating from
trans-[Pt(NH3)2{5´-d(G-N7-T2CTC2TC)}Cl]7- (2), the latter as a G-H8 proton originating
from trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}2]14-.89 This assignment is supported by ion-
exchange FPLC which shows the disappearance of the peak originating from
5´d(GT2CTC2TC)8- (1) (peak b, Figure 3) and the appearance of two new peaks with
respective shorter and longer retention times (peaks a and c, Figure 3). The peak with the
shorter retention time (peak a) must originate from a less negatively charged adduct and is
therefore assigned to trans-[Pt(NH3)2{5´-d(G-N7-T2CTC2TC)}Cl]7- (2). The peak with the
longer retention time (peak c) must originate from a higher negatively charged adduct and was
therefore assigned to trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}2]14 -.
Furthermore, 1H NMR spectroscopy shows, that the T-H6 resonances of the thymine
residues in the vicinity of the platinated 5´guanine in 2 undergo a slight downfield shift in the
1H NMR (Figure 2) compared to 5´d(GT2CTC2TC)8- (1). This observation is probably due to
decreased stacking interactions caused by the electron-withdrawing trans-Pt(II) entity as
observed earlier.89,93
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Figure 2: 1H-NMR spectra of 2 (a) and 1 (b) in D2O (pD 3.2); : G-H8 from 2;
●: G-H8 from trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}2]14 -.
a
b c
Figure 3: FPLC analysis of the monofunctional platination of 1;
peaks: a: 2, b: 1, c: trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}2]14 - ;
gradient: 0→50 % B, buffers: A: 0.02 M NaOH, B: 1.2 M NaCl in 0.02 M
NaOH.
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3.2 Hybridization and crosslinking of trans-[Pt(NH3)2{5´-d(G-N7-T2CTC2TC)}Cl]7-
(2) with 5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3)
The crosslinking reaction of trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2) with the
target sequence 5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3) was carried out at pH* 4.8 in D2O
at RT in the presence of 100 mM NaClO4 and 5 mM Mg(ClO4)2 (r3, Scheme 1). In order to
drive the reaction towards the side of the products, 1.5 equivalents of the target strand 3 were
applied.
5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3) was first dissolved in a 100 mM NaClO4 and
5 mM Mg(ClO4)2 solution in D2O, heated, slowly cooled down to RT to ensure efficient
Watson-Crick duplex formation and then added to the freeze-dried
trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2). This procedure was expected to facilitate
sequence-specific recognition of the homopurine tract within 3 by the monofunctionally
platinated Hoogsteen strand trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2) and lead to
subsequent formation of a site-specific trans-Pt(II) interstrand crosslink. The crosslinking
reaction was monitored by ion-exchange FPLC (Figure 4) and found to be complete within
72 h, yielding one major product (peak e, Figure 4). Figure 4 shows the FPLC chromatograms
of the crosslinking reaction after 22 and 71 h. It can be seen that the peak originating from the
monofunctionally platinated Hoogsteen strand 2 (peak a, Figure 5) almost disappears and the
height of the peak originating from the hairpin (3) decreases at the expense of a single new
peak (peak e, Figure 4). As the FPLC chromatograms did not provide peak intensity values the
half-life of trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2) could only roughly be estimated
to be 20-25 h. Reversed-phase HPLC analysis of the reaction mixture (Figure 5) also
demonstrates the presence of one major product as well as excess 3. The main product (peak
e, Figures 4 and 5) was subsequently purified by reversed-phase HPLC.
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Figure 4: Ion-exchange FPLC analysis of the crosslinking reaction;
peaks: a: 2, b: 1, c: trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}2]14-, d: 3, e: 4;
gradient: 0→55 % B in 40 min; buffers: A: 0.02 M NaOH, B: 1.2 M NaCl in
0.02 M NaOH.
d
e
Figure 5: Reversed-phase HPLC analysis of the crosslinking reaction; d: 3, e: 4;
gradient: 11→19 % B in 40 min; buffers: A: 50 mM TEAA, B: 50 mM TEAA in
75 % acetonitrile.
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4 Characterization of the trans-(NH3)2Pt(II) crosslinked DNA triple helix 4
4.1 Reversed-phase HPLC
The purity of the isolated product 4 was established by reversed-phase HPLC analysis. A
very smooth elution gradient in combination with a long elution time was applied to ensure
efficient separation and detection of any coexisting species. The obtained HPLC
chromatogram of the isolated product 4 (Figure 6) reveals a single peak with a retention time
different from that of the unplatinated Hoogsteen (1) and hairpin (3) strands as proven by
coelution experiments. HPLC analysis of the unplatinated, fully hybridized triplex 1•3 under
the same conditions shows the appearance of two peaks belonging to the Hoogsteen (1) and
the hairpin (3) strand, respectively.
Taken together, these findings strongly suggest that the isolated product 4 is neither
identical with 1 nor with 3. It is assumed that 4 is a crosslinked product. Furthermore, the
isolated compound 4 is expected to be pure as different crosslinked adducts have been
observed to have different retention times on a reversed-phase column.89
Figure 6: Reversed-phase HPLC chromatogram of the purified product 4;
gradient: 11→18 % B in 40 min; buffers: A: 50 mM TEAA, B: 50 mM TEAA in
75 % acetonitrile.
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4.2 ESI mass spectrometry
The isolated product 4 was subsequently characterized by ESI mass spectroscopy (Figures
7 and 8). The mass for the twofold positively charged trans-Pt(II) crosslinked DNA triplex 4
amounts to 9595.7 g mol-1. In the ESI MS spectrum masses of m/z 1597, 1917, 2396 for the
respective M6-/6, M5-/5 and M4-/4 ions are observed. The peaks at m/z 1597 and 1917 exhibit
characteristic Na+ and K+ adducts (Figure 7 b). A zoom scan of the peak at m/z 1917.7 (Figure
8) affords the resolution of the isotope pattern. The distance between the lines amounts to 0.2
mass units indicating that the peak at m/z 1917 belongs to a fivefold negatively charged ion.
Moreover, the observed isotope pattern is in agreement with the calculated one (Figure 8).
Thus, ESI MS analysis confirms the existence of a product, where the Hoogsteen strand
(1) is crosslinked via a trans-(NH3)2Pt(II) unit to the hairpin (3). A differentiation of linkage
isomers with this method is not possible as they would have the same mass.
Furthermore, ESI MS shows, that the isolated crosslinked product is pure. Masses for the
unplatinated Hoogsteen strand (1) and the unplatinated hairpin (3) are not detected in the ESI
MS spectrum.
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Figure 7: ESI MS spectrum of 4.
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Figure 8: ESI MS spectrum of 4; a) zoom scan of the peak at m/z 1917.7, b) theoretically
calculated isotope pattern.
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4.3 Gel electrophoresis
4.3.1 Denaturing 24 % PAGE gel
For a further characterization of the isolated product 4 gel electrophoresis was applied.
Gel electrophoresis exploits the different mobility of differently long oligonucleotides on the
gel under the influence of an electric field. Shorter oligonucleotides migrate faster, whereas
longer oligonucleotides have a lower mobility.
The crosslinked isolated product 4, the Hoogsteen (1) and the hairpin (3) strand were
labelled with 32P-γ-ATP and run on a 24 % denaturing PAGE gel (Figure 9). Radioactive
labelling of the isolated crosslinked product 4 was not very efficient and surprisingly, three
bands have been observed on the gel, two of which can be assigned to the unplatinated
Hoogsteen (1) and hairpin (3) strand. The third band represents a product with a lower
mobility which could be a crosslinked product. The observation of three bands on the gel was
rather unexpected in that the isolated crosslinked product had actually been shown to be pure.
1 2 3
Hoogsteen strand ( )1
Hairpin ( )3
crosslinked adduct
Figure 9: Autoradiogram of a denaturing 24 % polyacrylamide gel; lane 1: hairpin (3),
lane 2: crosslinked adduct, lane 3: Hoogsteen strand (1).
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4.3.2 Hydroxyl radical footprinting
For a more detailed gel-electrophoretic analysis a sample of the isolated product 4 was
sent to Dr. M. Boudvillain, CNRS, Orléans, France. There, hydroxyl radical footprinting122
was applied in order to determine the location of the trans-(NH3)2Pt(II) interstrand crosslink.
The hydroxyl radical, generated by iron(II)-promoted reduction of hydrogen peroxide,123
attacks the deoxyribose sugars. This results in unspecific and sequence-independent cleavage
of the DNA backbone.124
First, the isolated product 4 was 5´ labelled with 32P-γ-ATP and loaded on a 24 %
denaturing PAGE gel. Labelling occurred at both the Hoogsteen and the hairpin strand but
was not very efficient, probably due to platination of the two 5´G residues. Again three bands,
originating from Hoogsteen strand (1), hairpin strand (3) and a putative crosslinked product 4
were detected on the gel (not shown). The crosslinked adduct 4 was subsequently purified on
the gel. Next, both the purified crosslinked adduct 4 (labelled) and the labelled hairpin (3)
were subjected to a hydroxyl radical footprinting experiment. Conditions have been used
under which on average less than one cleavage per molecule occurred. The cleavage products
have been analyzed on a 24 % denaturing PAGE gel (Figure 10).
If the trans-(NH3)2Pt(II) unit in 4 was located between the two 5´ guanines, the shortest
cleavage product of 4 would be the Hoogsteen strand containing the trans-(NH3)2Pt(II) unit
coordinated to a single guanine residue. If one residue other than the two 5´guanine residues
was involved in a trans-(NH3)2Pt(II) interstrand crosslink, hydroxyl radical footprinting would
yield one or several fragments shorter than the Hoogsteen strand. From Figure 10 it is evident
that the smallest major cleavage product of the crosslinked adduct migrates as a 12-mer. This
is therefore assigned to the Hoogsteen strand containing the trans-(NH3)2Pt(II) unit
coordinated to one single guanine residue. Furthermore, a band migrating exactly as the
Hoogsteen strand is present, probably due to deplatination reactions during the footprinting
experiment and sample handling. Additionally, there is a very faint pattern of shorter cleavage
products migrating exactly as the cleavage products of the hairpin (Figure 10). This faint
pattern of shorter cleavage products could arise from a crosslinked adduct with the
trans-(NH3)2Pt(II) crosslink being located at a position different from the 5´guanine of the
hairpin. However, in this case, 5´labelling of the hairpin should be much more efficient which
would result in stronger bands for this adduct. The other possibility is that the faint pattern of
shorter cleavage product results from the presence of a tiny amount of the hairpin (3) due to
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deplatination reactions during the footprinting experiment and sample handling. With regard
to the fact that the crosslinked adduct has been shown to be HPLC pure and thus, only one
linkage isomer of 4 should be present, the second explanation is favoured.
1 2 3
Hoogsteen strand ( )1
Hairpin ( )3
crosslinked adduct
12mer
Figure 10: Autoradiogram of a 24 % denaturing PAGE gel showing the Hoogsteen strand
(1) (lane 1) as well as the the cleavage products of the hairpin (3) (lane 2) and the
crosslinked product 4 (lane 3) after hydroxyl radical footprinting.
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4.4 UV spectroscopy
Finally, the melting profile of the crosslinked adduct 4 was analyzed by UV spectroscopy
(Figure 11). Similarly to the melting profile of the unplatinated triplex (1•3) the trans-
(NH3)2Pt(II) crosslinked triplex 4 shows a biphasic melting behaviour. The transition at 336 K
reflects dissociation of the Hoogsteen strand from the Watson-Crick duplex whereas the
transition at 348 K reflects the dissociation of the Watson-Crick duplex. The hyperchromicity
for the transition of the trans-(NH3)2Pt(II) crosslinked triplex 4 to the coil state amounts to
approximately 15 % (Figure 11).
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Figure 11: Melting curve of 4.
From the melting profile of 4 it is evident that compared to the unplatinated triplex (1•3)
the second transition at 348 K remains unaffected by the trans-(NH3)2Pt(II) crosslink in 4,
while the first transition, which reflects the dissociation of the Hoogsteen strand, takes place
at a significantly higher temperature (∆T = 28 K) in 4. Thus, binding of the Hoogsteen strand
to the hairpin is significantly enhanced by the trans-(NH3)2Pt(II) crosslink. This results in an
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increase of the thermal stability of the DNA triple helix 4. Similar observations have been
made in case of a DNA triple helix containing a disulfide bridge between the Hoogsteen
strand and the Watson-Crick duplex.120
The increase in thermal stabilities of crosslinked DNA triple helices has been found to
result from the entropic consequences of crosslinking rather than from net enthalpic
differences.119 On the basis of configurational arguments it is evident that denaturation of a
crosslinked triplex is accompagnied by a lower melting entropy than denaturation of an
uncrosslinked triplex due to a more constrained final state of the denatured crosslinked triplex.
Thus, for a crosslinked triplex a net entropic stabilization exists. Furthermore, from Figure 11
it is evident, that the hyperchromicity of the crosslinked triplex 4 is somewhat lower than for
the unplatinated triplex (1•3). This observation is tentatively explained as follows: The
hyperchromic effect upon melting of the triplex is a result of disruption of base stacking
interactions. In case of the trans-(NH3)2Pt(II) crosslinked triplex 4 stacking interactions
between base pairs adjacent to the crosslink are probably still partly present so that the
hyperchromicity is not that pronounced as in the case of the uncrosslinked triplex (1•3).
5 Discussion
The results show that the crosslinking reaction of
trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2) with the homopurine target within
5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3) proceeds sequence-specifically with formation of
a site-specific interstrand crosslink between the two 5´guanine residues, yielding almost
exclusively the trans-(NH3)2Pt(II) crosslinked DNA triple helix (4).
The trans-(NH3)2Pt(II) interstrand crosslink has unambiguously been determined to be
located between the two 5´guanines by a hydroxyl radical footprinting experiment. However,
this sequencing method does not allow for a differentiation between the two potential
coordination sites G-N7 and G-N1 of the 5´guanine of the hairpin. It is assumed that the 5´G-
N7 position is involved in the interstrand crosslink rather than G-N1 position. First, the G-N1
position is protonated under the conditions of the crosslinking reaction121 which would
hamper its platination and second, it is expected to be engaged in Watson-Crick hydrogen
bonding with the 3´terminal cytosine.
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The crosslinking reaction leading to formation of the crosslinked triplex 4 was found to
be complete within 72 h. The half-life of the monofunctional adduct 2 was roughly estimated
to be 20-25 h. This value is slightly higher than results obtained in similar crosslinking
reactions.125
In general, for formation of an interstrand crosslink two main pathways exist.126 The first
pathway implies a direct nucleophilic attack of the G residue within the purine tract of the
hairpin on the platinated 5´G of the Hoogsteen strand. The second pathway proceeds through
solvent-associated intermediates with the rate-limiting step being hydrolysis of the chloride
ion of the monofunctional adduct. The exact mechanism, however, has not yet entirely been
elucidated.126 Studies on trans-(NH3)2Pt(II) interstrand crosslink formation within triplex
structures have demonstrated that when the platinated G residue was located at the 5´-
terminus of the Hoogsteen strand and therefore well solvent-accessible, interstrand crosslink
formation took place via a solvent-associated mechanism rather than through direct
nucleophilic attack.125
Sterically, formation of a trans-(NH3)2Pt(II) interstrand crosslink between the 5´G-N7
position of the Hoogsteen strand and the 5´G-N7 position of the central purine-rich strand
requires a switch of the 5´-platinated guanine of the Hoogsteen strand from the anti to the syn
conformation. Model building suggests that the two crosslinked guanine bases will adopt a
head - head orientation under these circumstances.84 Figure 12 depicts the nucleobase triple
involved in such a trans-(NH3)2Pt(II) interstrand crosslink.
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Figure 12: Nucleobase triple involved in the interstrand crosslink in 4.
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The thermal stability of the crosslinked triplex 4 is significantly higher compared to the
uncrosslinked triplex (1•3). The UV melting profile of 4 shows that the triplex→duplex
transition (dissociation of the Hoogsteen strand) occurs at a significantly higher temperature
(∆T = 28 K) whereas the hybridization of the Watson-Crick duplex remains unaffected by the
presence of the trans-(NH3)2Pt(II) crosslink.
With respect to antigene strategy this model crosslinking reaction demonstrates that, in
principle, homopurine sequences in double-stranded DNA can sequence-specifically be
targeted and efficiently be sterically blocked through crosslinking of the antigene
oligonucleotide via a trans-(NH3)2Pt(II) unit.
It is evident, that the in vivo application of monofunctionally trans-Pt(II) modified
deoxyoligonucleotides is largely hampered by their instability towards enzymatic degradation.
However, a potential solution to these problems is e.g. the use of nuclease-resistant
oligonucleotide-analogues (cf. chapter III). Further problems can be represented by inefficient
cellular uptake of these potential antigene reagents.
Furthermore, it still has to be established in how far the presence of sulfur-containing
amino acids and proteins, which are known to react strongly with Pt(II) complexes,127,128
would effect the action of monofunctionally trans-(NH3)2Pt(II) modified
oligonucleotide(analogues) in vivo. However, although several features of this approach still
have to be optimized, the principle to achieve long-lasting steric blockage of a DNA target
sequence by an antigene oligonucleotide crosslinked via a trans-(NH3)2Pt(II) moiety seems
reasonable and promising.
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Chapter II Solid-phase synthesis of monofunctionally trans-Pt(II)
modified homopyrimidine deoxyoligonucleotides
1 Introduction
The potential use of monofunctionally trans-Pt(II) modified deoxyoligonucleotides in
antigene and antisense strategy has been explained in the general introduction and
demonstrated in chapter I of this thesis. The lack of an efficient and site-specific synthesis of
these potential antisense / antigene reagents is still a major impediment for their potentially
successful in vivo application. Among the different strategies employed, the incorporation of
preplatinated building blocks into an oligonucleotide by solid-phase DNA synthesis appears to
be most rewarding for the synthesis of site-specifically platinated oligonucleotides.99,100
The latter method was first successfully applied for the synthesis of trans-Pt(II) modified
oligonucleotides by incorporation of the building block trans-[Pt(NH3)2(THP)Cl]
(THP  = thymidine-H-phosphonate) into deoxyoligonucleotides.99 However, unfortunately,
ligand exchange reactions at the Pt(II) center (substitution of the chloro ligand by pyridine)
occurred during the synthesis protocol rendering the trans-Pt(II) modified oligonucleotide
inactive for further crosslinking reactions.99
A potential solution of this problem would be the use of the thyminate protecting group
mentioned earlier instead of a chloro ligand. The thyminate ligand would protect the Pt(II)
center during the automated DNA synthesis protocol and could be substituted by a chloro
ligand afterwards, yielding the desired monofunctionally trans-Pt(II) modified
deoxyoligonucleotide. In trans-position to this thyminate ligand a suitable platinated building
block would have to be coordinated either to a fully protected DNA building block (e.g THP)
or, analoguously, to a ligand containing a functional group that allows conjugation of the
building block to the sugar-phosphate backbone of DNA.
This chapter describes a methodology, in which two newly synthesized trans-Pt(II)
modified building blocks, containing such thyminate protecting groups have been linked via a
ligand to the 5´-terminus of the sugar phosphate backbone of an oligonucleotide using solid-
phase DNA synthesis.129
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2 Design of trans-Pt(II) modified building blocks for use in solid-phase DNA
synthesis
Scheme 1 shows the synthesis cycle applied in solid-phase DNA synthesis according to
the phosphoramidite method.130 The basic steps of this protocol are:
1. Detritylation of the 5´-hydroxyl group of the terminal 2´deoxyribose, usually
achieved by treatment with trichloroacetic acid (TCA) in methylene chloride.
2. Addition of a protected deoxyribonucleoside-3´phosphoramidite to the growing chain
in the presence of tetrazole, followed by a capping step (not shown in Scheme 1)
3. Oxidation of the intermediate phosphite to the corresponding phosphotriester,
achieved by treatment with an aqueous iodine solution in the presence of collidine.
Removal of the base protecting groups and cleavage of the oligonucleotide from the solid
support is usually accomplished by treatment with concentrated aqueous ammonia at 50 °C
overnight.
A suitable preplatinated building block has to be compatible with such a DNA synthesis
protocol. Furthermore, an essential prerequisite is its solubility in organic solvents.
Conjugation of a preplatinated building block to the 5´-terminus of an oligonucleotide by
solid-phase DNA synthesis (Scheme 2) can in principle be achieved by linkage via a
phosphate bond (approach I, Scheme 1) and via an amide bond (approach II, Scheme 1). The
latter approach requires 5´-terminal functionalization of an immobilized oligonucleotide by an
aminolinker and the platinated building block has to contain a ligand with a free carboxyl
group. For approach I (Scheme 1) the platinated building block has to contain a ligand with a
free hydroxyl function via which it can be converted into the corresponding phosphoramidite
(Scheme 1).131,132
Two potentially suitable building blocks are compounds 8 and 9 (Scheme 2). Building
block 8 contains an aminohexanol ligand providing a free hydroxyl function. Building block 9
contains a glycine ligand providing a free carboxyl function. Furthermore, both 8 and 9 are
coordinated to a thyminate derivative which serves to protect the Pt(II) center during the
synthesis protocol and the deprotection step, and which can post-synthetically be substituted
by a chloro ligand93-98 (Scheme 1). The lipophilic cyclohexylmethyl residue at the N1 position
of the thyminate ligand affords sufficient solubility of 8 and 9 in organic solvents. In both 8
and 9 the Pt(II) center is coordinated to four nitrogen atoms, so that 8 and 9 are expected to be
stable against synthesis and deprotection conditions.
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Scheme 1: Solid-phase DNA synthesis protocol (phosphoramidite method) and strategies
for introduction of preplatinated building blocks (approaches I and II).
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Scheme 1 (continued): Removal of the CHMT ligand and its substitution by a chloro ligand.
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3 Synthesis and characterization of the preplatinated building blocks
trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) and
trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9)
Building blocks 8 and 9 have both been synthesized from
trans-[Pt(NH2CH3)2(CHMT)Cl] (7) (Scheme 2). Synthesis and characterization of complexes
7, 8 and 9 are described in the following sections.
Cl
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Scheme 2: Synthesis of building blocks 8 and 9.
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3.1 Synthesis and characterization of trans-[Pt(NH2CH3)2(CHMT)Cl] (7)
Trans-[Pt(NH2CH3)2(CHMT)Cl] (7) was synthesized by a slight modification of a
published procedure80 from trans-[Pt(NH2CH3)2(DMF)Cl]+NO3- (7b) and K(CHMT) (6)
(Scheme 2). First, 1-N-cyclohexylmethylthymine (5) was synthesized from thymine and
bromomethylcyclohexane in a standard alkylation reaction133 and subsequently converted into
its potassium salt 6134 (Scheme 2).
An interesting feature of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) is its high solubility in
chloroform. Compound 7 was analyzed by IR and NMR spectroscopy. Figure 1 shows the
1H NMR spectrum of 7 in CDCl3. Relative to 1-N-cyclohexylmethylthymine (5), the T-H6
proton in 7 undergoes a slight upfield shift of 0.08 ppm as, compared to a proton, Pt(II) is a
weaker Lewis-acid which causes a less deshielding effect on the T-H6 proton. The resonances
for the amino protons of the methylamine ligands in 7 exhibit platinum satellites due to 1H -
 195Pt coupling. The protons of the methyl groups of the methylamine ligands give rise to a
triplet due to coupling with the amino protons (3J = 6.51 Hz) and similar platinum satellites
are observed. The 195Pt NMR spectrum of 7 shows one signal at -2338 ppm, consistent with a
PtN3Cl coordination sphere.135,136
The coordination of Pt(II) to the CHMT-N3-position is additionally evidenced by IR
spectroscopy. In the double bond stretching region of the IR spectrum two characteristically
split intense bands at 1660 and 1570 cm-1 occur. They are assigned to the ν(O-C-N-C-O)
vibrations, which indicate platinum binding to N3 of the CHMT ligand.94,96,137 In the low
frequency region of the spectrum an intense band at 336.5 cm-1 is observed and attributed to
the Pt-Cl stretching vibration.
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Figure 1: 1H NMR spectrum of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in CDCl3.
3.2 Synthesis and characterization of
trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8)
From literature, Pt(II) complexes with both monodentate (coordination via N) and
bidentate (formation of N,O chelate) coordinated 2-amino-1-ethanol are known.138-140 In
addition, complexes of the type trans-[Pta2(1-MeT)(ama)]+ [a = NH3, NH2CH3 , ama = amino
alcohol (2-amino-1-ethanol, 3-amino-1-propanol)], whereby Pt(II) coordinates to the amino
group of the amino alcohol have been synthesized.131 These complexes fulfil the structural
requirements for use in solid-phase DNA synthesis as discussed in section 2 of this chapter,
but their application is hampered by their insolubility in organic solvents.
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8), highly soluble in organic solvents
like chloroform and dioxane, was obtained in a similar way by reaction of
trans-[Pt(NH2CH3)2(CHMT)Cl] (7) with one equivalent of aminohexanol in a methanol /
water mixture (3 d, 60°C).
Characterization of 8 was achieved by 1H and 195Pt NMR spectroscopy as well as ESI MS
and IR spectroscopy. Coordination of Pt(II) to the NH2 group of the aminohexanol ligand is
confirmed by 195Pt NMR, which shows a single signal signal at -2616 ppm, consistent with a
PtN4 coordination sphere.135,136  In addition, the 1H NMR spectrum (Figure 2) shows
downfield shifts of 3.17 ppm and 0.17 ppm for the resonances of the amino group and the
ζ-CH2 group, respectively, compared to 1-amino-6-hexanol. The resonance for the ζ-CH2
protons of the aminohexanol ligand appears as a multiplet and is significantly broadened,
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possibly due to 1H-195Pt coupling. The protons of the methyl groups of the methylamine
ligands appear as a triplet due to coupling (3J = 6.12 Hz) with the protons of the amino group.
The ESI MS spectrum of compound 8 shows a peak at m/z 595 for the singly positively
charged ion of 8.
Similar to the IR spectrum of 7, in the IR spectrum of 8 two characteristically split intense
bands at 1660 and 1560 cm-1 are observed.94,96,137
NH  (ahol)2
α - CH2
ζ - CH2
CDCl3
T-5-CH3
Figure 2: 1H NMR spectrum of  trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) in
CDCl3.
3.3 Synthesis and characterization of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9)
Ternary complexes of cis and trans-Pt(II) with model nucleobases and glycine
monodentately coordinated through the amino group have been described earlier.141-143
Monodentate coordination of glycine to a Pt(II) complex with only one available coordination
site occurs exclusively via nitrogen.144 At a pH where the amino group (pKa = 9.8) of glycine
is protonated initial coordination to an oxygen atom of the deprotonated carboxyl group (pKa
= 2.35) takes place, but even in acidic solution a slow irreversible isomerization from O-
bound to N-bound glycine complex takes place.144 In organic solvents like DMF and DMSO
the protonated form of the carboxylate group is favoured so that initial coordination of Pt(II)
to nitrogen takes place.145
Trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9) was synthesized by reaction of
trans-[Pt(NH2CH3)2(CHMT)(DMF)]+BF4- (7a) with one equivalent of glycine in DMF with a
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minimal amount of water (just allowing glycine to dissolve) at RT. The reaction proceeded
smoothly and yielded exclusively the N-bound glycine complex 9 in a yield of 66 %.
Platinum binding to the amino group of glycine was confirmed by 195Pt NMR
spectroscopy, which showed one single peak at -2605 ppm, consistent with a PtN4
coordination sphere.135,136 Figure 3 shows the 1H NMR spectrum of 9 in DMF-d7.
Surprisingly, the T-H6 and T-5-CH3 resonances are doubled. In addition, the resonances for
the amino protons and the methyl groups of the methylamine ligands are split. An explanation
for this observation is not straightforward. Doubling of the signals seems to depend on the
presence of the methylamine ligands. The 1H NMR spectrum of the water-soluble analogue
10, which contains ammine ligands (Figure 4), does not display this phenomenon.
NH  (gly)2
α - CH (gly)2 
T-5-CH3
Figure 3: 1H NMR spectrum of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9) in DMF-d7.
The ESI MS spectrum of 9 shows a peak at m/z 553 for the onefold positively charged
ion of 9. In the IR spectrum of 9 two characteristically split intense bands at 1660 and
1560 cm-1 are observed, similar to the IR spectrum of complex 7.94,96,137
Compound 9 is highly soluble in DMF and should be suitable for an application in solid-
phase DNA synthesis from this point of view. The solubility of 9 in water is rather poor.
Coordination of Pt(II) to the amino group of glycine changes the acid-base equilibrium of
glycine. It is well established, that upon coordination of the electron-withdrawing Pt(II) to the
amino group the acidity of neutral glycine increases dramatically.141,142 In order to gain
information on the change of the acid-base equilibrium of glycine in complexes structurally
similar to 9, the water-soluble analogue trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10) was
synthesized in the reaction of trans-[Pt(NH3)2(1-MeT)(H2O)]+ with one equivalent of glycine
in water. Compound 10 was characterized by NMR spectroscopy. The 1H NMR spectrum of
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10 (Figure 4) shows in contrast to the 1H NMR spectrum of 9 only single resonances for the
T-H6 and the T-5-CH3 protons. The α-CH2 resonance of the glycine ligand appears as a triplet
due to 3J coupling with the amino protons of the glycine ligand which had not undergone H-D
exchange as yet. The 195Pt NMR spectrum of 10 in D2O shows one signal at -2557 ppm,
consistent with a PtN4 coordination sphere.135,136
2.02.53.03.54.04.55.05.56.06.57.0 ppm
α - CH (gly)2 
T-N1-CH3
Figure 4: 1H NMR spectrum of trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10) in D2O
(pH* 5.8).
Figure 5 shows the results of the pH*-dependent 1H NMR measurements of 10 in D2O.
The resonance originating from the α-CH2 protons of the glycine ligand shows a marked pH
dependence due to (de)protonation of the neighbouring carboxyl group. A pKa value of 3.2
has been calculated which is in agreement with results obtained for cis- and
trans-[Pta2(1-MeC)(gly-N)]+ (a = NH3, NH2CH3).141,142 Thus, the results show that the well-
established acidification of neutral glycine upon coordination of the electron-withdrawing
Pt(II) to the amino group is also seen for trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10). The
calculated pKa value of 3.2 for deprotonation of the carboxyl group compares to that observed
for cis- and trans-[Pta2(1-MeC)(gly-N)]+ (pKa = 2.8 and 2.5, respectively).141,142
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Figure 5: pH*-dependence of 1H NMR chemical shifts of the α-CH2 (gly) protons within
trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10).
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4 Conjugation of trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) to the
5´-terminus of homopyrimidine deoxyoligonucleotides via a phosphate bond by
solid-phase DNA synthesis
4.1 Solution-phase test coupling experiments
4.1.1 Conversion of trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) into its
phosphoramidite 8a
Incorporation of trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) into an
oligonucleotide by solid-phase DNA synthesis requires its conversion into the corresponding
phosphoramidite (Scheme 1). In order to investigate the feasibility of the conversion of 8 into
the corresponding phosphoramidite 8a (Scheme 3), 8 was dissolved in dioxane and reacted
with chloro(N,N-diisopropyl)-β-cyanoethoxyphosphine (11) in the presence of triethylamine.
As evidenced by 31P NMR, almost complete conversion of 8 into 8a was achieved. In the
31P NMR spectrum two signals at 180 ppm, 148 ppm occurred, showing the presence of
excess chloro(N,N-diisopropyl)-β-cyanoethoxyphosphine (11) and 8a, respectively.
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Scheme 3: Conversion of building block 8 into the corresponding phosphoramidite 8a.
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The next step, the isolation of 8a proved to be rather troublesome. All attempts to isolate
8a resulted in its complete degradation, as evidenced by 31P NMR spectroscopy. The
instability of phosphoramidites and their sensitivity to moisture is well known.146,147
Therefore, the required large scale synthesis of 8a seemed not feasible. This was an incentive
to test the feasibility of the reverse coupling strategy. In contrast to the normal coupling
strategy (Scheme 1) the reverse coupling strategy involves initial conversion of the 5´-
terminus of an immobilized oligonucleotide into a phosphoramidite (Scheme 6, conversion of
16 into 16a) followed by a condensation reaction with the free hydroxyl group of a second
reaction component.148 Thus, application of the reverse coupling strategy does not require the
synthesis of 8a but only of building block 8.
4.1.2 Condensation of trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) with
5´-O-DMTr-deoxythymidine-3´-phosphoramidite (12)
In order to establish the viability of this reverse coupling strategy a model solution-phase
experiment was carried out. To this end, building block 8 was reacted with 5´O-DMTr-dT-3´-
phosphoramidite (12) in the presence of o-NPT (Scheme 4). After oxidation and removal of
the ß-cyanoethyl group this experiment should yield the coupled product 13. Indeed, LC MS
analysis of the crude product obtained in this reaction reveals the presence of 13. Compound
13 was purified by reversed-phase HPLC and analyzed by 1H, 31P and 195Pt NMR as well as
ESI MS.
The 195Pt NMR spectrum of 13 shows one signal at -2621 ppm, consistent with a PtN4
coordination sphere.135,136 The signal of 0.18 ppm in the 31P NMR is consistent with a
phosphodiester.149,150
All the non-exchangeable protons in 13 could be assigned by a 1H, 1H COSY experiment
(Figure 6). As expected, the H6 signal of the platinated thymine residue in 13 appears at
higher field than the H6 resonance of the unplatinated thymine residue . The respective T-H6
protons of both thymine residues can be assigned through 4J coupling with the respective T-
CH3 protons. Also the other signals can be fully assigned (Figure 6).
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Scheme 4: Condensation reaction of building block 8 with 5´O-DMTr-dT-3´-
phosphoramidite (12);
a) o-NPT, b) I2 / collidine, c) 25 % aq NH3, d) 80 % aq AcOH, e) DCl (pD 2.2).
Subsequently, compound 13 was converted into the water-soluble compound 14 by
treatment of 13 with 80 % acetic acid (Scheme 4).
In order to investigate the conditions required to remove the CHMT ligand, compound 14
was subjected to DCl (pD 2.2) for several days at 40 °C and the removal of the CHMT
protecting group was observed by 1H NMR and LC MS. Figure 7 shows the 1H NMR spectra
obtained after various time intervals. It can be seen that in the course of time one new T-H6
resonance appears which belongs to 1-N-cyclohexylmethylthymine (5) whereas the T-H6
resonance of the platinated thymine residue of compound 14 gradually disappears. Complete
removal of the CHMT ligand (conversion of 14 into 15) is achieved after 108 h. Exchange of
the CHMT ligand by a chloro ligand was additionally monitored by 195Pt NMR spectroscopy
which shows one signal at -2312 ppm, consistent with a PtN3Cl coordination sphere in
15135,136 and by LC MS.
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Figure 6: 1H,1H COSY spectrum of compound 13 in CD3OD.
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Figure 7: Conversion of 14 into 15 (followed in time); b: T-H6 resonance of 1-N-
cyclohexylmethylthymine, c: T-H6 resonance of the platinated thymine residue
of 14, a: T-H6 resonance of the unplatinated thymine residue of 14 and 15.
4.1.3 Conclusions
The results described in section 4.1 demonstrate that building block 8 can be condensed
with 5´-O-DMTr-deoxythymidine-3´-phosphoramidite (12) according to the reverse coupling
strategy. Furthermore, the CHMT ligand in 14 has successfully been removed and substituted
by a chloro ligand (conversion of 14 into 15). Thus, monofunctional trans-Pt(II) modification
of an oligonucleotide according to approach I (Scheme 1) is in principle feasible.
Unfortunately, for the removal of the CHMT ligand quite acidic conditions are required. As
these conditions can cause depurination reactions151 this approach would be mainly suited for
the synthesis of monofunctionally trans-Pt(II) modified homopyrimidine oligonucleotides.
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4.2 Solid-phase coupling experiments
4.2.1 Optimization of conditions for the reverse coupling strategy
A reverse coupling strategy was extensively applied in order to functionalize
deoxyoligonucleotides with Hoechst 33258 minor groove binders.152-154 This reverse coupling
strategy is not routinely used as it is inherently more troublesome than the normal standard
protocol. E.g., in the addition step of the standard DNA synthesis protocol, the incoming
protected deoxynucleotide phosphoramidite is used in a high excess (Scheme 1). Thus, partial
degradation (due to residual traces of water) does not have a dramatic effect on the yield of the
desired oligonucleotide. However, if the reverse protocol is applied, degradation of the
immobilized phosphoramidite has a more dramatic effect on the yield of the desired product.
For a successful application of this non-standard reverse coupling strategy reaction conditions
had thus first to be optimized.
In order to establish optimal conditions for conversion of the 5´-terminus of an
immobilized deoxyoligonucleotide into the corresponding phosphoramidite, immobilized dT4
(16) was assembled and phosphitylated. Subsequently, only the oxidation step was carried out
(Scheme 5). After deprotection and cleavage from the solid support this protocol is expected
to yield the dT4-5´-terminal phosphoramidate 16b, provided the phosphitylating step
(conversion of 16 into 16a, Scheme 5) is successful. FPLC analysis of the crude product
shows the presence of one major product as well as of a minimal amount of residual
dT4-5´OH (evidenced by coinjection of a dT4-5´OH reference sample), indicating that the 5´-
terminal conversion of 16 into the phosphoramidite 16a proceeded in approximately 70-80 %
yield.
The efficiency of the coupling step was evaluated in a similar way. To this end,
immobilized dT4 (16) was phosphitylated, and the resulting immobilized phosphoramidite
(16a) reacted with DMTrO(CH2)5OH (17) in the presence of o-NPT, oxidized and detritylated
(Scheme 5). In case of an efficient coupling of 17 to 16a this protocol would yield the
conjugate 18 after deprotection and cleavage from the solid support. FPLC analysis of the
crude product shows the presence of one major product as well as of minimal amounts of
residual dT4-5´-OH and dT4-5´-amidate (16b). Compound 18 was obtained in approximately
60 – 70 % yield when the phosphitylation step was carried out twice for 30 minutes each
using a 1.0 M chloro(N,N-diisopropyl)-β-cyanoethoxyphosphine (11) / 1.2 M DiPEA solution
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in acetonitrile and if the coupling step was carried out for 120 min using a 0.1 M solution of
DMTrO(CH2)5OH and a 0.2 M solution of o-NPT in acetonitrile.
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Scheme 5: Conversion of 16a into the corresponding phosphoramidate 16b and
condensation of 16a with 17;
a) 11, DiPEA, b) 17, o-NPT, c) I2 / collidine, d) TCA, e) 25 % aq NH3; DNA =
dT3.
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4.2.2 Conjugation of trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) to the
5´-terminus of immobilized dT4 (16) and d(T3CTC2TC) (19)
At this stage, dT4 (16) and d(T3CTC2TC) (19), immobilized by a 3´-O-succinyl bond to
controlled pore glass (CPG) were phosphitylated with 11 (Scheme 6) according to the
procedure described in section 4.2.1. The newly formed immobilized 5´-phosphoramidites
16a and 19a were subsequently reacted with 8 under the influence of o-NPT, to afford, after
oxidation (I2 / collidine) immobilized 20 and 21, respectively (Scheme 6). Subjecting 20 and
21 to concentrated aqueous ammonia led to decyanoethylation and concomitant release from
the solid support yielding compounds 22 and 23. The crude reaction mixtures were analyzed
by LC MS.
Table 1 shows the results obtained by LC MS for conjugation of 8 to 16a. Three major
products are observed which are assigned to the coupled product 22 in an estimated yield of
30 %, dT4-5´OH  (33 %) and dT4-5´-phosphoramidate (16b) (33 %).
Table 2 shows the results obtained by LC MS for the conjugation of 8 to 19a. According
to the peak intensities of the HPLC chromatogram, the yield of 23 is estimated to be
approximately 20%. Furthermore, significant amounts of d(T3CTC2TC)-5´OH as well as
d(T3CTC2TC)-5´PO3H have been found.
Table 1: LC MS analysis of crude product obtained by conjugation of 8 to 16a
tr / min mass amount / % assignment
7.10 1156(M+), 579 (M2+) 33.63 dT4-5´OH
10.13 1318(M+), 660(M2+) 32.82 16b
12.50 1812 (M+), 906 (M2+) 33.54 22
Table 2: LC MS analysis of crude product obtained by conjugation of 8 to 19a
tr / min mass amount / % assignment
5.76 1349(M2+) 15.11 d(T3CTC2TC)-5´PO3H
7.77 1309(M2+) 18.91 d(T3CTC2TC)-5´OH
8.83 1390(M2+), 928(M3+) 20.61 no
11.03 1638(M2+), 1092(M3+) 19.74 23
11.76 multiple masses 25.62 no
54
O
O
P
O(CH2)2CN
O
T
O D     N     A O
NH
O
O
R1O
O
O
P
OR2
O
T
O D     N     A OR3
PCl N(iPr)2
O(CH2)2CN
O
P
OR2
Pt NH2(CH2)6O
a
a
R1
5´ 3´
R1 = H
R1 = P(OCH2CH2CN)N(iPr)2
5´ 3´
R1 = Cl,   R2 = R3 = H
R1 = CHMT,   R2 = R3 = H
R1 = CHMT,   R2 = (CH2)2CN
R3 = C(CH2)2CNH
OO
a
b, c
d
e
O
11
16 19
16a 19a
20 21
22 23
24 25
Pt
NH2CH3
NH2CH3
NH2(CH2)6OH
+ Cl-
CHMT
8
Scheme 6: Conjugation of building block 8 to the 5´-terminus of the immobilized
oligonucleotides 16a and 19a;
a) 11, DiPEA b) 8, o-NPT, c) I2 / collidine, d) 25 % aq NH3, e) aq HCl, pH 2.3;
16, 20, 22, 24: DNA = dT3; 19, 21, 23, 25: DNA = d(T2CTC2TC).
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4.2.3 Removal of the CHMT protecting group in 22 and 23
The removal of the CHMT ligand and its exchange by a chloro ligand (conversion of 22
into 24 and 23 into 25, Scheme 6) was effected by subjecting 22 and 23 to hydrochloric acid
(pH 2.3) at 40 °C for 48 h to yield the monofunctionally trans-Pt(II) modified tetranucleotide
24 and nonanucleotide 25 as proven by LC MS.
4.2.4 Discussion
The results show that coupling of building block 8 to the 5´-terminus of an immobilized
oligonucleotide is in principle feasible. The coupling yields of the platinated oligonucleotides
22 and 23 are in the range of 20 – 30 % and thus moderate. In the crude reaction mixtures
obtained in both coupling experiments LC MS analysis reveals the presence of dT4-5´OH and
d(T3CTC2TC)-5´OH, respectively. This indicates that the phosphitylation step (conversion of
the resin-bound fully protected deoxyoligonucleotides 16 and 19 into the corresponding
5´phosphoramidites 16a and 19a) does not proceed in optimal yields. Furthermore, in both
experiments the presence of the respective 5´-phosphoramidate and 5´-phosphate shows that
conjugation of 8 to 16a and 19a, respectively, does not take place quantitatively.
As anticipated from the results obtained in the solution-phase test coupling reaction
(section 4.1.2) the newly synthesized platinated building block 8 has been proven to be
compatible with the DNA synthesis protocol. In agreement with this, in neither of the two
experiments Pt(IV) adducts or Pt(II) adducts where ligand exchange has taken place during
the ammonia treatment, have been detected.
The moderate yields of platinated oligonucleotides 22 and 23 of about 20-30% have to be
at least partly ascribed to the inherent disadvantages of the reverse coupling strategy. Still the
yields are comparable with the yields obtained in different attempts to implement platinated
building blocks into oligonucleotides by means of solid-phase DNA synthesis.99,100
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5 Conjugation of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9) to the 5´-terminus
of homopyrimidine deoxyoligonucleotides via an amide bond by solid-phase
synthesis
5.1 Conjugation of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9) to the 5´-terminus
of immobilized 5´-functionalized d(T2CTC2TC) (28)
In order to sidestep the drawbacks associated with the reverse coupling strategy applied in
section 4.2 of this chapter, attempts for the conjugation of
trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+ BF4- (9) to the 5´-terminus of an immobilized
oligonucleotide according to approach II (Scheme 1) were made. The latter strategy would be
equivalent to the normal coupling strategy applied in solid-phase DNA synthesis (cf. section 2
of this chapter) in that the platinated building block 9 is activated (converted into an active
ester by HATU in the presence of DiPEA) prior to coupling to the 5´-functionalized
immobilized oligonucleotide 28.
To this end, d(T2CTC2TC) (27), immobilized by a 3´-O-succinyl bond to controlled pore
glass (CPG) was functionalized at the 5´-terminus with the C6 amino linker 26 (Scheme 7).
The newly formed immobilized 5´-functionalized fully protected oligonucleotide 28 was
reacted with excess 9 under the influence of HATU in the presence of DiPEA. Deprotection
and cleavage from the solid support (NH3 / H2O, 12 h, RT) afforded the conjugate 29. The
crude product obtained in this coupling reaction was analyzed by LC MS (Table 3). The
results show that condensation of 28 with 9 yields the coupled product 29 in almost 80 %
yield. Only minor amounts of unreacted deprotected 28 have been detected by LC MS (Table
3).
Table 3: LC MS analysis of crude product obtained by conjugation of 9 to 28
tr mass amount / % assignment
14.40 1296 (M2+) 17.09 28 + Bz
17.80 1513(M2+),1009 (M3+) 79.35 29
18.18 1246(M2+),831(M3+) 3.55 28
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When forced ammonolysis conditions (concentrated aqueous ammonia, 50 °C, 12 h) as
required for the removal of iBu protecting groups of guanines,130 were applied to 29, complete
decomposition of 29 into 5´-NH2CH2CONH(CH2)6O-d(T2CTC2TC)-3´OH and
trans-[Pt(NH2CH3)2(CHMT)NH3]+ occurred as shown by LC MS.
5.2 Discussion
The results show that conjugation of building block 9 to the 5´-NH2 terminus of the
immobilized deoxyoligonucleotide 28 proceeds almost quantitatively and thus in a much
better yield than coupling of building block 8 to the 5´-terminus of an immobilized
deoxyoligonucleotide via a phosphate bond. Thus, with this approach drawbacks of the
inherently more difficult reverse coupling concept as applied in section 4.2.2 of this chapter
can be circumvented. Still, due to the involvement of the CHMT protecting group, this
method is restricted to the synthesis of monofunctionally trans-Pt(II) modified
homopyrimidine deoxyoligonuclotides.
While at RT the Pt(II) center in 29 withstands treatment with concentrated aqueous
ammonia, forced ammonolysis conditions (50 °C, 12 h) lead to complete degradation of 29.
Obviously, at higher temperatures the NH3 nucleophile attacks the Pt(II) center, resulting in
the formation of 5´-NH2CH2CONH(CH2)6O-d(T2CTC2TC)-3´OH and
trans-[Pt(NH2CH3)2(CHMT)NH3]+.
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6 Conclusions
This chapter describes the development of two new methodologies for the solid-phase
synthesis of monofunctionally trans-Pt(II) modified homopyrimidine deoxyoligonucleotides.
The preplatinated building blocks 8 and 9 have been synthesized and conjugated via a ligand
to the 5´-terminus of immobilized homopyrimidine deoxyoligonucleotides. Building block 8
has been coupled to an oligonucleotide by a phosphate bond using a reverse coupling strategy,
whereas building block 9 has been conjugated to an oligonucleotide by an amide bond using a
“normal” coupling strategy. While conjugation of building block 8 to the 5´-terminus of the
immobilized oligonucleotides 16a and 19a proceeds in moderate yields, conjugation of
building block 9 to the 5´-terminus of the immobilized oligonucleotide 28 occurs almost
quantitatively. This observation has at least partly to be ascribed to the inherent disadvantages
of the reverse coupling strategy.
After conjugation of building blocks 8 and 9 to oligonucleotides, the CHMT ligand could
be substituted by a chloro ligand resulting in the formation of monofunctionally trans-Pt(II)
modified homopyrimidine deoxyoligonucleotides with crosslinking ability.
In principle, the methodologies developed allow sequence-independent and site-specific
monofunctional trans-Pt(II) modification of oligonucleotides. However, since for the removal
of the CHMT protecting group acid treatment at a rather low pH is required, at which
depurination reactions will certainly occur,151 these methodologies are restricted to the
synthesis of monofunctionally trans-Pt(II) modified homopyrimidine deoxyoligonucleotides
with potential application mainly in antigene strategy.
A potential strategy for extending these methodologies to the synthesis of
monofunctionally trans-Pt(II) modified mixed pyrimidine / purine oligonucleotides is feasible
either by the use of a protecting group other than CHMT, which is removable at a slightly
higher pH to avoid depurination,151 or by use of a different DNA backbone which is not
susceptible to acid degradation. The latter potential solution is adressed in chapter III of this
thesis.
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Chapter III Solid-phase synthesis of monofunctionally trans-Pt(II)
modified PNA oligomers and crosslinking reaction with a
complementary oligonucleotide
1 Introduction
The solid-phase synthesis approaches towards monofunctional trans-Pt(II) modification
of deoxyoligonucleotides described in chapter II are, due to the involvement of the thyminate
protecting group, restricted to the synthesis of monofunctionally trans-Pt(II) modified
homopyrimidine oligonucleotides for potential use mainly in antigene strategy.129 The
development of a solid-phase method allowing the synthesis of monofunctionally trans-Pt(II)
modified oligonucleotide heterosequences, containing both pyrimidines and purines, for
potential use also in antisense strategy is a further requirement.
An extension of the methods described in Chapter II to the synthesis of monofunctionally
trans-Pt(II) modified oligonucleotide heterosequences can be achieved either by the design of
a different protecting group, which is, in contrast to CHMT, removable at a slightly higher
pH, where no depurination reactions within DNA occur, or by the use of an oligonucleotide
analogue, which is not susceptible to acid degradation. Indeed, considering the fact that to
date acid-stable backbone-modified oligonucleotide analogues exist,48,50 the latter alternative
seems quite rewarding.
One acid-stable oligonucleotide analogue is the so-called peptide nucleic acid (PNA), in
which the sugar-phosphate backbone is replaced by a peptide backbone.30 PNA strands that
contain all four natural nucleobases form duplexes with RNA and single-stranded DNA
targets with high affinity and sequence-specificity. Base pairing takes place according to the
Watson-Crick rules with an antiparallel orientation of the strands preferred.31
Based on its high chemical and biological stability (e.g. stability against enzymatic
degradation)155 PNA is a very promising candidate for regulation of gene expression both in
antigene and antisense strategy. The potential application of PNA in antisense strategy is
based on steric blocking of ribosomes or essential translation factors, as PNA-RNA hybrids,
in contrast to DNA-RNA hybrids, are not substrates for RNase H.40,56 While triplex forming
homopyrimidine PNAs targeted to the coding region of RNA efficiently interrupt ribosome
elongation in vitro,40,41 duplex forming mixed purine / pyrimidine PNAs do not cause
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sufficient steric blockage when targeted to the coding region.55-57 As a consequence, so far
only homopurine tracts within a coding region of RNA can be blocked by triplex forming
homopyrimidine PNAs, whereas this is not possible for heterosequences that are located in the
coding region. A potential solution to this problem would be to enhance the stability of a
PNA-RNA duplex by a trans-(NH3)2Pt(II) interstrand crosslink. An essential prerequisite for
this approach would be a solid-phase synthesis method that allows the facile preparation of
site-specifically monofunctionally trans-Pt(II) modified PNA oligomers.
2 Different methods of solid-phase PNA synthesis and design of
trans-Pt(II) modified PNA building blocks
For solid-phase assembly of PNA basically four different methodologies exist
(Scheme 1). Method I involves Boc / N-Cbz-protected PNA monomers (Scheme 1, R = Boc,
PG = Cbz).33,156-158 The Boc group provides protection of the primary amino function in the
backbone and the Cbz groups protect exocyclic amino functions in the nucleobases. Removal
of the Boc group (deblocking) prior to the addition step (Scheme 1), is achieved by treatment
with TFA. Removal of the Cbz protecting groups and cleavage from the solid support is
achieved by treatment with HF.
Furthermore, orthogonal protecting group strategies suitable for the solid-phase synthesis
of DNA / PNA chimeras, have been developed, using either Fmoc / N-acyl PNA monomers159
[method II, Scheme 1, R = Fmoc, PG = Bz (A, C) and iBu (G), deblocking with 20%
piperidine / DMF] or MMTr / N-acyl protected PNA monomers58,160,161 [method III,
Scheme 1, R = MMTr, PG = Bz (A, C) and iBu (G), deblocking with 3% TCA/ DCM].
Removal of the N-acyl base protecting groups and release from the solid support is in both
cases achieved by ammonolysis.
Method IV involves Fmoc / N-Bhoc-protected PNA monomers for solid-phase PNA
assembly162 (Scheme 1, R = Fmoc, PG = Bhoc, deblocking with 20% piperidine / DMF).
Removal of the N-Bhoc groups and release from the solid support is accomplished by
treatment with TFA in the presence of a scavenger (m-cresol).
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incorporation of a trans-a2Pt(II)Cl (a = NH3, NH2CH3) unit into PNA oligomers.
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Scheme 1 also depicts strategies for incorporation of a trans-a2Pt(II)Cl unit (a = NH3,
NH2CH3) into a PNA oligomer. Similar to the coupling strategy described in chapter II,
conjugation of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9) to the N-terminal amino group
of immobilized PNA seems feasible. It was expected that 9 would be compatible with the
solid-phase PNA synthesis protocol according to methods II and III. The CHMT ligand would
protect the Pt(II) center in 9 during solid-phase synthesis and deprotection (ammonolysis) and
later on it would be substitutable by a chloro ligand upon acid treatment. A low pH, applied
during removal of the CHMT ligand, would not cause depurination reactions. Thus, in
principle the synthesis of monofunctionally trans-Pt(II) modified mixed purine / pyrimidine
PNA oligomers seems feasible.
An alternative approach (approach II, Scheme 1) implies incorporation of a
monofunctionally trans-Pt(II) functionalized protected PNA monomer into a PNA oligomer.
To this end, two new preplatinated PNA building blocks 33 and 34 have been designed
(Scheme 3), which were expected to be compatible with solid-phase PNA synthesis according
to method IV. As for 33, an essential element is its compatibility with the piperidine treatment
step applied in method IV for removal of the Fmoc group. Piperidine is a nucleophile and
could therefore replace the chloro ligand. In aprotic solvents under anhydrous conditions such
as applied in method IV, however, the exchange of the chloro ligand was expected to be
suppressed, as a chloride ion is not stabilized by solvent molecules in this case. Furthermore,
unlike in DNA synthesis and in contrast to PNA synthesis according to methods II and III
(Scheme 1) in method IV removal of the base protecting groups and cleavage from the solid
support is not effected by ammonolysis but under acidic conditions with TFA. TFA is not
supposed to replace the labile chloro ligand in 33.
For the case of insufficient compatibility of 33 with the piperidine treatment step,
building block 34 was synthesized. It contains a CHMT ligand instead of a chloro ligand. The
former ligand would protect the Pt(II) center against piperidine and would be post-
synthetically substitutable by a chloro ligand (cf. chapter II).
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3 Solid-phase synthesis of a monofunctionally trans-Pt(II) modified
homopyrimidine PNA pentamer
First, the feasibility of approach I (Scheme 1) was explored. To this end, the fully
protected PNA pentamer c5 was assembled following a well-established solid-phase synthesis
protocol161 (method II, Scheme 1). Thus, sequential elongation of glycine anchored via an
ester bond to functionalized (4-hydroxymethylbenzoic acid, HMBA) polystyrene beads with
Fmoc / N-acyl protected building blocks yielded resin-bound c5 (30). It was subsequently
reacted with excess 9 under the agency of the condensation reagent HATU in the presence of
DiPEA. Afterwards, a capping procedure was carried out. Deprotection and cleavage from the
solid support was effected by ammonolysis (NH3 / MeOH, 12 h, 20 °C).
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LC MS analysis of the crude product (Table 1) reveals that conjugation of 9 to the N-
terminal amino group of immobilized c5 proceeded almost quantitatively. An incomplete
coupling reaction of 9 to 30 would have led to the presence of acetylated (capped) c5gly. LC
MS analysis gives, however, no evidence for the presence of acetylated c5gly.
The coupled product 31 is, however, not entirely compatible with the deprotection and
cleavage conditions as evidenced by LC MS. Under mild deprotection conditions (NH3 /
MeOH, 12 h, RT), where removal of the Bz protecting groups is not even complete as
indicated by the presence of 31 having still one or two Bz protecting groups (Table 1),
deplatination reactions occur leading to formation of gly-c5gly and trans-
[Pt(NH2CH3)2(CHMT)NH3]+. As in chapter II, section 5, this observation must be rationalized
by a nucleophilic attack of NH3 on the Pt(II) center in 31, leading to substitution of the
gly-c5gly ligand in 31 by NH3. However, as can be seen from Table 1, this reaction only takes
place to a small extent and the desired product 31 can still be obtained in approximately 50 %
yield. Subsequently, conjugate 31 was purified by reversed-phase HPLC.
Table 1: LC MS analysis of the coupling reaction of 9 with immobilized c5 (33)
tr mass amount / % assignment
11.24 694 [M2+] 9.19 gly-c5gly
17.67 1866[M+], 933[M2+] 49.93 31
18.66 1971[M+], 986[M2+] 19.65 31 + 1 Bz
19.13 496 [M+] 7.36 trans-[Pt(NH2CH3)2(CHMT)NH3]+
19.91 2077[M+], 1039[M2+] 13.86 31 + 2 Bz
The results show that the functionalization of PNA oligomers with building block 9 is
feasible. However, this approach is not well suited for the synthesis of monofunctionally
trans-Pt(II) modified mixed purine / pyrimidine PNA oligomers, as the forced ammonolysis
conditions required for removal of the G-iBu protecting groups130 are not compatible with
building block 9. As in section 5 of chapter II, at higher temperatures the observed ligand
exchange reaction would take place to a much larger extent. For this reason this approach was
not further pursued. Instead, the feasibility of approach II (Scheme 1) involving the newly
synthesized building blocks 33 and 34 (Scheme 3) was explored in more detail.
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4 Solid-phase synthesis of monofunctionally trans-Pt(II) modified mixed
pyrimidine / purine PNA oligomers
4.1 Synthesis and characterization of the preplatinated building blocks
trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) and
trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34)
4.1.1 Synthesis
Trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) was synthesized by reacting
trans-[Pt(NH3)2(DMF)Cl]+BF4- with one equivalent Fmoc/N-Bhoc G (32) in DMF at RT
(Scheme 3). The reaction proceeded almost instantaneously without the formation of much
side products giving trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) in 75 % yield.
Trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) was synthesized by reacting
trans-[Pt(NH2CH3)2(CHMT)(DMF)]+BF4- (7a) with one equivalent Fmoc/N-Bhoc G (32) in
DMF at RT (Scheme 3). The reaction was complete within two days affording 34 in 80 %
yield.
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4.1.2 Characterization of trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33)
4.1.2.1 NMR spectroscopy and ESI MS
Trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) was characterized by ESI MS as well as
NMR spectroscopy. The ESI MS spectrum shows a peak at m/z 1006 for the singly positively
charged ion of 33. Calculated and found isotope pattern are in perfect agreement. The 195Pt
NMR spectrum of 33 in DMF-d7 shows one signal with a chemical shift of -2289 ppm, which
is consistent with a PtN3Cl coordination sphere.135,136 Coordination of Pt(II) to the G-N7
position in 33 is evidenced by a characteristic lowfield shift of the G-H8 resonance of
0.87 ppm in the 1H NMR163 compared to the free ligand Fmoc/N-Bhoc G (32). Similarly, the
G-N9-CH2 protons are shifted to lower field by 0.19 ppm. The NOESY spectrum of 33 (not
shown) displays crosspeaks between the G-H8 proton and the G-N9-CH2 protons as well as
between the G-H8 proton and the protons of the NH3 ligands. Furthermore, 1H NMR
spectroscopy in DMF-d7 at RT shows both for Fmoc/N-Bhoc G (32) and
trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) two signals for the respective methylene (G-
N9-CH2) protons (Figures 2 and 3). This observation is explained by hindered rotation about
the tertiary amide bond. Due to restricted rotation around the tertiary amide bond 32 and 33
exist in both a cis- and a trans-conformation.157,164 In the cis-conformation, the side chain
carbonyl group points towards the glycine placing the methylene protons in proximity to the
2-aminoethyl protons164 (Figure 1).
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At 297 K trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) exists as a 57:43 cis : trans and
Fmoc/N-Bhoc G (32) as a 61:39 cis : trans mixture of the two amide rotamers as gauged by
the integrals of the 1H NMR signals.
Temperature-dependent 1H NMR measurements in DMF-d7 reveal that the two G-N9-
CH2 resonances of Fmoc/N-Bhoc G (32) merge at around 357 K, whereas for
trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) no coalescence is observed until this
temperature (Figures 2 and 3). These data suggest that in 33 the rotational barrier of the
interconversion between the cis and trans conformation is increased.
The respective G-H8 resonances of both 32 and 33 are doubled up to 338 K (Figures 2
and 3). Coalescence of these resonances occurs for both 32 and 33 already at 338 K and does
not coincide with the coalescence of the methylene proton resonances. This suggests that
below 338 K the nucleobase rotation around the G-N9-C9 bond in 32 and 33 is also slow on
the NMR time-scale. If this rotation was fast, only one G-H8 resonance should be observed,
regardless of cis- and trans- conformation. This might lead to the conclusion that in addition
to restricted rotation around the tertiary amide bond in 32 and 33 also the nucleobase rotation
around the G-N9-C9 bond is restricted to some extent.
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Figure 2: Temperature-dependent 1H NMR spectra of 32 in DMF-d7;
a: G-H8 resonance, b: G-N9-CH2 resonances.
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Figure 3: Temperature-dependent 1H NMR spectra of 33 in DMF-d7;
a: G-H8 resonance, b: G-N9-CH2 resonances.
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4.1.2.2 Compatibilty of trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) with solid-phase
PNA synthesis
The compatibility of trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) with the solid-phase
PNA synthesis protocol according to method IV (Scheme 1) is essential. No ligand exchange
reactions at the Pt(II) center (e.g. substitution of the chloro ligand by piperidine) may occur as
in this case a platinated PNA conjugate would have no crosslinking ability. The compatibility
of 33 with the solid-phase PNA synthesis protocol according to method IV (Scheme 1) was
assessed by subjecting 33 to the various reagents of this synthesis protocol. 195Pt NMR
spectroscopy was applied to probe changes in the coordination sphere of the Pt(II) center in
33.
First, 33 was treated with a 20 % solution of piperidine in DMF, which normally serves to
remove the N-terminal Fmoc group (Scheme 1). This reagent is most critical for building
block 33, as piperidine is a nucleophile and could therefore replace the labile chloro ligand.
However, in a dry aprotic solvent (e.g. dry DMF) this ligand exchange reaction is expected to
be rather slow. In agreement with this assumption, 195Pt NMR shows up to approximately one
hour no ligand exchange reactions. After several hours an additional 195Pt NMR signal at
-2396 ppm is observed, indicating most probably substitution of the chloro ligand by
piperidine.
Second, building block 33 was subjected to a mixture of TFA / m-cresol (4 / 1, v/v), used
normally for removal of the Bhoc protecting groups and cleavage from the solid support
(Scheme 1). After one hour 195Pt NMR spectroscopy shows exclusively the original signal at
-2290 ppm, indicating that the Pt(II) center in 33 is not effected by these two reagents.
Third, to a solution of 33 in DMF a mixture of one equivalent of HATU and two
equivalents DiPEA was added. These reagents normally effect conjugation of a protected
PNA monomer to the 5´-terminus of immobilized PNA (Scheme 1). Even after one day at RT,
only the original signal at -2290 ppm is observed in the 195Pt NMR spectrum indicating that
ligand exchange did not occur.
Fourth, 33 was treated with capping solution (acetic acid anhydride / DiPEA). Again,
195Pt NMR spectroscopy shows full compatibility of 33 with this reagent.
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4.1.3 Characterization of trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34)
4.1.3.1 NMR spectroscopy and ESI MS
N7-platination within trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) is
verified in the 1H NMR spectrum by the characteristic downfield shift of the G-H8 resonance
of 1.03 ppm.163 Similar to building block 33 the G-H8 resonance in 34 is also doubled which
suggests that, as in 33, there is restriction of the nucleobase rotation. The 195Pt NMR spectrum
of 34 displays one signal at -2476 ppm, consistent with a PtN4 coordination sphere.135,136
The ESI MS spectrum shows compound 34 as the singly positively charged ion of 34 at
m/z 1219.
9 8 7 6 5 4 3 2 1 ppm
G-H8 G-N9-CH2
Figure 4: 1H NMR spectrum of 34 in DMF-d7.
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4.1.3.2 Compatibility of trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) with
solid-phase PNA synthesis
As the Pt(II) center in trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) is
surrounded by four nitrogen atoms, 34 was expected to be stable against HATU / DiPEA,
piperidine / DMF and acetic anhydride / DiPEA. However, TFA treatment was supposed to
remove at least partly the acid-labile CHMT ligand.
In order to study the effect of TFA on the CHMT ligand
trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) was subjected to a TFA / m-cresol
(4/1, v/v) solution at RT for 1 h. The 195Pt NMR spectrum of the freeze-dried sample shows
two signals at –2119 ppm and –2483 ppm, consistent with PtN3O and PtN4 coordination
spheres,135,136 respectively. In combination with ESI MS, the latter signal is assigned to
originate from compound 34a and the former from compound 34b. Thus, TFA treatment
effects not only removal of the Bhoc base protecting group resulting in formation of 34a but
also partly the removal of the CHMT ligand and its exchange for a TFA ligand resulting in
formation of 34b. According to the integrals of the 195Pt NMR signals the removal of the
CHMT ligand is approximately 50 %.
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4.1.4 Conclusions
The synthesized building blocks trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) and
trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34) are potentially suitable for an
application in solid-phase PNA synthesis according to method IV (Scheme 1). Both 33 and 34
show the required high solubility in DMF. Building block 33 has been shown to be completely
compatible with the solid-phase PNA synthesis protocol according to method IV (Scheme I).
Building block 34 is not entirely stable against TFA as indicated by a partial removal of the
CHMT ligand and its exchange with TFA (Scheme 4). The latter observation does, however,
not represent a major problem. Exchange of the CHMT ligand by TFA can be circumvented
by using HCl instead of TFA for deprotection and cleavage from the solid support in method
IV. In this case the CHMT ligand would be replaced by a chloro ligand which would lead
directly to the formation of the desired monofunctionally trans-Pt(II) modified PNA oligomer.
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4.2 PNA assembly on a Rink functionalized PEG-PS resin using Fmoc / N-Bhoc
building units
The application of approach II (Scheme 1) requires solid-phase PNA synthesis conditions
according to method IV (Scheme 1) involving Fmoc / N-Bhoc protected PNA monomers. The
standard protocol for a common Expedite 8909 DNA synthesizer involves polyethylene glycol
polystyrene (PEG-PS) resin as solid support which is functionalized with a Fmoc-Pal or
Fmoc-Xal linker.162 As a consequence of the higher costs of these linkers and the fact that
solid-phase PNA synthesis has to be carried out for practical reasons on a peptide synthesizer,
the PNA synthesis protocol was slightly modified. Instead of a Pal or Xal linker the
commonly in peptide synthesis employed Fmoc-Rink linker165 was used.
Thus, first, PEG-PS resin was functionalized with a Fmoc-Rink linker (Scheme 5). In
order to evaluate the efficiency of this functionalized resin the PNA sequence gattcgc was
assembled. Thus, sequential elongation of Rink anchored via an amide bond to PEG-PS resin
with Fmoc / N-Bhoc protected PNA monomers yielded the resin-bound gattcgc (35)
(Scheme 5). Deprotection and cleavage from the solid support, achieved by treatment with
TFA / water (9/1, v/v) at RT for 45 min, yielded crude 36.
LC MS analysis of the crude product (Table 1) shows that the main product is the desired
PNA 7-mer gattcgc (36). Only a small amount (7.5 %) of the PNA 6-mer attcgc is detected.
The coupling efficiency is thus rather good. Furthermore, the presence of minor amounts of
gattcgc with re-bound benzhydryl cation (bhc) shows that the use of a scavenger is required
which prevents the highly reactive benzhydryl cation formed during TFA treatment from re-
binding to the electron-rich aromatic rings.
Table 2: LC MS analysis of crude product of gattcgc test synthesis
tr mass amount / % assignment
18.65 1953 (M+), 977 (M2+) 76.87 Ac-gattcgc (36)
20.75 1662 (M+) 7.54 Ac-attcgc
21.45 1060 (M2+) 15.58 Ac-gattcgc (36) + bhc
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4.3 Conjugation of trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) to the N-terminus
of immobilized PNA oligomers
4.3.1 Synthesis and characterization of monofunctionally trans-Pt(II) modified PNA
oligomers
In order to explore the feasibility of approach II (Scheme 1) in combination with building
block 33, the PNA oligomer attcgc has been assembled according to the method described in
section 4.2 of this chapter. The resulting resin-bound, fully protected PNA oligomer attcgc
(37) was reacted with excess 33 under the agency of the coupling reagent HATU in the
presence of DiPEA (Scheme 6). Afterwards a capping procedure was carried out.
Deprotection and cleavage from the solid support was subsequently effected by treatment with
TFA in the presence of m-cresol. The crude reaction mixture was analyzed by LC MS
(Table 3). The HPLC chromatogram shows two main peaks with retention times of 13.41 and
13.67 min, respectively. In combination with ESI MS, the peak at 13.41 min can be assigned
as capped (acetylated) attcgc. The peak at 13.67 min yields peaks at m/z 2215.2, 1108.6 and
738.8 in the ESI MS, which can be assigned as the M+, M2+ and M3+ ions of the
monofunctionally platinated PNA oligomer trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) (Table 3).
Compound 43 was subsequently purified by reversed-phase HPLC and its purity was
established by LC MS (Figure 5).
In order to establish the reproducibility of this approach two more coupling experiments
with different PNA oligomers were carried out. To this end, the PNA / peptide conjugate
attcgc-lys (38) and the PNA oligomer atctcagc (39) were assembled and similarly reacted with
excess 33 under the agency of the coupling reagent HATU in the presence of DiPEA
(Scheme 6). Afterwards a capping procedure was carried out. Deprotection and cleavage from
the solid support was subsequently achieved by treatment with TFA in the presence of
m-cresol. LC MS analysis of the crude reaction mixtures (Tables 4 and 5) reveals that the
respective main products in both experiments are the monofunctionally trans-Pt(II) modified
PNA oligomers 44 and 45. The major side products in both experiments are the respective
capped (acetylated) PNA (n-1)-mers Ac-attcgc-lys and Ac-atctcagc. The monofunctionally
trans-Pt(II) modified PNA oligomers 44 and 45 have similarly been purified by reversed-
phase HPLC. The purity of 44 and 45 was again established by LC MS.
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80
Table 3: LC MS analysis of crude product obtained by conjugation of 33 to 37
tr mass amount / % assignment
13.41 1662 (M+), 831 (M2+) 31.11 Ac-attcgc
13.67 2215 (M+), 1108 (M2+) 739 (M3+) 67.89 43
Table 4: LC MS analysis of crude product obtained by conjugation of 33 to 38
tr mass amount / % assignment
17.41 1790 (M+), 895 (M2+) 52.15 Ac-attcgc-lys
18.16 1172 (M2+), 782 (M3+) 47.85 44
Table 5: LC MS analysis of crude product obtained by conjugation of 33 to 39
tr mass amount / % assignment
14.74 1094 (M2+), 730 (M3+), 41.08 Ac-atctcagc
15.26 2741 (M+), 1371 (M2+), 914 (M3+) 42.62 45
4.3.2 Discussion
The results described in this section demonstrate that an efficient synthesis of
monofunctionally trans-Pt(II) modified PNA oligomers is feasible by conjugation of 33 to the
N-terminus of immobilized PNA. Tables 3, 4 and 5 show that in all coupling experiments the
respective monofunctionally trans-Pt(II) modified PNA oligomer is obtained as the major
product. As major side product the respective capped PNA (n-1)-mers (Ac-atctcagc, Ac-attcgc
and Ac-attcgc-lys) are detected. This indicates that coupling of 33 to immobilized PNA is less
effective than coupling of the unplatinated Fmoc / N-Bhoc-PNA monomers. The reason for
this is not entirely clear. One explanation could be a less effective preactivation reaction
(HATU / DiPEA mediated formation of an active ester). The trans-(NH3)2Pt(II)Cl moiety in
33 might exert steric hindrance on the carboxyl group and thereby “shield” it against
conversion into the active ester. Another explanation could be the acidification of the G-
NH(1) proton due to N7-platination.166 This acidified G-NH(1) proton could interfere with the
preactivation step in that it partly neutralizes the reaction mixture so that quantitative
conversion of the carboxyl group into the active ester is prevented. Nevertheless, despite this
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lower coupling efficiency, the desired monofunctionally trans-Pt(II) modified PNA oligomers
43, 44 and 45 could be obtained in reasonably high yields (40–60 %) by this solid-phase
approach.
Building block 33 proved entirely compatible with the applied synthesis protocol in that
exchange of the chloro ligand was not observed. The presence of platinated PNA adducts, in
which the chloro ligand was exchanged by e.g. piperidine was ruled out by LC MS.
The monofunctionally trans-Pt(II) modified PNA oligomers 43, 44 and 45 have
successfully been purified by reversed-phase HPLC. The conjugates 43, 44 and 45 were stable
and performed no suicide reactions (long range intrastrand crosslinks). Thus, this solid-phase
method allows the convenient site-specific and sequence-independent monofunctional trans-
Pt(II) modification of PNA oligomers.
5 Synthesis and characterization of the trans-(NH3)2Pt(II) crosslinked PNA / DNA
double helix 47
5.1 Analysis of the crosslinking reaction of trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43)
with the deoxyoligonucleotide 5´d(GCGAATG) (46) by reversed-phase HPLC
An essential prerequisite for the potential application of the synthesized monofunctionally
trans-Pt(II) modified PNA oligomers 43, 44 and 45 in antisense strategy is their sequence-
specific crosslinking reaction with a complementary RNA target. In a model experiment, the
crosslinking ability of trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) with the deoxyoligonucleotide
target 5´d(GCGAATG) (46) was investigated. Instead of a RNA target a DNA target was
applied in order to avoid problems with hydrolysis of RNA. The deoxyoligonucleotide 46 is
not entirely complementary to the base sequence in 43 in that it contains a 3´-terminal guanine
instead of a cytosine. This modification was chosen in order to increase the rate of interstrand
crosslink formation between 43 and 46 as Pt(II) has a greater affinity for guanine than for
cytosine.92
The structure of a DNA / PNA duplex has been described in detail earlier.167 It is a right
handed Watson-Crick base paired helix with a wide and deep major groove and a narrow and
shallow minor groove. An antiparallel orientation of the strands is preferred and the duplex
has elements of both A- and B-form DNA. E.g., the DNA backbone torsion angles are close to
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those in A-DNA while the base-sugar moieties of the DNA strand are in a B-like
conformation with anti-glycosidic torsion angles and sugars predominantly near the C2´endo
range.167
Thus, the reaction of trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) with 5´d(GCGAATG) (46) at
neutral pH in water at RT should lead to the formation of the trans-(NH3)2Pt(II) crosslinked
PNA / DNA duplex 47 with antiparallel orientation of the strands (Scheme 7). The trans-
(NH3)2Pt(II) interstrand crosslink would be located between the platinated N-terminal guanine
of trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) and the 3´guanine of 5´d(GCGAATG) (46).
Furthermore, the formation of the trans-(NH3)2Pt(II) interstrand crosslink requires the rotation
of the platinated guanine around the N9-C9 bond in 43, analoguously to the anti→syn rotation
of a nucleobase within a deoxyoligonucleotide.89 The two guanines involved in an interstrand
crosslink would under these circumstances most likely adopt a head-tail arrangement as
previously shown in a trans-(NH3)2Pt(II) crosslinked antiparallel DNA duplex.89
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Scheme 7: Crosslinking reaction of 43 with 46.
Trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) was reacted with 5´d(GCGAATG) at pH 6.5 in
water at RT. Figure 6 shows the reversed-phase HPLC chromatogram after 11 d. After 11 d
the different components of the reaction mixture were separated by reversed-phase HPLC and
analyzed by MALDI-TOF mass spectrometry.
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Figure 6: Reversed-phase HPLC chromatogram of the crosslinking reaction of 43 with 46;
gradient: 0→23 % B in 30 min; buffers: A: 50 mM TEAA, B: 50 mM TEAA in
75 % acetonitrile.
5.2 Characterization of the HPLC fractions by MALDI-TOF mass spectrometry
The HPLC fractions of the crosslinking reaction have been analyzed by matrix assisted
laser desorption time of flight mass spectrometry (MALDI-TOF MS).
According to MALDI-TOF MS analysis (Figure 7), the HPLC fractions I, II and III
contain unreacted 5´d(GCGAATG) (46). Fraction IV contains a product with a mass of
2178.6 which can be assigned either to 43 with the chloro ligand being removed during the
MALDI-TOF experiment (fragmentation) or to a product resulting from a suicide reaction
(formation of an intrastrand crosslink within 43). Fraction V contains a product with a mass of
4325.07 which corresponds to a PNA / DNA hybrid containing a trans-(NH3)2Pt(II)
interstrand crosslink. Additionally, in fraction V the masses for the unplatinated gattcgc (36)
and the unplatinated 5´d(GCGAATG) (46) are detected, probably due to fragmentation of the
crosslinked product 47 during the MALDI-TOF experiment (Figure 7).
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Figure 7: MALDI-TOF spectra of HPLC fractions I (a), IV (b) and V (c).
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Thus, MALDI-TOF analysis confirms the presence of a DNA / PNA hybrid containing a
trans-(NH3)2Pt(II) unit but gives no information on the location of the interstrand crosslink.
For the determination of the location of the interstrand crosslink a gel-electrophoretic
sequencing experiment has to be carried out.
5.3 Characterization of the isolated trans-(NH3)2Pt(II) crosslinked PNA / DNA
duplex 47 by hydroxyl radical footprinting
The location of the trans-(NH3)2Pt(II) interstrand crosslink within 47 can be determined
by a sequencing experiment involving hydroxyl radical mediated strand cleavage122 of the
deoxyoligonucleotide moiety in 47. To this end, a sample of HPLC fraction V was labelled
with 32P-γ-ATP and subjected to a hydroxyl radical footprinting experiment performed by Dr.
M. Boudvillain, CNRS Orléans, France. Conditions have been used under which on average
less than one cleavage per molecule occurred. The cleavage products have been analyzed on a
denaturing 24 % polyacrylamide gel (Figure 8). Lane 1 represents the isolated crosslinked
PNA / DNA duplex 47 after hydroxyl radical footprinting. Lanes 2 and 3 represent
5´d(GCGAATG) (46) after and without hydroxyl radical footprinting, respectively. Since
hydroxyl radical mediated strand cleavage yields oligonucleotide-3´-phosphate and -3´-
phosphoglycolate fragments,122,124 for cleavage of every residue in 46 two distinct bands are
observed. Hydroxyl radical footprinting of the 5´labelled trans-[Pt(NH3)2(g-N7-attcgc){3´d(G-
N7-TAAGCG)}] (47) should yield the same cleavage products as the 5´labelled
5´d(GCGAATG) (46). As can be seen from Figure 8, for 47 there are two bands for every
residue. Only for the 3´G one of the bands has disappeared. Furthermore, a band for the
unplatinated 7-mer 46 is seen. The latter observation could be explained by the occurrence of
deplatination reactions during the footprinting experiment and sample handling. For the
former observation, however, an explanation is not immediately evident. Cleavage of the 3´G
residue within 47 might be less efficient due to the steric constraints caused by the trans-
(NH3)2Pt(II) interstrand crosslink. The site containing the trans-(NH3)2Pt(II) interstrand
crosslink could be distorted to such an extent that the H4´ and H5´ sugar protons, which
represent the preferential sites for attack by the hydroxyl radical,124 are sterically less available
for an attack by the hydroxyl radical. Furthermore, it is possible that the PNA part in 47
causes similar effects.
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In conclusion, the results of the hydroxyl radical footprinting experiment strongly suggest
that the trans-(NH3)2Pt(II) interstrand crosslink in 47 is located between the N-terminal
guanine of the PNA strand and the 3´G of 5´d(GCGAATG) (46).
1 2 3
5´d(GCGAATG)
G
C
G
A
A
T
G
PNA / DNA crosslink
Figure 8: Autoradiogram of a denaturing 24 % polyacrylamide gel;
lane 1: PNA / DNA crosslink after hydroxyl radical footprinting,
lane 2: 5´d(GCGAATG) after hydroxyl radical footprinting,
lane 3: 5´d(GCGAATG) reference.
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5.4 Discussion
The results of section 5 show that the monofunctionally trans-Pt(II) modified PNA
oligomer 43 performs a crosslinking reaction with the complementary deoxyoligonucleotide
46 yielding a trans-(NH3)2Pt(II) crosslinked PNA / DNA duplex as shown by MALDI-TOF
analysis. Gel-electrophoretic studies strongly suggest that the trans-(NH3)2Pt(II) interstrand
crosslink within the PNA / DNA duplex is located between the N-terminal guanine of the
PNA part and the 3´guanine of the oligonucleotide 5´d(GCGAATG) (46). The crosslinking
reaction between 43 and 46, however, is slow and proceeds in a low yield. This observation
was rather unexpected and there is no obvious and straightforward explanation.
One explanation for the slow and low-yield crosslinking reaction could be inefficient
hybridization of 43 with 46 with a concomitant suicide reaction of 43. Indeed, MALDI-TOF
analysis of HPLC fraction IV indicates a product with a mass of 2178.6 corresponding to 43
minus chloride. This mass indicates either a product resulting from a suicide reaction of 43 or
unreacted 43 with the chloro ligand being removed during the MALDI-TOF measurement
(fragmentation). However, as hybridization of PNA with deoxyoligonucleotides is usually fast
and strong and as DNA / PNA hybrids of comparable length have melting temperatures of
313 K168 it is expected that hybridization of 43 with 46 should be efficient.
An alternative explanation for the slow interstrand crosslink formation could be restricted
rotation of the platinated N-terminal guanine around the N9-C9 bond in 43. The formation of
an interstrand crosslink between 43 and 46 requires the rotation of the platinated guanine
residue in 43 around the N9-C9 bond to place the trans-(NH3)2Pt(II)Cl unit in proximity to the
N7-position of the opposite 3´guanine. Slow nucleobase rotation around the N9-C9 bond has
been observed for the protected PNA monomer 32 and building block 33 (cf. section 4.1.2.1
of this chapter). If the rotation of the platinated N-terminal guanine around the N9-C9 bond in
43 is also restricted this could indeed effect the rate and yield of the crosslinking reaction of
43 with 46.
A third explanation could be that the trans-(NH3)2Pt(II) interstrand crosslink within a
PNA / DNA duplex would induce too much steric distortion so that crosslink formation is not
favourable. PNA / DNA duplex structures differ significantly from DNA duplex structures167
and the steric effect of a trans-(NH3)2Pt(II) interstrand crosslink within a PNA / DNA duplex
can differ significantly from that within a DNA duplex. An answer to these questions is not
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yet available. For a detailed investigation of these features molecular modelling studies would
be necessary.
6 Conclusions
Section 3 of this chapter describes the development of a solid-phase approach towards the
synthesis of monofunctionally trans-Pt(II) modified homopyrimidine PNA oligomers.
Building block 9 was quantitatively conjugated to the N-terminal amino group of the
immobilized homopyrimidine PNA pentamer (30) (Scheme 2). In principle, this method
allows the sequence-independent and site-specific monofunctional trans-Pt(II) modification of
PNA oligomers. However, building block 9 has been shown to be incompatible with the
forced ammonolysis conditions required for removal of the G-iBu base protecting groups.130
Therefore, this method is mainly suited for the synthesis of monofunctionally trans-Pt(II)
modified homopyrimidine PNA sequences.
In section 4 of this chapter the development of a solid-phase synthesis method for the
synthesis of monofunctionally trans-Pt(II) modified mixed purine / pyrimidine PNA
oligomers is reported. This method involved first the design and synthesis of the trans-Pt(II)
modified PNA building block 33 which has been shown to be entirely compatible with the
applied PNA synthesis protocol according to method IV (Scheme 1). By contrast to solid-
phase PNA synthesis according to method II and III (Scheme 1) method IV involves an acid-
labile linker and acid-labile base protecting groups. Thus, removal of the base protecting
groups and cleavage from the solid support is achieved under acidic conditions instead of
ammonolysis. This difference renders method IV advantageous since the synthesized
preplatinated building blocks are better compatible with acid treatment.
Building block 33 has been conjugated to the N-terminus of three different immobilized
PNA sequences to yield the monofunctionally trans-Pt(II) modified PNA oligomers 43, 44
and 45 in acceptable yields of 40 – 60 %. The major side-products in all coupling experiments
were the respective unplatinated PNA (n-1)-mers, indicating that coupling of building block
33 to an immobilized PNA oligomer is somewhat less efficient compared to an unplatinated
Fmoc / N-Bhoc protected PNA monomer. Reasons for this observation have been discussed
but based on the experimental data an ultimate explanation is not possible. Despite this minor
drawback the coupling yields obtained are still quite satisfactory. Furthermore, the
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monofunctionally trans-Pt(II) modified PNA oligomers 43, 44 and 45 have been successfully
purified by reversed-phase HPLC. Thus, the method developed gives a practicable access to
the synthesis of monofunctionally trans-Pt(II) modified mixed purine / pyrimidine
oligonucleotide analogues of any desired sequence for potential application both in antigene
and antisense strategy.
The monofunctionally trans-Pt(II) modified PNA oligomer 43 undergoes a crosslinking
reaction with the complementary DNA sequence 46 yielding a trans-(NH3)2Pt(II) crosslinked
PNA / DNA duplex as evidenced by MALDI-TOF mass spectrometry. The location of the
interstrand crosslink has not unambiguously been established but the results of the gel-
electrophoretic studies strongly suggest that it is located between the N-terminal guanine of
the PNA part and the 3´guanine of 5´d(GCGAATG) (46). Thus, it can be assumed that
sequence-specific recognition between 43 and 46 takes place prior to formation of a site-
specific interstrand crosslink. The resulting structure is very likely the trans-(NH3)2Pt(II)
crosslinked PNA / DNA duplex 47.
The fact that 43 performs a sequence-specific crosslinking reaction with a complementary
deoxyoligonucleotide demonstrates the potential application of the newly synthesized
monofunctionally trans-Pt(II) modified PNA oligomers 43, 44 and 45 in antisense strategy. It
again underscores the impact of the developed solid-phase synthesis approach described in
section 4 of this chapter.
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Chapter IV Effect of Pt(II) coordination to N1 of adenine on Hoogsteen
hydrogen bonding with thymine
1 Introduction
In DNA, the N7 sites of guanine and adenine nucleobases are the major binding sites for
the antitumor drug cisplatin.169 The major coordination product is the 1,2 d(GpG) intrastrand
crosslink followed by the 1,2 d(ApG) intrastrand crosslink. Interestingly, the latter is at least
five times more mutagenic than the major d(GpG) adduct.170
Apart from the resulting geometric distortion of DNA, which is reasonably well
investigated,171 the Pt(II) electrophile effects electronic features of the coordinated nucleobase
resulting in potential alteration of H bonding properties and base stacking. The effect caused
by the electron withdrawing Pt(II) moiety on purines is e.g. reflected in significant changes of
acid-base properties. For example, binding of Pt(II) to the guanine N7 position acidifies the
proton at the N1 position by 1.5 - 2 log units.166 As for adenine, an acidification of the N1
position of approximately one logarithmical unit has been observed.80
A N7-platinated guanine within a DNA duplex still forms a Watson-Crick pair with
cytosine, which has been manifested by means of NMR studies173 and X-ray
crystallography.174-176 Furthermore, in a crystal, the model nucleobase 1-MeC was found to
form Watson-Crick hydrogen bonds to the model compound trans-[Pt(NH2CH3)2(9-MeGH-
N7)(1-MeC-N3)]X2.81 In solution, concentration-dependent 1H NMR studies of several N7-
platinated guanine complexes and 1-MeC in DMSO demonstrated that Pt(II) binding at N7
even stabilizes the Watson-Crick G / C pair, as demonstrated by an increase of the association
constant.177,178 These results are in agreement with theoretical studies, according to which
metal ion binding to N7 of guanine was calculated to stabilize the Watson-Crick G / C base
pair in general.179-181
For adenine, it was proposed that metal ion binding at N7 effects hydrogen bonding
little181 or not at all.182 So far, no empirical studies exist adressing the question as to what
extent N1- or N7-coordinated Pt(II) influences the Hoogsteen or Watson-Crick hydrogen
bonding properties of adenine with thymine. In general, A / T base pairs possess a lower
stability than G / C base pairs. As a consequence, observation of hydrogen bonds between A
and T is not possible in hydrogen bonding solvents like DMSO.183 The poor hydrogen-
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bonding solvent chloroform, however, has been shown to be a convenient medium for
investigation of hydrogen bonding between chloroform-soluble adenine and thymine
derivatives.184 An investigation of hydrogen bonding properties of a platinated adenine with
thymine should also be possible in this solvent if chloroform-soluble Pt(II)-adenine complexes
were available. With regard to the fact that the plethora of adenine model compounds that
have so far been synthesized,185,186 do not fulfil this criterion, the synthesis of chloroform-
soluble Pt(II)-adenine complexes is required before hydrogen bonding studies can be
conducted.
2 Synthesis and characterization of the chloroform-soluble complexes
trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50) and
trans-[Pt(NH2CH3)2(CHMT)(TBS-ado)]+BF4- (51)
2.1 Synthesis
Pt(II) binding to naturally occurring adenine nucleobases and their N9-blocked model
compounds mostly occurs through the endocyclic N1 and N7 nitrogen atoms.187 Rarely,
binding to N3 is observed.188 From model chemistry it is known that for Pt(II) the
coordination behaviour is governed by pH. At acidic pH the most basic site N1 (pKa ≅ 4) is
protonated and consequently Pt(II) coordination takes place preferentially at the N7 position.
At pH ≥ 4, when both N1 and N7 are deprotonated, usually a mixture of linkage isomers is
formed. For example, monofunctional Pt(II)dien distributes almost equally between the N7
and N1 sites in neutral adeosine, and in 5´AMP it slightly favors the N7 site.189,190
Reasons for the distribution patterns with Pt(II) are not yet very well understood, although
it appears that the exocyclic amino group exercises a steric hindrance, which is larger for
metals approaching N1 than N7.191-194 Similarly, ancillary ligands already bonded to Pt(II)
effect the distribution between the two endocyclic nitrogens.195 The adenine N1 position is the
themodynamically more stable binding site for Pt(II) as compared to N7. In agreement with
this, migration of a monofunctional Pt(II) moiety from the N7 to the N1 position at high
temperatures has been observed.196
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So far, all platination reactions in combination with adenine model nucleobases have
been carried out in an aqueous medium. Not much is known about coordination of Pt(II) to
this base in an aprotic solvent.
In order to achieve solubility of Pt(II)-adenine complexes in chloroform, a prerequisite for
hydrogen bonding studies, highly lipophilic adenine derivatives as ligands are required. To
this end, the adenine derivatives 9-N-cyclohexylmethyladenine (CHMA, 48) and 2´,3´,5´-tris-
(tert-butyldimethylsilyl)-adenosine (TBS-ado, 49) have first been synthesized.
Subsequently, 48 and 49 have been reacted with
trans-[Pt(NH2CH3)2(CHMT)(DMF)]+NO3- (7b) and
trans-[Pt(NH2CH3)2(CHMT)(DMF)]+BF4- (7a), respectively, in DMF to yield the chloroform-
soluble complexes 50 and 51 (Scheme 1). Surprisingly, in both cases platination proceeds
with high regioselectivity yielding the respective N1-linkage isomers
trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50) and
trans-[Pt(NH2CH3)2(CHMA)(TBS-ado)]+BF4- (51) (Scheme 1).
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Scheme 1: Synthesis of 50 and 51 by reaction of 48 with 7b and 49 with 7a.
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2.2 NMR spectroscopic characterization
2.2.1 Trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50)
Trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50) has been fully characterized by NMR
spectroscopic methods. Tables 1, 2 and 3 list the 1H, 13C and 195Pt NMR data for compounds
48 and 50. The 195Pt NMR spectrum of 50 in deuterated methanol shows one signal at -2584
ppm which is consistent with a PtN4 coordination sphere.135,136
Table 1: 1H NMR data for 48 and 50
A-H2 A-H8 A-N9-
CH2
A-6-NH2 T-H6 T-CH3 T-N1-
CH2
Pt-NH2 Pt-
NH2CH3
48a s, 8.37 s, 7.75 d, 4.02 s, 5.61
48b s, 8.19 s, 8.15 d, 4.06 s, 7.18
48c s, 8.18 s, 8.08 d, 4.06 n.o.
50a s, 8.69 s, 7.63 d, 3.94 s, 9.07 s, 6.91 s, 1.70 d, 3.65 m, 5.13;
m, 4.50
t, 2.21
50b s, 8.85 s, 8.44 d, 4.15 s, 9.30 s, 7.38 s, 1.82 d, 3.50 m, 5.11 t, 2.24
50c s, 9.0 8.19 d, 4.12 n.o. s, 7.32 s, 1.92 d, 3.64 m, 4.55 t, 2.15
a CDCl3, b DMF-d7, c CD3OD; n.o. = not observed
Table 2: 13C NMR data for 48 and 50
A-C6 A-C2 A-C4 A-C8 A-C5 A-C9 T-C5 T-C6 T-CO(4) T-CO(2)
48a 155.6 152.9 150.3 140.9 119.6 50.0
50b 157.6 155.3 149.4 144.5 120.5 51.1 109.8 143.0 174.0 159.0
a CDCl3, b CD3OD
Table 3: 195Pt NMR data for 50
solvent CDCl3 CD3OD DMF-d7
δ (ppm) - 2599 - 2584 - 2594
94
Compared to free CHMA (48) in CDCl3, the A-H2 resonance in 50 has been shifted
downfield by 0.32 ppm, whereas the A-H8 proton undergoes a slight upfield shift of
0.11 ppm. Furthermore, a remarkable downfield shift of 3.46 ppm for the resonance of the
exocyclic amino protons is observed in 50.
In DMF-d7, the low-field shifts of the A-H2 and A-H8 resonance in 50 amount to 0.66
and 0.29 ppm, respectively, compared to 48. Furthermore, a downfield shift of 2.12 ppm for
the resonance of the exocyclic amino protons in 50 is observed.
In CD3OD, low-field shifts of 0.81 ppm for A-H2 and 0.11 ppm for A-H8 are observed
for 50, in agreement with reported data.196-199
Coordination of Pt(II) to the N1-position in 50 is evidenced by two-dimensional NMR
experiments, a 195Pt-1H HMQC experiment and pH*-dependent 1H NMR measurements.
Figure 1 displays the 1H,1H NOESY spectrum of 50. The A-H8 proton is identified by its
crosspeak with the A-N9-CH2 protons whereas the A-H2 proton shows crosspeaks to the
amino protons and the methyl group protons of the methylamine ligands. Furthermore, as
expected, the T-H6 resonance in 50 exhibits crosspeaks to the T-N1-CH2 and the T-5-CH3
resonances.
A long-range 1H, 13C experiment (Figure 2) reveals the expected coupling of A-H2 with
A-C2 (1J), A-C4 (3J) and A-C6 (3J) as well as of A-H8 with A-C8 (1J), A-C4 (3J), A-C5 (3J),
and A-C9 (3J). The assignment of the 13C NMR resonances (Table 2) of the CHMA ligand is
based on literature data for 9-N-methyladenine200,201 as well as for [Pt(dien)(ado-N1)].196
Finally, the 1H,195Pt HMQC experiment (Figure 3) shows coupling (3J = 20 Hz) between
A-H2 and the 195Pt resonance.
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Figure 1: 1H, 1H NOESY spectrum of 50 in CD3OD;
crosspeaks: a: A-H2 / Pt-NH2, b: A-H8 / A-N9-CH2, c: T-H6 / T-N1-CH2,
d: A-H2 / Pt-NH2CH3.
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Figure 2: Long-range 13C, 1H COSY spectrum of 50 in CD3OD;
a: A-H2 / A-C4 (3J), b: A-H2 / A-C6 (3J), c: A-H8 / A-C5 (3J),
d: A-H8 / A-C4 (3J), e: T-H6 / T-CO(2) (3J), f: T-H6 / T-CO(4) (3J).
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Figure 3: 1H,195Pt HMQC spectrum of 50 in CD3OD.
Coordination of Pt(II) to the adenine N1 position in 50 was furthermore evidenced by
pH*-dependent 1H NMR measurements (Figure 4). At a characteristically low pH the A-H8
resonance of 50 undergoes a large downfield shift due to protonation of the A-N7 position
whereas the effect on the 1H chemical shift of the A-H2 resonance is less pronounced (Figure
4). From the pH*-dependent 1H NMR chemical shifts of the A-H2 and A-H8 resonances of 50
in D2O a pKa value of 0.9 for (de)protonation of the A-N7 position has been derived, in
agreement with results for similar compounds.80
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Figure 4: pH*-dependence of the A-H2 and A-H8 1H NMR resonances of 50.
Temperature-dependent 1H NMR studies of complex 50 have been carried out in D2O. In
D2O, A-H2 occurs as two resonances (1:1) up to ca. 318 K, irrespective of pH* (Figure 5).
Above this temperature, coalescence takes place and this process is fully reversible. A similar
splitting of A-H2 in related complexes has been reported earlier80 and is assigned to hindered
rotation of the nucleobases about the Pt-N bonds. This hindered rotation depends on the
presence of methylamine ligands (the NH3 analogues do not display this behaviour) and the
solvent water. The role of water could be to bridge exocyclic groups of the two trans-
positioned bases, as seen in the X-ray crystal structure of
trans-[Pt(NH2CH3)2(1-MeT)(9-MeA-N1)]ClO4⋅3.25H2O.80 While direct hydrogen bonding
between the exocyclic groups of the two bases is excluded on steric grounds (distance ca.
4 Å), the dual function of a water molecule to act as a H bond acceptor for A-N(6)H2 and a H
donor for T-O4 or T-O2 is ideal for this purpose. The rate of rotation at the coalescence point
can be estimated to kc = 2.22 ∆ν = 27.33 Hz. Furthermore, the rotational barrier at the
coalescence temperature is calculated to 69.30 kJ mol–1.172
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Figure 5: Temperature-dependent 1H NMR spectra of 50 in D2O.
2.2.2 Trans-[Pt(NH2CH3)2(CHMT)(TBS-ado)]+BF4- (51)
All signals in trans-[Pt(NH2CH3)2(CHMT)(TBS-ado)]+BF4- (51) have been assigned by
two-dimensional NMR spectroscopy. Thus, A-H8 in 51 is identified by its crosspeaks with the
H1´, H2´ and H3´protons of the ribose moiety in the 1H, 1H NOESY spectrum (Figure 6). The
A-H2 resonance exhibits crosspeaks to the resonances of the amino protons and the methyl
protons of the methylamine ligands. A long range 1H, 13C COSY experiment (Figure 7) shows
the expected coupling of A-H8 with A-C8 (1J), A-C4 (3J), A-C5 (3J), whereas A-H2 displays
couplings with A-C2 (1J), A-C4 (3J) and A-C6. The assignment of the 13C NMR resonances of
the TBS-ado ligand of 51 (Table 5) is based on literature data for adenosine and [Pt(dien)(ado-
N1)]2+.196
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The 195Pt NMR spectrum of 51 in CD3OD shows one signal at -2580 ppm which is
comparable with the 195Pt NMR spectrum of 50 in the same solvent and consistent with a PtN4
coordination sphere.135,136
The 1H NMR spectrum of 51 in CDCl3 (Table 4) shows characteristic low-field shifts of
0.5 ppm for the A-H2 resonance and 0.09 ppm for the A-H8 resonance compared to the free
ligand TBS-ado (49) in the same solvent.199-201 The protons of the exocyclic amino group of
51 show a very significant low-field shift of 3.25 ppm compared to free TBS-ado (49).
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Figure 6: 1H, 1H NOESY spectrum of 51 in CD3OD.
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Figure 7: 13C, 1H long-range COSY spectrum of 51; a: A-H2 / A-C4 (3J),
b: A-H2 / A-C6 (3J), c: A-H8 / A-C5 (3J), d: A-H8 / A-C4 (3J),
e: T-H6 / T-CO(2), f: T-H6 / T-CO(4), g: H1´/ A-C8, f: H1´ / A-C4.
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Table 4: 1H NMR data for 49 and 51
A-H2 A-H8 A-6-NH2 T-H6 T-5-CH3 Pt-NH2 Pt-NH2CH3
49a s, 8.16 s, 8.34 s, 5.51 - - - -
51a s, 8.66 s, 8.43 s, 8.76 s, 6.92 s, 1.92 m, 4.47,
m, 3.82
t, 2.27,
t, 2,10
51b s, 9.05 s, 8.46 n.o. s, 7.32 s, 1.91 m, 4.65 t, 2.11
Table 4 (continued)
H1´ H2´ H3´ H4´ H5´ H5´´
49a d, 6.02 dd, 4.69 dd, 4.32 m, 4.12 dd, 4.03 dd, 3.79
51a d, 5.95 * * * dd, 3.66 dd, 3.52
51b d, 6.06 dd, 4.71 t, 4.40 m, 4.16 dd, 4.07 dd, 3.55
a CDCl3, b CD3OD; * not assignable due to overlap
Table 5: 13C NMR data for 51
A-C6 A-C2 A-C4 A-C8 A-C5 T-C5 T-C6 T-CO(4) T-CO(2)
51b 157.7 155.6 148.9 142.6 121.6 110.5 142.9 174.4 158.9
Table 5 (continued)
C1´ C2´ C3´ C4´ C5´
51b 89.7 77.0 73.6 87.3 63.8
b CD3OD
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2.3 Discussion
The reactions of 48 and 49 with trans-[Pt(NH2CH3)2(CHMT)(DMF)]+NO3- (7b) and
trans-[Pt(NH2CH3)2(CHMT)(DMF)]+BF4- (7a), respectively, in DMF lead with high
regioselectivity to formation of the respective N1-linkage isomers
trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50) and
trans-[Pt(NH2CH3)2(CHMA)(TBS-ado)]+BF4- (51) (Scheme 1). The reason for this
coordination behaviour is not straightforward. In the analoguous reaction of
trans-[Pt(NH2CH3)2(1-MeT)(H2O)]+ with 9-N-methyladenine in aqueous solution (pH 5.5, 48
h, 60 °C) only a slight preference for the adenine N1 position as the Pt(II) coordination site
has been observed.80 Thus, solvent effects may influence the coordination behaviour.
Furthermore, the DMF ligand within 7a and 7b is sterically more demanding than the aqua
ligand in trans-[Pt(NH2CH3)2(1-MeT)(H2O)]+ which may influence the distribution between
N1 and N7 platination. Based on the experimental data an explanation for the observed
regioselective N1 platination of the adenine derivatives 48 and 49 is not available.
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3 Investigation of hydrogen bonding interactions of the N1-platinated complexes
50 and 51 with 1-N-cyclohexylmethylthymine (5)
3.1 General considerations
A prediction to what extent Pt(II) binding to adenine N1 will effect the Hoogsteen
hydrogen bonding properties of adenine with the complementary thymine, is difficult. On the
one hand, an acidification of the protons of the exocyclic amino group is expected, resulting
in an increase of the hydrogen bond donating ability. On the other hand, the electron-
withdrawing Pt(II) decreases the basicity of the A-N7 position and therefore its hydrogen
bond accepting ability.
The thymine derivative 5 can be hydrogen-bonded to 50 and 51 both according to
Hoogsteen and reverse Hoogsteen geometry (Figure 8). The nucleobase triple in which 5
forms Hoogsteen hydrogen bonds to 50 (or 51) represents a model of a metalated nucleobase
triple within parallel triplex DNA in which the two strands of the Watson-Crick duplex are
crosslinked by a trans-a2Pt(II) moiety (cf. chapters I and III). Thus, also from this point of
view an investigation of the alteration of hydrogen bonding properties due to platination
seems relevant.
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Figure 8: Hydrogen-bonded associates of 50 and 51 with 5 according to a) Hoogsteen
geometry and b) reverse Hoogsteen geometry.
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3.2 Concentration-dependent 1H NMR studies in CDCl3
1H NMR chemical shifts of H-bonded protons can be used as indicators of the hydrogen
bond strength.202 Thus, H bond formation results in downfield shifts of the protons involved.
From concentration-dependent 1H NMR measurements equilibrium constants for the
association of the respective species can be derived. However, it has to be taken into account
that 1H NMR data obtained at RT represent averages over all coexisting H-bonded associates
and do not allow a detailed evaluation of type and relative population of these in solution.
In order to study the influence of Pt(II) bound to the adenine N1 position on the overall
association with thymine, concentration-dependent 1H NMR measurements of an equimolar
mixture of 50 and 1-N-cyclohexylmethylthymine (5) in deuterated chloroform were carried
out. For comparison, concentration-dependent 1H NMR measurements of an equimolar
mixture of CHMA (48) and 5 as well as pure 5 (Figure 9) were performed at RT.
From Figure 9 it is evident that upon dilution of the equimolar 48 / 5 mixture, both the T-
NH (curve a) and the A-NH2 resonances (curve e) undergo significant 1H NMR highfield
shifts. The highfield shift of 2.84 ppm for the T-NH resonance is more pronounced than that
of 0.71 ppm observed for the A-NH2 resonance. This is largely due to the fact that for the two
A-NH2 protons only an averaged signal is observed. From these data, an association constant
of 56.5 ± 9 M-1 was calculated (Table 6), which is in agreement with reported data.203
Upon dilution of the solution of 5 in CDCl3, the T-NH resonance similarly shifts to
higher field (Figure 9). The concentration-dependent highfield shift of 0.86 ppm is
significantly less pronounced than for the T-NH resonance in the 5 / 48 mixture. Furthermore,
the T-NH resonance of pure 5 in CDCl3 appears at all concentrations at higher field than the
T-NH resonance of the 5 / 48 mixture. This illustrates that hydrogen bonds between
homodimers of 5 are weaker than that in 5 / 48 pairs. An association constant of
4.72 ± 0.23 M-1 for the self-association of 5 has been calculated (Table 6), again in agreement
with literature data.203-205
Upon dilution of the equimolar 50 / 5 mixture, only a highfield shift of the T-NH
resonance of 1.18 ppm occurs, whereas the chemical shift of the A-NH2 resonance remains
largely unaffected and actually undergoes a slight downfield shift of 0.09 ppm (Figure 9). The
concentration-dependent 1H NMR chemical shift of the T-NH proton in the 50 / 5 mixture is
almost the same as for pure 5. The T-NH resonance of 5 in the 50 / 5 mixture appears at only
slightly lower field compared to the T-NH resonance of the pure 5 solution. This observation
leads to the conclusion that within the 50 / 5 mixture the T-NH of 5 is not engaged in strong
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hydrogen bonds like e.g. in the 48 / 5 mixture. However, hydrogen bonding interactions
between 50 and 5 might be present to some extent to account for the slight downfield shift of
the T-NH relative to the T-NH of the pure 5 solution.
Taken together, the observations suggest that hydrogen bonding interactions between 50
and 5 are minimal and that 5 undergoes self-association rather than pairing with 50 in a
Hoogsteen or reverse Hoogsteen type fashion.
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Figure 9: Concentration-dependent chemical shifts of the T-NH and A-NH2 protons
a: T-NH (48 / 5), b: T-NH (50 / 5), c: A-NH2 (50 / 5), d: T-NH (5 / 5),
e: A-NH2 (48 / 5).
Table 6 : association constants
A / T 56.5 ± 9 M-1
T / T 4.72 ± 0.23 M-1
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3.3 Temperature-dependent 1H NMR studies in CDCl3
If hydrogen bonds according to the Hoogsteen or reverse Hoogsteen pattern between 50
and 5 and 51 and 5 were present at low temperatures, both the T-NH and the A-NH2
resonances should undergo highfield shifts upon raising the temperature. To this end,
temperature-dependent 1H NMR spectra of equimolar 50 / 5 and 51 / 5 mixtures in CDCl3
have been recorded (Figure 10).
Figure 10 shows the temperature-dependent 1H NMR spectra of an equimolar 50 / 5
mixture in CDCl3. Upon raising the temperature, only the T-NH resonance shifts to higher
field, whereas the A-NH2 resonance remains largely unaffected. Below 270 K the A-NH2
resonance initially splits up into two and eventually into three resonances. This is probably
due to hindered rotation of the exocyclic amino group in combination with hindered
nucleobase rotation. It is noted that its chemical shift virtually does not change. Above 285 K
the T-NH resonance even appears at higher field than the A-NH2 resonance.
A similar temperature dependence of the T-NH and the A-NH2 resonances is seen for the
equimolar 51 / 5 mixture in CDCl3 (Figure 11). In Figure 11 the temperature-dependent shifts
of the T-NH resonance for the equimolar 50 / 5 and 51 / 5 mixtures as well as for pure 5 in
CDCl3 are summarized. It is evident, that despite some differences in absolute values, in all
three cases the temperature-dependent shifts of the T-NH resonances are rather similar. The
T-NH resonance of 5 within the 50 / 5 and the 51 / 5 mixtures appears at all temperatures at
slightly lower field than the T-NH resonance of the pure 5 system. This could be due to the
presence of a minimal amount of hydrogen bonding interactions between 50 and 5 as well as
between 51 and 5. However, the observation that the concentration-dependence of the T-NH
resonance is almost the same as for the pure 5 leads to the conclusion that in the presence of
50 and 51, self-association of 1-N-cyclohexylmethylthymine (5) prevails.
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Figure 10: Temperature-dependent 1H NMR spectra of an equimolar 50 / 5 mixture in
CDCl3; a: T-NH, b: A-NH2.
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Figure 11: Temperature dependence of the T-NH resonance of 5 within equimolar mixtures
of a: 50 / 5, b: 51 / 5 and c: 5 / 5 in CDCl3.
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3.4 Investigation of hydrogen bonding between 51 and
3´,5´-diacetyl-2´-deoxyuridine (52) within a slow exchange regime
3.4.1 Low temperature 1H NMR spectroscopy
For a more detailed study of hydrogen bonding between 51 and the uridine derivative
3´,5´-diacetyl-2´-deoxyuridine (52) one- and two-dimensional 1H NMR spectroscopy at low
temperatures down to 128 K in a freon mixture206-208 was applied by Dr. K. Weisz at the Freie
Univesität, Berlin, Germany. At these low temperatures, any coexisting hydrogen-bonded
associates are in slow exchange which allows an analysis of the preferred association modes
of 51 with 52 by 1H,1H NOESY spectroscopy. No crosspeaks due to chemical exchange are
supposed to appear and thus the NOE contacts directly identify protons in close spatial
proximity. Recently, the preferred association modes within U / U homodimers and A / U
heterodimers have been established by this method.209,210
1H NMR measurements of a 1:2-mixture of 51 and 3´,5´-diacetyl-2´deoxyuridine (52)
were carried out in freon at various temperatures from 273 K down to 128 K (Figure 12).
Figure 12 shows that until 193 K only one uridine imino resonance at 11.7 ppm is present
which originates from hydrogen-bonded homodimers of 52. At 153 K additional uridine
imino resonances at 14.01 and 13.58 ppm are observable. At 128 K in total four different
uridine imino resonances with chemical shifts of 14.41, 14.01, 13.58 and 13.51 ppm (marked
as a, b, c, d in Figure 12) are observable which, based on NOE connectivities (see below),
must arise from hydrogen-bonded 51 / 52 pairs. In addition, at 128 K two uridine NH
resonances at 12.2 and 11.7 ppm are observable which originate from homodimers of 52209
(marked as e and f in Figure 12). The resonances at 13.51 (d) and 14.41 ppm (a) disappear
above 133 K indicating that they arise from kinetically labile associates, whereas the signals
at 13.58 (c) and 14.01 ppm (b) are in slow exchange already at 153 K, reflecting their relative
kinetic stability.
From the integrals of the NMR signals at 153 K it has been calculated that approximately
40 % of 52 are associated with 51 and that the remaining 60 % represent homodimers of 52.
With regard to the fact that two equivalents of 52 are present in the mixture this means that
approximately only 80 % of 51 are associated with 52 and that also free, non-hydrogen
bonded 51 is present in the mixture.
111
273 K
193 K
153 K
143 K
133 K
128 K
15.0 14.0 13.0 12.0 11.0 ppm
a b c
d
e f
Figure 12: Low field portions of 1H NMR spectra of a 51 / 52 (1 / 2) mixture in freon at
various temperatures; a: U-NH (14.41 ppm), b: U-NH (14.01 ppm),
c: U-NH (13.58 ppm), d: U-NH (13.51 ppm), d: U-NH (12.2 ppm),
U-NH (11.7 ppm).
In order to establish the association geometries of the hydrogen-bonded 51 / 52 pairs a
1H,1H NOESY spectrum was recorded at 128 K in freon (Figure 14). In 51 / 52 pairs with
Hoogsteen or reverse Hoogsteen geometry crosspeaks of the uridine NH proton of 52 with the
A-NH2 protons and the A-H8 proton of 51 should appear (Figure 13). A-H8 resonances can
be identified by their NOE contacts with the H1´, H2´and H3´-sugar protons.
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Figure 13: Expected NOE contacts within a 51 / 52 pair with a) Hoogsteen and b) reverse
Hoogsteen geometry; a = NH2CH3, R1 = cyclohexylmethyl, R2 = 2´,3´,5´-tris-
(tert-butyldimethylsilyl)-ribose, R3 = 3´,5´-diacetyl-2´deoxyribose.
Figure 14 shows portions of the 1H, 1H NOESY spectrum of a 51 / 52 mixture in freon at
128 K. The uridine NH resonance at 13.58 ppm exhibits crosspeaks to the A-H8 resonance at
8.35 ppm and to A-NH2 resonances at 8.69 and 9.18 ppm. The U-NH resonance at 14.01 ppm
exhibits crosspeaks to the A-H8 resonance at 8.78 ppm and to A-NH2 resonances at 8.98 and
9.64 ppm. The resonances at 8.35 and 8.78 ppm have been identified as A-H8 resonances
through their crosspeaks to H1´, H2´ and H3´-sugar protons (Figure 14). Based on these NOE
connectivities the uridine imino resonances at 13.58 ppm and 14.01 ppm have tentatively
been assigned to arise from hydrogen-bonded 51 / 52 pairs with Hoogsteen and reverse
Hoogsteen geometry. A differentiation between these two geometries is not possible on the
basis of the NOE connectivities.
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Figure 14: Portions of the NOESY spectrum of the 51 / 52 mixture in freon at 128 K.
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The kinetically labile U-NH resonances at 13.51 and 14.41 ppm must arise from U-NH
protons which are engaged in strong hydrogen bonding interactions (stronger than formed
within 52 homodimers) as they appear at rather low field These resonances exhibit no
crosspeaks to exocyclic A-NH2 resonances of 51 but only a crosspeak to a resonance at
8.55 ppm. This resonance at 8.55 ppm is tentatively assigned to the A-H2 resonance of 51 as
it shows no crosspeaks to sugar protons. The only crosspeak is to a resonance at 4.1 ppm,
which is tentatively assigned to the resonance for the amino protons of the methylamine
ligands. At first glance, the presence of crosspeaks between the resonance at 8.55 ppm and the
two uridine imino resonances at 13.51 and 14.41 ppm is not immediately evident. One
possible explanation could be hydrogen bond formation between a uridine NH proton and the
O4 atom of the CHMT ligand in 51 (Figure 15). Platination of the N3 position of thymine
increases the pKa value of the T-O4 position significantly94-98 and therefore increases its
hydrogen bond accepting ability. Thus, a hydrogen bond between a uridine NH and O4 of the
CHMT ligand should be comparatively strong which would account for the observed
low-field shift of the uridine NH resonance. Furthermore, the presence of such a hydrogen
bond could explain the observed crosspeak between the putative A-H2 resonance at 8.55 ppm
and the two uridine NH resonances at 13.51 and 14.41 ppm. An associate like the one
depicted in Figure 15 would be stabilized by only one hydrogen bond, which would explain
its kinetic lability.
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Figure 15: Possible hydrogen bond between the uridine NH of 52 and O4 of the CHMT
ligand within 51; a = NH2CH3, R1 = cyclohexylmethyl, R2 = 2´,3´,5´-tris-(tert-
butyldimethylsilyl)-ribose, R3 = 3´,5´-diacetyl-2´deoxyribose.
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The resonance at 8.11 ppm is, based on its NOE contacts to the sugar protons (Figure 14),
unambiguously assigned to a A-H8 resonance. As it exhibits no crosspeak to uridine NH
resonances it is assigned to the A-H8 resonance originating from free, non-hydrogen bonded
51. Thus, 51 is not quantitatively associated with 52.
3.4.2 Determination of the 1JNH coupling constant
15N labelled uracil derivatives can be used to probe hydrogen bonding interactions, since
the 1JNH coupling constant is a direct measure for the strength of a hydrogen bond. There is a
strong linear correlation between the chemical shift of the imino proton and the 1JNH coupling
constant for imino groups hydrogen-bonded to a nitrogen acceptor.211 Normally, the 1JNH
couplings range from approximately -84 to -89 Hz.211 A decrease in the absolute size of the
1JNH coupling correlates with a downfield shift of the imino proton and indicates a gradual
shift of the proton from the donor to the acceptor with a concomitant lengthening of the
covalent NH bond.211 Variations of approximately 4 Hz upon hydrogen bond formation have
been observed so far.212-214 For an adenine-uracil base pair analogue in chloroform, the
formation of the base pair resulted in a decrease in |1JNH| from 91.3 to 87.5 Hz.215
In a mixture of 51 and 3-15N-labelled 3´,5´-diacetyl-2´deoxyuridine in freon at 133-138 K
a 1JNH coupling constant of 87.6 Hz has been determined for both the putative Hoogsteen and
reverse Hoogsteen base pair geometries. This compares with a 1JNH coupling constant of
84 Hz measured for the unplatinated Hoogsteen A / U pair.210 Low temperature 1H NMR
studies in freon show furthermore that the uridine NH resonances of both the 51 / 52
Hoogsteen and reverse Hoogsteen pairs appear at higher field than the uridine NH resonance
of the unplatinated Hoogsteen A / U pair.210 Both observations are consistent with a decrease
of the strength of the hydrogen bond between N7 of 51 and NH of 52 compared to the
unplatinated Hoogsteen A / U pair. This result was not unexpected in that coordination of the
Pt(II) electrophile at the A-N1 position in 51 decreases the basicity of the A-N7 position and
thus diminishes its hydrogen bond accepting ability. Information on the strength of the
hydrogen bond between the exocyclic A-NH2 protons and a carbonyl group of the uracil base
within 52 is, unfortunately, not available. For a quantitative evaluation of the strength of this
hydrogen bond a 15N label has to be introduced into the exocyclic amino group. In this case,
the 1JNH coupling constant would be a measure for the hydrogen bond strength between the
protons of the exocyclic amino group and O2 or O4 of 52.
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Table 7: 1JNH coupling constants in an unplatinated Hoogsteen A / U pair and a 51 / 52 pair
1JNH δ (ppm) U-NH
A / U (H) 84 Hz210 14.32210
51 / 52 (H, rH) 87.6 Hz 13.58, 14.01
4 Discussion
Concentration-dependent 1H NMR measurements in chloroform at room temperature
suggest that in the presence of 50, 1-N-cyclohexylmethylthymine (5) undergoes self-
association rather than Hoogsteen or reverse Hoogsteen pairing with 50. The concentration-
dependent shift of the T-NH resonance of 5 in the 50 / 5 mixture is of the same order of
magnitude as for pure 5 in CDCl3.
Similarly, temperature-dependent 1H NMR measurements in CDCl3 show that down to
220 K in the presence of 50 and 51, 1-N-cyclohexylmethylthymine (5) undergoes self-
association rather than forming hydrogen bonds to 50 and 51. The temperature-dependent
shift of the T-NH resonance in the 50 / 5 and the 51 / 5 mixtures is again of the same order of
magnitude as for pure 5.
In agreement with this observation, low temperature 1H NMR measurements of a 51 / 52
mixture in freon only show homodimers of 52 up to 193 K. Only below 153 K two kinds of
hydrogen-bonded 51 / 52 heterodimers have been detected in addition to homodimers of 52.
The 51 / 52 heterodimers have, based on NOE connectivities, tentatively been assigned as 51 /
52 pairs with Hoogsteen and reverse Hoogsteen geometry. Below 143 K two additional
kinetically labile uridine NH resonances appear which cannot be assigned unambiguously.
From these low temperature measurements it is furthermore evident that 51 is not
quantitatively associated with 52 but that a small amount of free 51 is present.
One feature which could effect the formation of hydrogen bonds between 50 and 5 as
well as between 51 and 52 could be the formation of ion pairs of 50 and 51 with their
respective counterions. It is feasible that in CDCl3, the nitrate and tetrafluoroborate
counterions are not well solvated and rather hydrogen-bonded to the protons of the exocyclic
amino groups in 50 and 51, respectively. In this case, hydrogen bond formation between 50
and 5 as well as between 51 and 52 would be hindered, so that indeed self-association of 5
would prevail. Furthermore, it is known that the dielectric constant of freon mixtures
significantly increases at very low temperatures.216 If at these low temperatures the increased
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polarity of the solvent leads to a better solvation of the BF4- counter ion, the observed
existence of hydrogen-bonded 51 / 52 heterodimers at 153 K could be rationalized.
In conclusion, the question has to be raised if the conditions applied are appropriate for a
detection of hydrogen bonds of the N1-platinated adenine derivatives 50 and 51 to the
thymine and uridine derivatives 5 and 52. Hydrogen bond formation in CDCl3 can, in
principle, also be troubled by residual traces of water, which can never be completely
removed. However, if relevant, this problem should also effect pairing between the free bases
48 and 5. This is apparently not the case.
The ultimate way to gain information on the alteration of the Hoogsteen hydrogen
bonding strength within a N1-platinated adenine / thymine pair compared to a non-platinated
A / T pair, would be to introduce a 15N label into the exocyclic amino group of the N1-
platinated adenine derivative. In this case, the absolute value of the 1JNH coupling constant
would reflect the strength of the hydrogen bond between the protons of the exocyclic amino
group and T-CO(4). It could be estimated to what extent the expected increase of the
hydrogen bond strength compensates the observed weakening of the hydrogen bond between
A-N7 and uridine NH. In this way, information on the overall change of the hydrogen bond
strength in a N1-platinated adenine / thymine pair would be available.
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C Experimental Section
1 Starting compounds and general procedures
K2PtCl4 was purchased from Heraeus. Trans-[Pt(NH3)2Cl2],217 trans-
[Pt(NH2CH3)2Cl2],218 trans-[Pt(NH3)2(1-MeT)Cl]80, 1-N-cyclohexylmethylthymine (5)133
1-N-methylthymine,219 9-N-cyclohexylmethyladenine (48)220 and 2´,3´,5´-tris-(tert-
butyldimethylsilyl)-adenosine (49)221 have been synthesized according to literature
procedures. Bromomethylcyclohexane was from Fluka, adenine and thymine have been
purchased from Acros and Aldrich, respectively. Oligonucleotides were synthesized in the
group of Prof. J.H. van Boom, Leiden University, Leiden, The Netherlands, or purchased from
Oswel, Southampton, England. Methanol, DMF and dioxane were dried over molecular sieves
(3 Å and 4 Å) prior to use. Acetonitrile used for HPLC was HPLC grade. All other chemicals
were p.a. grade and used without further purification. Deutrated solvents were purchased from
Sigma and Deutero. All reactions involving silver nitrate or silver tetrafluoroborate were
carried out under exclusion of daylight. Millipore water was obtained using a MilliQ Plus
apparatus.
Compounds for which an elemental analysis is not reported were fully characterized by
NMR and ESI MS.
Automated DNA synthesis was carried out on a Gene Assembler Special DNA
synthesizer (Pharmacia, Sweden) according to the phosphoramidite method.130 Protected
nucleoside phosphoramidites were obtained from PerSeptive Biosystems (USA).
Deoxyribonucleoside building blocks immobilized on CPG were obtained from PerSeptive
Biosystems (30 µmol / g). O-NPT was synthesized according to a published procedure.222
Solid-phase PNA synthesis was performed on a 433A Peptide Synthesizer (Applied
Biosystems) using as the solid-support PEG-PS resin functionalized with a RINK linker or on
a Pharmacia Gene Assembler using highly cross-linked polystyrene beads as the solid-support.
Fmoc / N-acyl protected PNA monomers were provided by the group of Prof. J. H. van Boom.
The Fmoc / N-Bhoc protected PNA monomers were obtained from PE Biosystems. Fmoc /
Boc protected L-lysine was from NovaBiochem. TFA and m-cresol were from Fluka.
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2 Analytical methods
NMR spectroscopy
1H NMR spectra were recorded on Bruker DPX 300 (300.13 MHz) or DMX 600
(600.13 MHz) spectrometers using a 5 mm multi-nucleus probe. A variable temperature unit
was used to keep the temperature constant. Chemical shifts (δ) are given in ppm relative to
tetramethylsilane (TMS), when measured in CDCl3 or sodium-3-
(trimethylsilyl)propansulfonate (TSP), when measured in D2O. 13C NMR spectra were
recorded on a Bruker DPX 300 spectrometer (75.48 MHz) and calibrated externally to TMS.
31P NMR spectra were measured on a Bruker DPX 300 spectrometer (121.50 MHz) using
85 % H3PO4 as external standard. 195Pt NMR spectra were recorded on a Bruker DPX 300
spectrometer (64.38 MHz) using K2PtCl4 (δ = -1614 ppm) as an external standard.
Concentration-dependent 1H NMR measurements and determination of the association
constant
In the dilution experiments a 1:1 mixture of the two components in CDCl3 was diluted
stepwise in the concentration range 80 – 5 mM and each time a 1H NMR spectrum was
recorded. The measurements were carried out at 296 K under argon atmosphere in deuterated
chloroform that had been dried over 4 Å molecular sieves. The added amount of CDCl3 was
weighed every time. The concentration-dependent shift of the NH protons involved in
hydrogen bonding were fitted with a non-linear least squares program after Newton-
Gauss.177,223 Three independent dilution experiments were performed and evaluated for each
system.
Measurement of pH / pD values
pH measurements were carried out at 298 K with a Radiometer PHM 80 pH meter using a
Hamilton combination glass electrode. The pH meter was calibrated with Fischer-certified
buffer solutions of pH 4.00, pH 7.00 and pH 11.00.
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The pD value of solutions in D2O was calculated by addition of 0.4 units to the measured
value (pD = pH* + 0.4).224 For determination of pKa values the uncorrected pH value (pH*)
was used.
UV spectroscopy
UV spectra were measured on a Lambda 15 Perkin-Elmer spectrometer. Melting curves
were measured using heatable quartz cuvetts. The heating rate was 1 °C min-1.
ESI mass spectrometry and LC MS
ESI mass spectra were recorded on a Finnigan MAT TSQ-70 instrument equipped with a
custom-made Electrospray interface. LC MS analysis was carried out on a Jasco LC MS
system with mass detection on a Perkin Elmer Sciex API 165 equipped with an Electrospray
Interface. In both cases positively charged ions were detected.
The ESI MS spectrum of the trans-(NH3)2Pt(II) crosslinked triple helix 4 was measured
on a Finnigan LCQ Deca instrument. Negatively charged ions were detected.
MALDI-TOF mass spectrometry
MALDI TOF MS spectra were obtained on a PE-Biosystems Voyager DE-PRO MALDI-
TOF mass spectrometer, equipped with delayed extraction and a reflector. Samples were
irradiated with short pulses of a nitrogen laser emitting at 337 nm. The matrix used was 3-
hydroxy-picolinic acid (3-HPA). The matrix solution consisted of 8/1 3-HPA (10 mg/ml in
water/acetonitrile 1/1) / diammonium citrate (50 mg/ml in water). The samples were diluted to
10 pmol/µl  and mixed 1/1 with matrix solution. 1 µl of this solution was put on the target and
allowed to dry.
Elemental analysis
Elemental analysis was carried out on an Elemental Analyzer CHNS-932 (LECO) or
1106 (Carlo Strumentazione).
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HPLC / FPLC
HPLC analysis and purifications were carried out on a Jasco HPLC system. FPLC
analysis was carried out on a Pharmacia FPLC instrument using a MonoQ column. FPLC
Buffers (pH 12): A, 100 mM NaOH; B, 100 mM NaOH in 1.2 M NaCl.
Gel electrophoresis
Gel electrophoresis was carried out on a 24% Acrylamide/Bisacrylamide gel (19:1) under
denaturing conditions (7 M urea, 1 M Tris-Borate-EDTA Buffer, 3 h, 3000 V).
3 Synthesis
Trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}{(5´d(G-N7-A2GAG2AGCT2GCTC2TCT2C)}]27-
(4)
5.89 x 10-4 mmol of trans-[Pt(NH3)2Cl(D2O)]+NO3-, obtained in situ by reaction of
trans-[Pt(NH3)2Cl2] with one equivalent of AgNO3 in water at RT overnight,89 was reacted
with 1.66 mg (5.89 x 10-4 mmol) of 5´d(GT2CTC2TC) (1) at pH* 3.2 at RT in D2O to yield
after 48 h trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7- (2). Compound 2 was lyophilized and
reacted with 6.35 mg (8.84 x 10-4 mmol) of 5´d(GA2GAG2AGCT2GCTC2TCT2C)21- (3) at
pH* 4.8 at RT in 1.5 ml of a 100 mM NaClO4 and 5 mM Mg(ClO4)2 solution. After 72 h the
reaction was complete and yielded
trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}{(5´d(G-N7-A2GAG2AGCT2GCTC2TCT2C)}]27- (4)
as the major product. Compound 4 was isolated by reversed-phase HPLC using an Alltech
Alltima C18 5µ (10 x 250 mm) column. A gradient elution (11→19 % B in 40 min) was
applied by building up a gradient starting with buffer A (50 mM TEAA) and applying buffer
B (50 mM TEAA in 75 % acetonitrile) with a flow rate of 5 ml/min. Subsequently, 4 was
converted into the Na+ form by running it over a Dowex column.
ESI MS: m/z 1597 (M6-/6), 1917 (M5-/5), 2396 (M4-/4).
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1-N-cyclohexylmethylthymine (5)
6.076 g (48.2 mmol) of thymine and 6.667 g (48.2 mmol) of K2CO3 were suspended in
150 ml of DMSO and stirred for 1 h at room temperature. 2.224 ml (15.9 mmol) of
bromomethylcyclohexane was added and the reaction mixture stirred for 3 h at 70° C and then
for 14 h at RT. KBr was removed by filtration. 200 ml of water were added to the filtrate and
the solution was extracted 3 times with 150 ml of dichloromethane. Purification of the crude
product by silica gel chromatography (eluent: dichloromethane/methanol, 100 / 0 to 97.5 / 2.5,
v / v) afforded 1.68 g (47 %) pure 1-N-cyclohexylmethylthymine (5).
1H NMR (CDCl3, δ, ppm): 8.42 (s, N(3)H), 6.93 (d, 4J = 1.12 Hz, H6), 3.52 (d, 3J = 7.11 Hz,
T-N1-CH2), 1.92 (d, 4J = 1.07 Hz, T-5-CH3), 1.70, 1.21, 0.96 (m, cyclohexylmethyl)
13C NMR (CDCl3, δ, ppm): 164.24 (C-4), 151.1 (C-2), 141.0 (C-6), 110.05 (C-5), 54.52
(CH2N), 37.29, 30.36, 26.14, 25.52, (cyclohexyl), 12.30 (T-5-CH3);
ESI MS: m/z 223 (M+);
elemental analysis: found (calculated): C: 64.7 (64.8), H: 8.1 (8.1), N: 12.5 (12.6).
K(1-N-cyclohexylmethylthyminate) (6)
To a suspension of 0.799 g (3.594 mmol) 1-N-cyclohexylmethythymine in 20 ml
millipore water was added 0.2015 g (3.591 mmol) of potassium hydroxide (KOH) and 30 ml
of ethanol. The solution was stirred for 1 h at RT and subsequently the solvents were
evaporated. The residue was dissolved in dioxane / water (1/1, v/v) and freeze-dried to yield
0.908 g (97 %) of K(1-N-cyclohexylmethylthyminate) (6).
Trans-[Pt(NH2CH3)2(CHMT)Cl] (7)
To 0.502 g (1.531 mmol) of trans-[Pt(NH2CH3)2Cl2] in 30 ml of DMF was added 0.247 g
(1.454 mmol) of AgNO3 and the reaction mixture stirred overnight. AgCl was filtered off and
0.4402 g (1.691 mmol) of K(CHMT) (6) was added. The reaction mixture was stirred at RT
for 3 d. DMF was largely removed in vacuo. Addition of diethylether lead to isolation of
0.555 g (70.5 %) of analytically pure trans-[Pt(NH2CH3)2(CHMT)Cl] (7).
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1H NMR (CDCl3, δ, ppm): 6.85 (d, 4J = 1.01 Hz, H6), 4.19 (s, Pt-NH2), 3.52 (d, 3J = 7.20 Hz,
T-N1-CH2), 2.37 (t, 3J = 6.51 Hz, Pt-NH2CH3), 1.89 (d, 4J  = 0.86 Hz, T-5-CH3), 1.75, 1.21,
0.96 (m, cyclohexyl);
195Pt NMR (CDCl3, δ, ppm): - 2338;
IR (ν, cm-1): 3272, 3193, 3107, 2928, 2851, 1664, 1633, 1571, 1461, 1438, 1354, 1097, 774,
586, 464, 337;
ESI MS: m/z 515 (M+);
elemental analysis: found (calculated): C: 32.7 (32.7), H: 5.3 (5.3), N: 11.0 (10.9).
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8)
To 0.259 g (0.504 mmol) of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in 30 ml of methanol
and 20 ml of H2O was added 0.0612 g (0.522 mmol) of 6-amino-1-hexanol and the reaction
mixture was stirred for 3 d at 60 °C under argon atmosphere. The solvents were removed in
vacuo and the residue washed with boiling diethylether to remove residual 6-amino-1-
hexanol. This procedure yielded 0.222 g (70 %) analytically pure 8.
1H NMR (CDCl3, δ, ppm): 6.85 (d, 4J = 0.78 Hz, H6), 6.06 (m, NH2 (ahol)), 5.02 (m, Pt-
NH2), 3.64 (t, 3J = 6.23 Hz, α-CH2 (ahol)), 3.50 (d, 3J = 6.97 Hz, NCH2(CHMT)), 2.86 (m, ξ-
CH2 (ahol)), 2.39 (t, 3J = 6.12 Hz, Pt-NH2CH3), 1.80 (T-5-CH3), 1.98, 1.67, 1.44, 1,20, 0.90,
(m, ahol, cyclohexyl);
195Pt NMR (δ, ppm): - 2607 (CD3OD), -2597 (CDCl3);
ESI MS: m/z 595 (M+);
IR (ν, cm-1): 3179, 2923, 2852, 1661, 1633, 1558, 1539, 1455, 1346, 1329, 1084, 1054, 1027,
1004, 787, 589, 496, 451.
Trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9)
To a solution of 0.130 g (0.253 mmol) of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in 10 ml
DMF was added 0.047 mg (0.241 mmol) of AgBF4 and the reaction mixture stirred for 7 h.
AgCl was filtered off and 0.018 g (0.240 mmol) of glycine in a small amount of water was
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added. The reaction mixture was stirred for 2 d at RT. After removal of DMF in vacuo 0.106 g
(65.8 %) of analytically pure trans-[Pt(NH2CH3)2(CHMT)(gly-N) ]+BF4- (9) were obtained.
1H NMR (CD3OD, δ, ppm): 7.25 (d, 4J = 1.0 Hz, H6), 5.22 (m, NH2 (gly)), 4.57 (m, Pt-NH2),
3.58 (d, 3J = 7.21 Hz, NCH2(CHMT)), 3.51 (s, CH2 (gly)), 2.26 (t, 3J = 6.2 Hz, Pt-NH2CH3),
1.86 (d, 4J = 0.83 Hz, T-5-CH3), 1.73, 1.19 ,1.013 (m, cyclohexylmethyl);
195Pt NMR (CD3OD, δ, ppm): - 2605;
IR (ν, cm-1): 3178, 2924, 2852, 1661, 1634, 1557, 1540, 1455, 1346, 1084, 1054, 1027, 1004,
782, 587, 496, 451;
ESI MS: m/z 553 (M+);
elemental analysis: found (calculated): C: 30.9 (30.0), H: 5.3 (5.0), N: 11.4 (10.9).
Trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10)
To a suspension of 0.115 g (0.285 mmol) of trans-[Pt(NH3)2(1-MeT)Cl] in 10.5 ml H2O
was added 0.044 g (0.259 mmol) of AgNO3 and the reaction mixture was stirred for 17 h at
40 °C. AgCl was filtered off and 0.016 g (0.213 mmol) of glycine was added. The reaction
mixture was stirred for 72 h at 60 °C with the pH being kept at 7.5 by addition of KOH
solution. After filtration, the reaction mixture was lyophilyzed and the residue recrystallized
from a mixture of water and acetone to give 0.088 g (70 %) of analytically pure
trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3- (10).
1H NMR (D2O, δ, ppm): 7.27 (d, 4J = 0.96 Hz, H6), 4.95 (s, NH2(gly)), 3.83 (s, Pt-NH3), 3.41
(t, 3J = 6.5 Hz, CH2(gly)), 3.30 (s, T-N1-CH3), 1.81 (s, T-5-CH3);
195Pt NMR (D2O, δ, ppm): - 2557;
IR (ν, cm-1): 3182, 2926, 2854, 1661, 1634, 1557, 1442, 1354, 1051, 773, 606, 464.
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-O-DMTr}]+ (13)
To a solution of 8.5 mg (13.5 µmol) of trans-
[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) in dioxane was added 13 µmol of 5´-O-
DMTr-deoxythymidine-3´-phosphoramidite (12) and o-NPT (53.5 µmol) in acetonitrile. After
10 min an aqueous solution of I2/collidine was added. The solvents were removed and the
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residue dissolved in 1000 µl methanol containing 200 µl of concentrated aqueous ammonia.
After 10 h at 20 °C, the sample was freeze-dried and purified by reverse-phase HPLC (Alltima
C 18 column, 50 mmol aqueous ammonium bicarbonate/acetonitrile buffer, gradient: 40-
70 % acetonitrile) to give trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-O-
DMTr}]+ (13).
1H NMR (CD3OD, δ, ppm): 7.68 (s, H6, (dT)), 7.42, 7.30, 7.23, 6.87 (m, DMT) 7.24 (s, H6,
(CHMT)), 6.38 (dd, 3J = 5.80 Hz, 3J = 8.29 Hz, H1´), 5.02 (t, H3´), 4.50 (m, Pt-NH2), 4.26 (q,
H4´), 3.82 (t, 3J = 6.1 Hz, α-CH2 (ahol)), 3.77 (s, OCH3), 3.58 (d, 3J = 7.25 Hz,
NCH2(CHMT)), 3.43 (m, H5´, H5´´), 2.77 (m, ξ-CH2 (ahol)), 2.58 (m, H2´´), 2.46 (m, H2´),
2.26 (t, 3J = 6.5 Hz, Pt-NH2CH3), 1.87 (s, T-5-CH3 (CHMT)), 1.30 (s, T-5-CH3 (dT)), 1.66
1.44, 1.22, 0.89 (m, ahol, cyclohexylmethyl);
195Pt NMR (CD3OD, δ, ppm): δ = -2621;
31P NMR (CD3OD, δ, ppm): δ = 0.18;
LC MS: m/z = 1201.5 (M+).
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-OH}]+ (14)
To the purified trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-O-DMTr}]+
(13) was added 800 µl of concentrated acetic acid and the reaction mixture was shaken for 1 h
at RT. The sample was freeze-dried and to the residue 500 µl of millipore water was added.
Subsequently, the sample was freeze-dried again and 500 µl of millipore water were added.
The supernatant solution was removed and freeze-dried. This procedure yielded pure
trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-OH}]+ (14).
ESI MS: m/z 900 (M+).
Trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)-dT-5´-OH}Cl]+ (15)
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-OH}]+ (14) was subjected to
DCl (pD 2.2, 40 °C) to yield trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)-dT-5´-OH}Cl]+ (15)
after 108 h.
195Pt NMR: -2312 ppm;
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ESI MS: m/z 713 (M+).
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)dT4-3´-OH}]+ (22) and
Trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)d(T3CTC2TC)-3´-OH}]+ (23)
Immobilized dT4 (16) and 5´d(T3CTC2TC) (19) (0.2 µmol) were synthesized on a Gene
Assembler (Pharmacia) following a standard protocol130 and phosphitylated by treating it
twice for 30 min with a 1.0 M 11 / 1.2 M DiPEA solution in acetonitrile. The immobilized 5´-
phosphoramidites 16b and 19b were reacted with
trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl- (8) [15 µmol, 0.05 M solution in
dioxane/acetonitrile (1/1)] in the presence of o-NPT (30 µmol, 0.2 M solution in acetonitrile).
Decyanoethylation and release from the solid-support were achieved by treatment with
concentrated aqueous ammonia for 12 h at 20 °C.
LC-MS analysis of the crude products was carried out on a PE Sciex API 165 mass unit
connected to a Jasco HPLC system. HPLC analysis was performed using a Merck
LiChrosphere 100 RP18 column (pore size 5 µm, diameter 4 mm, length 250 mm) and 10 mM
aqueous ammonium acetate / acetonitrile (gradient: 5-50% acetonitrile) buffer.
As for conjugation of 8 to 16a, the coupled product 22 was found in the ESI MS at m/z
1812 (M+) and 906 (M2+/2). Additionally, tetrathymidylic acid and the corresponding
5´amidate 16b were detected at m/z 1155.6 (M+) and m/z 1318.5 (M+), respectively.
As for conjugation of 8 to 19a the coupled product 23 was found in the ESI-MS at m/z 1638
(M2+/2) and 1091.8 (M3+/3). Additionally, masses for d(T3CTC2TC)-5´phosphate and
d(T3CTC2TC)-5´OH have been detected at m/z 1349 (M2+/2) and 1309 (M2+/2), repectively.
Trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)dT4-3´-OH}Cl]+ (24) and
Trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)d(T3CTC2TC)-3´-OH}Cl]+ (25)
Compounds 22 and 23 have been subjected to pH 2.3 at 40 °C for 48 h yielding the
monofunctionally trans-Pt(II) modified tetranucleotide 24 and nonanucleotide 25 as evidenced
by LC MS.
ESI MS: 24: 1625.5 (M+), 813 (M2+/2); 25: 1545 (M2+/2)
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Trans-[Pt(NH2CH3)2(CHMT){NH2CH2CONH(CH2)6O(PO3H)d(T2CTC2TC)-3´-OH}]+
(29)
Fully protected 5´d(T2CTC2TC) was assembled on a 1.0 µmol scale and reacted with
MMTrHN(CH2)6OP{(OCH2CH2CN)N(iPr)2} (26) under the influence of o-NPT yielding,
after treatment with TCA, compound 28. Immobilized 28 was transferred into a syringe. A
solution of 15.71 mg (24.5 µmol) of trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9), 8.706 g
(22.9 µmol) of HATU and 50 µl of DiPEA in 450 µl DMF was added and the reaction
mixture was shaken for 2 h yielding immobilized 29. After washing with DMF and
dichloromethane 29 was deprotected and cleaved from the solid-support by treatment with
concentrated aqueous ammonia for 20 h at RT. The coupling yield was around 60 % as
gauged by LC MS. Compound 29 was purified by reversed-phase HPLC using an Alltima C18
column (5 µm pore size, length: 250 mm, diameter: 10.0 mm). A gradient elution
(14→22 % B in 5 CV) was performed by building up a gradient starting with buffer A
(50 mM TEAA) and applying buffer B (acetonitrile) with a flow rate of 1 ml/min.
ESI MS: m/z 1513 (M2+/2), 1009.7 (M3+/3).
Trans-[Pt(NH2CH3)2(CHMT)(NH2CH2CONHc5-gly)]+ (31)
Solid-phase PNA synthesis was performed on a Pharmacia Gene Assembler using highly
cross-linked polystyrene beads as the solid-support (loading 26 - 28 µmol/g) on a 1 µmol
scale. The support was functionalized with a glycine moiety via a 4-hydroxymethylbenzoic
acid linker. Assembly of c5 was performed using solutions of 0.3 M of Fmoc/N-acyl protected
PNA monomers in DMF, 0.3 M DiPEA in acetonitrile/DMF (1/1, v/v). Prior to coupling the
monomers were pre-activated for 1 min by mixing equal amounts of the PNA monomer (15
eq per µmol support), HATU and DiPEA solutions. The protocol for one PNA chain
extension cycle consisted of (1) wash: acetonitrile/DMF (1/1, v/v), 2.5 ml; (2) coupling: PNA
+ HATU + DiPEA in acetonitrile/DMF (1/1, v/v), 15 min; (3) wash: acetonitrile/DMF (1/1,
v/v), 2.5 ml; (4) capping: Ac2O/2,6-lutidine/N-methylimidazole/tetrahydrofuran (1/1/1/7,
v/v/v/v), 2.0 ml; (5) wash: acetonitrile/DMF (1/1, v/v), 2.5 ml. The immobilized fully
protected c5 (30) was transferred into a syringe and a solution of 15.71 mg (24.5 µmol) of
trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4- (9), 19.36 mg (22.9 µmol) HATU and 50 µl of a
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0.9 M DiPEA solution in DMF was added. The reaction mixture was shaken for 2 h. After
washing the solid-support with 3 ml of DMF and 3 ml of CH2Cl2 a capping procedure
(Ac2O/2,6-lutidine/N-methylimidazole/tetrahydrofuran (1/1/1/7, v/v/v/v)) was carried out
followed by washing with 3 ml of DMF and 3 ml of CH2Cl2. The resin was dried in the air.
Deprotection and cleavage of the platinated PNA oligomer (31) from the solid-support was
achieved by treatment with methanolic ammonia for 20 h at RT. Compound 31 was purified
by reversed-phase HPLC using an Alltima C18 column (5 µm pore size, length: 250 mm,
diameter: 10.0 mm). A gradient elution (10→25 %B in 5 CV) was performed by building up a
gradient starting with buffer A (50 mM TEAA) and applying buffer B (acetonitrile) with a
flow rate of 1 ml/min. The coupling yield was 36 % as gauged by LC MS.
ESI MS: m/z 1866.2 (M+), 933.2 (M2+/2).
Trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33)
To a solution of 0.049 g (0.163 mmol) of trans-[Pt(NH3)2Cl2] in 2.5 ml of DMF was
added 0.031 g (0.159 mmol) of AgBF4 and the reaction mixture stirred overnight at RT. AgCl
was removed by filtration and 0.119 g (0.160 mmol) of Fmoc/N-Bhoc G PNA monomer (32)
was added. After stirring for 1 d at RT, DMF was removed in vacuo yielding 0.151 g (84 %)
of crystalline trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33).
1H NMR (DMF-d7, δ, ppm): 8.83 (ma), 8.81 (mi) (H8, rotamers), 8.0-6.98 (m, Fmoc, Bhoc),
5.51 (ma), 5.30 (mi) (G-N9-CH2, rotamers), 4.30, (m, Pt-NH3);
195Pt NMR (DMF-d7,δ, ppm): = -2289;
ESI-MS: m/z: 1006 (M+);
elemental analysis: found (calculated): C: 43.9 (43.8), H: 3.8 (3.8), N: 11.5 (11.8).
Trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34)
To a solution of 0.053 g (0.103 mmol) of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in 3 ml of
DMF was added 0.019 g (0.098 mmol) of AgBF4 and the reaction mixture stirred overnight at
RT. After removal of AgCl by filtration 0.074 g (0.100 mmol) of Fmoc/Bhoc-PNA G (32)
was added to the filtrate and the reaction mixture stirred for 2 d at RT. DMF was removed in
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vacuo to give 0.108 g (80 %) of crystalline
trans-[Pt(NH2CH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4- (34).
195Pt NMR: (DMF-d7, δ, ppm):- 2476;
ESI-MS: m/z 1219 (M+);
elemental analysis: found (calculated): C: 49.3 (49.6), H: 4.7 (4.8), N: 12.0 (11.8).
Monofunctionally trans-Pt(II) modified PNA oligomers 43, 44 and 45
Solid-phase PNA synthesis was performed on a 433A Peptide Synthesizer (Applied
Biosystems) using as the solid-support PEG-PS resin functionalized with a RINK linker
(loading 0.2 mmol/g) on a 1 µmol scale. Assembly of the monofunctionally trans-Pt(II)
modified PNA oligomers 43, 44, and 45 was performed using solutions of 0.1 M Fmoc/N-
Bhoc protected PNA monomers (and Fmoc / Boc protected L-lysine in case of 44) and
trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4- (33) in NMP. Prior to coupling the monomers
were pre-activated for 1 min by mixing equal amounts of the PNA monomer (25 eq per µmol
support), HATU and DiPEA solutions. At the beginning of the PNA assembly the Rink-
functionalized PEG-PS resin was washed with CH2Cl2 (5 x 2 ml) and NMP (5 x 1.5 ml). The
protocol for one PNA chain extension cycle constisted of (1) Fmoc deprotection: 20 %
piperidine in NMP (1 ml, 1 x 1 min, 4 x 0.5 min), (2) wash: NMP (5 x 1.5 ml), (3) coupling:
PNA + HATU + DiPEA in NMP, 15 min; (4) wash: NMP (5 x 0.5 ml) (5) capping:
0.5 M Ac2O/0.125 M DiPEA in NMP, (6) wash: NMP (5 x 0.5 ml). At the end, a final Fmoc
protection was carried out (20 % piperidine in NMP (1 ml, 1 x 1 min, 4 x 0.5 min)) followed
by a final wash (5 x 1.5 ml NMP, 5 x 2 ml CH2Cl2). The resin was air-dried. Deprotection and
cleavage from the solid-support was accomplished by treatment with TFA/m-cresol (4/1 v/v)
for 1 h. LC-MS analysis of the crude products was carried out on a PE Sciex API 165 mass
unit connected to a Jasco HPLC system. HPLC analysis was performed using an Alltech
Alltima C18 column (pore size 5 µm, diameter 4.6 mm, length 150 mm). A gradient elution
(0→25 %B in 30 min) was performed by building up a gradient starting with buffer A (1 %
TFA) and applying buffer B (1 % TFA in 75 % acetonitrile) with a flow rate of 1 ml/min.
Compounds 43, 44 and 45 were purified by reversed-phase HPLC using an Alltech Alltima
C18 5µ (10 x 250 mm) column. A gradient elution (9→16 %B in 40 min) was performed by
building up a gradient starting with buffer A (1 % TFA) and applying buffer B (1 % TFA in
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75 % acetonitrile) with a flow rate of 5 ml/min. The purity of compounds 43, 44 and 45 was
established by LC MS under the same conditions as used for analysis of the crude products.
ESI MS: 43: m/z 2215 (M+), 1108 (M2+/2), 739 (M3+/3)
44: m/z 1172 (M2+/2), 782 (M3+/3)
45: m/z 2741 (M+), 1371 (M2+/2), 914 (M3+/3)
Trans-[Pt(NH3)2(g-N7-attcgc){3´d(G-N7-TAAGCG)}]2+ (47)
2.572 x 10-8 mol of 43 were reacted with 5.145 x 10-8 mol of 5´d(GCGAATG) (46) in
500 µl of a 0.1 M NaClO4 solution at pH 6.5 at RT. In order to increase the solubility of 43,
100 µl of DMF were added and the reaction mixture left for 11 d at RT. Compound 47 was
purified by reversed-phase HPLC using an Alltech Alltima C18 5µ (4.6 x 150 mm) column. A
gradient elution (0→23 %B in 40 min) was performed by building up a gradient starting with
buffer A (50 mM TEAA) and applying buffer B (50 mM TEAA in 75 % acetonitrile) with a
flow rate of 5 ml/min.
MALDI-TOF MS: m/z 4325 (M+).
9-N-cyclohexylmethyladenine (48)
10.09 g (74.7 mmol) of adenine and 2.15 g (89.6 mmol) of NaH were suspended in
300 ml of DMF and stirred for 1 h at room temperature. 9.6 ml (69.3 mmol) of
bromomethylcyclohexane was added and the reaction mixture stirred for 3 h at 70 °C and then
for 14 h at RT. NaBr was removed by filtration over a glass filter. 200 ml water was added to
the filtrate and the solution extracted with methylene chloride (3 x 150 ml). The organic layer
was washed with water and the crude product purified by silica gel chromatography (eluent:
dichloromethane / methanol 100 / 0 to 95 / 5, v / v) to give 2.11 g (12.2 %) pure
9-N-cyclohexyladenine.
1H NMR (CDCl3, δ, ppm): 8.37 (s, H2), 7.75 (s, H8), 4.09 (d, A-N9-CH2), 5.61 (s, A-6-NH2)
13C NMR (CDCl3, δ, ppm): 155.59 (C-6), 152.94 (C-2), 150.29 (C-4), 140.88 (C-8) 119.58
(C-5), 50.0 (CH2N), 38.17, 30.58, 26.09, 25.46 (cyclohexyl);
ESI MS: m/z 232 (M+);
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elemental analysis: found (calculated): C: 62.3 (62.4), H: 7.4 (7.4), N: 30.3 (30.4).
Trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3- (50)
To a solution of 0.189 g (0.368 mmol) of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in 11 ml of
DMF was added a solution of 0.060 g (0.353 mmol) of AgNO3 in 4 ml DMF and the reaction
mixture was stirred for 6 h. AgCl was filtered off and 0.086 g (0.372 mmol) of 9-N-
cyclohexylmethyladenine (48) was added and the reaction mixture stirred for 24 h. DMF was
largely removed in vacuo and the product was recrystallized in methanol / diethylether (1/20,
v/v) to give 0.100 g (35 %) of analytically pure trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3-
(50).
1H NMR (CD3OD, δ, ppm): 9.04 (s, A-H2), 8.19 (s, A-H8), 7.35 (d, 4J = 0.95 Hz, T-H6), 4.55
(m, Pt-NH2), 4.11 (d, 3J = 7.22 Hz, A-N9-CH2), 3.64 (d, 3J = 6.82 Hz, T-N1-CH2), 1.92 (d, 4J
= 0.58 Hz, T-5-CH3), 2.15 (t, 3J = 6.24 Hz, Pt-NH2-CH3); 1.70, 1.22, 1.06 (m, cyclohexyl);
1H NMR (CDCl3, δ, ppm): 9.074 (s, A-6-NH2), 8.69 (s, A-H2), 7.63 (s, A-H8), 6.91 (s, T-H6),
5.13, 4.50 (m, Pt-NH2), 3.94 (d, 3J = 7.09 Hz, A-N9-CH2), 3.65 (d, 3J = 6.73 Hz, T-N1-CH2),
1.70 (s, T-5-CH3), 2.21 (t, 3J = 6.20 Hz, Pt-NH2-CH3); 1.75, 1.22, 1.06 (m, cyclohexyl);
1H NMR (DMF-d7, δ, ppm): 9.30 (s, A-6-NH2), 8.85 (s, A-H2), 8.44 (s, A-H8), 7.38 (s, T-
H6), 5.11 (m, Pt-NH2), 4.15 (d, A-N9-CH2), 3.50 (d, T-N1-CH2), 2.24 (t, 3J = 6.10 Hz, Pt-
NH2-CH3), 1.82 (s, T-5-CH3), 1.70, 1.22, 1.06 (m, cyclohexyl);
13C NMR (CD3OD, δ, ppm): 157.6 (A-C6), 155.3 (A-C2), 149.4 (A-C4), 144.5 (A-C8), 120.5
(A-C5), 51.1 (A-C9), 109.8 (T-C5), 143.0 (T-C6), 174.0 (T-CO(4)), 159.0 (T-CO(2));
195Pt NMR (δ, ppm): - 2594 (DMF-d7), -2584 (CD3OD), -2599 (CDCl3);
ESI MS: m/z 709 (M+);
elemental analysis: found (calculated): C: 40.3 (40.5), H: 5.6 (5.8), N: 18.0 (18.2).
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Trans-[Pt(NH2CH3)2(CHMT)(TBS-ado)]+BF4- (51)
To a solution of 0.095 g (0.185 mmol) of trans-[Pt(NH2CH3)2(CHMT)Cl] (7) in 5 ml
DMF was added a solution of 0.034 g (0.175 mmol) of AgBF4 in 1 ml of DMF and the
reaction mixture was stirred for 10 h. AgCl was filtered off and 0.106 g (0.174 mmol) of TBS-
ado (49) was added. The reaction mixture was stirred for 48 h. DMF was removed in vacuo
and the residue recrystallized in diethylether / pentane to give 0.120 g (55.4 %) of analytically
pure trans-[Pt(NH2CH3)2(CHMT)(TBs-ado)]+BF4- (51).
1H NMR (CD3OD, δ, ppm): 9.05 (s, A-H2), 8.46 (s, A-H8), 7.32 (d, 4J = 1.02 Hz, T-H6), 6.06
(d, 3J = 5.55 Hz, H1´), 4.65 (m, Pt-NH2), 4.40 (t, 3J = 3.5 Hz, H3´), 4.16 (m, H4´), 4.07 (dd,
3J = 4.86 Hz, 2J = 11.31 Hz, H5´), 3.55 (dd, 3.85, 3J = 3.10 Hz, 2J = 11.31 Hz, H5´´), 3.64 (d,
3J = 7.05 Hz, T-N1-CH2), 2.11 (t, 3J = 6.0 Hz, Pt-NH2CH3), 1.91 (s, T-5-CH3), 1.80, 1.22 (m,
cyclohexyl) 0.90, 0.75, 0.09, 0.07, 0.06, 0.03 (s, TBDMS);
1H NMR (CDCl3, δ, ppm): 8.76 (s, A-6-NH2), 8.66 (s, A-H2), 8.43 (s, A-H8), 6.92 (s, T-H6),
5.95 (H1´), 4.47, 3.82 (m, Pt-NH2), 3.66 (dd, 3J = 7.10 Hz, 2J = 13.55 Hz, H5´), 3.52 (dd,
3J = 6.6 Hz, 2J = 13.55 Hz, H5´´), 2.27, 2.10 (t, 3J = 6.35 Hz, 3J = 6.03 Hz, Pt-NH2CH3), 1.92
(s, T-5-CH3), 0.90, 0.86, 0.10, 0.01, -0.02, (s, TBDMS);
13C NMR (CD3OD, δ, ppm): 157.7 (A-C6), 155.6 (A-C2), 148.9 (A-C4), 142.6 (A-C8), 121.5
(A-C5), 110.5 (T-C5), 142.9 (T-C6), 174.4 (T-CO(4)), 158.9 (T-CO(2)); 89,7 (C1´). 77.0
(C2´), 73.6 (C3´), 87.3 (C4´), 63.8 (C5´);
195Pt NMR (DMF-d7, δ, ppm): -2580;
IR (ν, cm-1): 3274, 2930, 2858, 1652, 1568, 1464, 1253, 1359, 1253, 1069, 1000, 836.1, 778,
670, 648, 591, 460;
elemental analysis: found (calculated): C: 42.6 (42.9), H: 6.8 (7.0), N: 10.7 (10.7).
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D Summary
The central aim of this thesis was to develop new methods for the synthesis of
monofunctionally trans-Pt(II) modified deoxyoligonucleotide or deoxyoligonucleotide
analogues by making use of solid-phase synthesis methodologies. A further aim was to assess
the potential application of these platinated oligonucleotide (analogues) in antigene and
antisense strategy. To this end, model crosslinking reactions with double- and single-stranded
deoxyoligonucleotide targets were carried out.
Chapter I demonstrates the general applicability of monofunctionally trans-Pt(II)
modified homopyrimidine oligonucleotides in antigene strategy. The monofunctionally trans-
Pt(II) modified deoxyoligonucleotide 2, obtained by post-synthetic trans-Pt(II) modification
of the pyrimidine-rich deoxyoligonucleotide 1 in solution, has been shown to recognize a
specific homopurine target within the double-stranded DNA fragment 3 with subsequent
formation of a trans-Pt(II) interstrand crosslink at a defined site (Figure 1). The resulting
trans-(NH3)2Pt(II)-bridged DNA triple helix 4 was characterized by gel-electrophoretic
studies, ESI MS and UV spectroscopy. It was demonstrated that, in comparison to the
respective unplatinated triplex 1•3, the thermal stability of 4 was significantly increased by
the trans-(NH3)2Pt(II) interstrand crosslink.
With respect to antigene strategy this means that, in principle, homopurine sequences in
double-stranded DNA can be targeted sequence-specifically and crosslinked irreversibly to
monofunctionally trans-Pt(II) modified antigene oligonucleotides. The crosslinked triple
helical adducts possess a greater thermal stability which results in increased steric blockage of
the target sequence by the antigene oligonucleotide. In this way it should in principle be
possible to influence the process of transcription in a highly specific manner.
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Figure 1: Formation of the trans-(NH3)2Pt(II) crosslinked DNA triple helix 4 by sequence-
specific crosslinking reaction of the monofunctionally trans-Pt(II) modified
oligonucleotide 2 with the DNA target 3.
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In Chapter II novel solid-phase methodologies for the synthesis of monofunctionally
trans-Pt(II) modified homopyrimidine deoxyoligonucleotides are described. These
methodologies involved the synthesis of the preplatinated building blocks 8 and 9. Building
blocks 8 and 9 have been conjugated to the 5´-terminus of deoxyoligonucleotides via a
phosphate bond and an amide bond, respectively (Figure 2). The CHMT ligand in both 8 and
9 serves as a protecting group. After conjugation of 8 and 9 to oligonucleotides it can be
substituted with a chloro ligand, thereby affording monofunctionally trans-Pt(II) modified
oligonucleotides. A drawback associated with these methodologies is that the post-synthetic
removal of the CHMT protecting group and its exchange by a chloro ligand requires a rather
low pH, which may effect depurination reactions.151 Therefore, this method is restricted to the
synthesis of monofunctionally trans-Pt(II) modified homopyrimidine deoxyoligonucleotides
for potential use mainly in antigene strategy.
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Figure 2: Solid-phase synthesis of monofunctionally trans-Pt(II) modified
oligonucleotides by conjugation of building blocks 8 and 9 to the 5´-terminus of
deoxyoligonucleotides.
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Chapter III descibes a novel solid-phase methodology for the synthesis of
monofunctionally trans-Pt(II) modified mixed pyrimidine / purine PNA oligomers. The
design and synthesis of the preplatinated PNA building block 33, which was shown to be
compatible with solid-phase PNA synthesis, was an essential prerequisite. Incorporation of 33
in two different PNA oligomers and a PNA-peptide conjugate by solid-phase PNA synthesis
yielded the monofunctionally trans-Pt(II) modified PNA oligomers 43, 44 and 45 (Figure 3).
The potential use of these monofunctionally trans-Pt(II) modified PNA oligomers in
antisense strategy has been demonstrated by a model crosslinking reaction in which
trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ (43) has been reacted with the complementary
oligonucleotide 5´d(GCGAATG) (46). As shown by MALDI TOF MS in combination with a
hydroxyl radical footprinting experiment, this crosslinking reaction proceeded sequence-
specifically, yielding, albeit in low yield, the trans-(NH3)2Pt(II) crosslinked PNA / DNA
duplex 47 (Figure 3).
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Figure 3: Solid-phase synthesis of monofunctionally trans-Pt(II) modified PNA oligomers
43, 44 and 45 by incorporation of 33 in PNA oligomers and crosslinking
reaction of 43 with the deoxyoligonucleotide target 46.
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Thus, the novel solid-phase methodology developed allows the facile synthesis of highly
sequence-specific antisense drugs with crosslinking ability. The synthesized
monofunctionally trans-Pt(II) modified PNA oligomers contain all four natural nucleobases
and are not susceptible to enzymatic degradation. From these two points of view these
potential antisense drugs are superior to the monofunctionally trans-Pt(II) modified
deoxyoligonucleotides obtained by the methodologies described in chapter II. The
methodology described in chapter III thus represents a facile and powerful new alternative
towards the synthesis of specifically platinated oligonucleotide analogues with potential
application both in antigene and antisense strategy.
Chapter IV deals with hydrogen bonding abilities of nucleobases involved in a trans-
Pt(II) interstrand crosslink within a DNA triplex in which the two strands of the Watson-Crick
duplex are crosslinked. As model compounds, the two chloroform-soluble trans-a2Pt(II)
crosslinked Watson-Crick A / T base pairs 50 and 51, in which the hydrogen bond between
A-N1 and T-N3 has been replaced by a linear trans-a2Pt(II) unit, have been synthesized. The
ability of these model compounds to perform Hoogsteen or reverse Hoogsteen hydrogen
bonds with the chloroform-soluble thymine derivative 1-N-cyclohexylmethylthymine (5) has
been investigated in the non-hydrogen bonding solvent chloroform (Figure 4). It has been
found that in CDCl3 in the presence of 50 and 51, 1-N-cyclohexylmethylthymine (5) rather
undergoes self-association than performing Hoogsteen or reverse Hoogsteen hydrogen bonds
with 50 and 51. By constrast, in equimolar mixtures of 5 and the unplatinated adenine
derivative 48 in CDCl3 hydrogen bonding interactions between 5 and 48 are definitely present
as shown by concentration-dependent 1H NMR measurements.
Low temperature 1H NMR measurements of a mixture of 51 and the uridine derivative 52
in freon (Figure 4) show down to 193 K only the presence of homodimers of 52. Only at
153 K two kinds of hydrogen-bonded 51 / 52 heterodimers in almost equal populations are
observable. The 51 / 52 heterodimers have, based on NOE connectivities, been assigned as 51
/ 52 pairs with Hoogsteen and reverse Hoogsteen geometries.
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Figure 4: Hydrogen bonding interactions between 50 and 51 and 5 in CDCl3 and 51 and
52 in freon.
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Zusammenfassung
Das Hauptziel dieser Arbeit war die Entwicklung neuer Methoden zur Synthese
monofunktionell trans-Pt(II) modifizierter Deoxyoligonukleotide bzw. Deoxyoligonukleotid-
Analoga. Ein Schwerpunkt lag dabei in der Anwendung von Methoden der
Festphasensynthese. Ein weiteres Ziel war es, anhand von Modell-Crosslinking-Reaktionen
Erkenntnisse über eine mögliche Anwendung der neuartig hergestellten monofunktionell
trans-Pt(II) modifizierten Deoxyoligonukleotide bzw. deren Analoga in der Antigen- und
Antisense-Strategie zu gewinnen.
Kapitel I zeigt die prinzipielle Anwendbarkeit von monofunktionell trans-Pt(II)
modifizierten Deoxyoligonukleotiden in der Antigen-Strategie. Das monofunktionell trans-
Pt(II) modifizierte Deoxyoligonukleotid 2, welches durch direkte Transplatin-Modifikation
des Deoxyoligonukleotids 1 in Lösung erhalten wurde, erkennt spezifisch eine
Homopurinsequenz innerhalb des DNA-Fragmentes 3. Nachfolgend kommt es zur
regiospezifischen Ausbildung eines trans-(NH3)2Pt(II) interstrand crosslinks (Abb. 1). Das
Produkt dieser Crosslinking-Reaktion ist die trans-(NH3)2Pt(II) verknüpfte DNA Tripelhelix
4, welche durch gelelektrophoretische Untersuchungen, ESI-Massenspektrometrie sowie UV-
Spektroskopie identifiziert bzw. charakterisiert wurde. Es zeigte sich, daß aufgrund der
Verknüpfung durch den trans-(NH3)2Pt(II) interstrand crosslink die platinierte Triplex 4 eine
größere thermische Stabilität besitzt als die entsprechende unplatinierte Triplex 1•3.
Im Hinblick auf die Antigen-Strategie bedeuten die Ergebnisse, daß es prinzipiell
möglich ist, durch Einsatz monofunktionell trans-Pt(II) modifizierter Oligonukleotide
Homopurinsequenzen innerhalb doppelsträngiger DNA Fragmente sequenzspezifisch zu
erkennen und diese durch Ausbildung eines interstrand crosslinks irreversibel mit dem
Antigen-Oligonukleotid zu verknüpfen. Die entsprechenden tripelhelicalen Strukturen
besitzen eine erhöhte thermische Stabilität, wodurch die sterische Blockierung der
Zielsequenz verstärkt wird. Auf diese Art und Weise sollte es prinzipiell möglich sein, den
Prozeß der Transkription gezielt zu beeinflussen.
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Abb. 1: Bildung der trans-(NH3)2Pt(II) verknüpften DNA Tripelhelix 4 durch
sequenzspezifisches Crosslinking des monofunktionell trans-Pt(II) modifizierten
Oligonukleotids 2 mit dem DNA Fragment 3.
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In Kapitel II werden neue Methoden zur Festphasensynthese monofunktionell trans-Pt(II)
modifizierter Homopyrimidin Oligonukleotide beschrieben. Hierzu war zunächst die Synthese
der platinierten Bausteine 8 und 9 notwendig. Nachfolgend wurden 8 und 9 dann über einen
ihrer Liganden durch eine Phosphodiester- bzw. Amid-Bindung an das 5´-Ende eines
Oligonukleotids gekuppelt (Abb. 2). Der CHMT Ligand in 8 und 9 dient als Schutzgruppe,
welche die Kompatibilität der Bausteine mit den Bedingungen der automatisierten DNA
Synthese leistet. Nach der Kupplung der Bausteine 8 und 9 an ein Oligonukleotid kann diese
Schutzgruppe entfernt und gegen einen Chloroliganden ausgetauscht werden, wobei die
gewünschten monofunktionell trans-Pt(II) modifizierten Oligonukleotide entstehen. Ein
Nachteil besteht darin, daß zur Entfernung des CHMT Liganden saure Bedingungen (pH 2)
erforderlich sind. Da unter diesen Bedingungen Depurinierungsreaktionen auftreten, sind die
beschriebenen Methoden nur zur Synthese monofunktionell trans-Pt(II) modifizierter
Homopyrimidin Oligonukleotide geeignet. Die beschriebenen Methoden können daher
hauptsächlich zur Synthese möglicher Antigen-Reagentien genutzt werden.
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Abb. 2: Festphasensynthese monofunktionell trans-Pt(II) modifizierter Oligonukleotide
durch Kupplung der platinierten Bausteine 8 und 9 an das 5´-Ende von
Deoxyoligonukleotiden.
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Kapitel III beschreibt die Entwicklung einer neuartigen Methode zur Festphasensynthese
monofunktionell trans-Pt(II) modifizierter Hetero-PNA-Oligomere. Hierzu war zunächst die
Synthese des platinierten PNA-Bausteins 33 erforderlich. Mit Hilfe der automatisierten PNA-
Synthese wurde 33 in zwei verschiedene PNA-Oligomere und ein PNA-Peptid-Conjugat
eingebaut und so die monofunktionell trans-Pt(II) modifizierten PNA-Oligomere 43, 44 und
45 synthetisiert (Abb. 3). Die mögliche Anwendung dieser monofunktionell trans-Pt(II)
modifizierten PNA-Oligomere in der Antisense-Strategie wurde anhand einer Modell-
Crosslinking-Reaktion demonstriert. Zu diesem Zweck wurde trans-[(NH3)2Pt(g-N7-
attcgc)Cl]+ (43) mit dem komplementären Deoxyoligonukleotid 5´d(GCGAATG) (46)
umgesetzt. Diese Reaktion führte in moderater Ausbeute zur sequenzspezifischen Ausbildung
eines interstrand crosslinks unter Bildung der trans-(NH3)2Pt(II) verknüpften DNA / PNA
Duplex 47.
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Abb. 3: Festphasensynthese monofunktionell trans-Pt(II) modifizierter PNA-Oligomere
durch Einbau von 33 in PNA-Oligomere und sequenzspezifische Verknüpfung
von 43 mit dem Deoxyoligonukleotid 46.
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Die in Kapitel III beschriebene Methode erlaubt somit eine relativ unproblematische
Synthese von hochgradig sequenzspezifischen monofunktionell trans-Pt(II) modifizierten
Antisense-Reagentien. Im Unterschied zu der in Kapitel II vorgestellten Methode bietet sie
den Vorteil, daß auch die Synthese monofunktionell trans-Pt(II) modifizierter
Heterosequenzen möglich ist, welche bei einer möglichen in vivo Anwendung aufgrund der
speziellen Eigenschaften von PNA zusätzlich stabil gegen enzymatischen Abbau sind. Daher
wird durch die Entwicklung der in Kapitel III beschriebenen Methode ein wichtiger Beitrag
zur Synthese speziell platinierter Oligonukleotid-Analoga für potentielle Anwendungen in der
Antigen- und Antisense-Strategie geleistet.
Kapitel IV befaßt sich mit der Fähigkeit zur Ausbildung von Wasserstoffbrücken von
Nukleobasen, welche in einem interstrand crosslink innerhalb einer DNA Tripelhelix, in
welcher die beiden Watson-Crick Stränge verknüpft sind, involviert sind. Als
Modellverbindungen wurden die chloroformlöslichen trans-a2Pt(II) (a = NH2CH3)
verknüpften Watson-Crick A / T Basenpaare 50 und 51 synthetisiert, in welchen die
Wasserstoffbrücke zwischen A-N1 und T-N3 gegen eine lineare trans-a2Pt(II) Einheit ersetzt
wurde. Die Fähigkeit dieser Modellverbindungen zur Ausbildung von Hoogsteen- bzw.
reversen Hoogsteen-Wasserstoffbrücken mit dem chloroformlöslichen Thyminderivat 1-N-
cyclohexylmethylthymin (5) wurde in dem nicht wasserstoffbrückenbildenden Solvens
Chloroform untersucht (Abb. 4). Es stellte sich heraus, daß in Gegenwart von 50 und 51, 1-N-
cyclohexylmethylthymin (5) eher Selbstassoziation eingeht als Hoogsteen- oder reverse
Hoogsteen-Wasserstoffbrücken mit 50 und 51 auszubilden. Zwischen dem unplatinierten
Adeninderivat 48 und dem Thyminderivat 5 werden in CDCl3 dagegen sehr wohl
Wasserstoffbrücken ausgebildet, wie anhand von konzentrationsabhängigen 1H NMR
Messungen gezeigt wurde.
Tieftemperatur- 1H NMR-Messungen eines Gemisches von 51 und dem Uridinderivat 52
in Freon (Abb. 4) zeigen bis 193 K nur das Vorhandensein wasserstoffbrückengebundener
Homodimere von 52. Erst bei 153 K wird das Vorhandensein zweier verschiedener
wasserstoffbrückengebundener 51 / 52 Heterodimere beobachtet. Aufgrund eines 1H,1H
NOESY Experimentes konnten diese Heterodimere 51 / 52 Paaren mit Hoogsteen- bzw.
reverser Hoogsteen-Geometrie zugeordnet werden.
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Abb. 4: Wasserstoffbrückenwechselwirkungen zwischen 50 bzw. 51 und 5 in CDCl3 und
zwischen 51 und 52 in Freon.
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2 Overview on described compounds
1* 5´d(GT2CTC2TC)8-
2 trans-[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}Cl]7-
3* 5´d(GA2GAG2AGCT2GCTC2TCT2C)21-
4 trans-
[Pt(NH3)2{5´d(G-N7-T2CTC2TC)}{(5´d(G-N7-A2GAG2AGCT2GCTC2TCT2C)}]27-
5 1-N-cyclohexylmethylthymine
6 K(1-N-cyclohexylmethylthyminate)
7 trans-[Pt(NH2CH3)2(CHMT)Cl]
7a** trans-[Pt(NH2CH3)2(CHMT)(DMF)]+BF4-
7b** trans-[Pt(NH2CH3)2(CHMT)(DMF)]+NO3-
8 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6OH}]+Cl-
8a** trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O-phosphoramidite }]+Cl-
9 trans-[Pt(NH2CH3)2(CHMT)(gly-N)]+BF4-
10 trans-[Pt(NH3)2(1-MeT)(gly-N)]+NO3-
11* chloro(N,N-diisopropyl)-β-cyanoethoxyphosphine
12* 5´-O-DMTr-deoxythymidine-3´-phosphoramidite
13 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-O-DMTr}]+
14 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)-dT-5´-OH}]+
15 trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)-dT-5´-OH}Cl]+
16* 5´-OH-dT4-3´-CPG
16a 5´-phosphoramidite-dT4-3´-CPG
16b 5´-phosphoramidate-dT4-3´-OH
17* DMTrO(CH2)5OH
18* 5´-HO(CH2)5OPO3H-dT4-3´-OH
19* 5´-OH-d(T3CTC2TC)-3´-CPG
19a 5´-phosphoramidite-d(T3CTC2TC)-3´-CPG
20 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)dT4-3´-CPG}]+
21 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)d(T3CTC2TC)-3´-CPG}]+
22 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)dT4-3´-OH}]+
23 trans-[Pt(NH2CH3)2(CHMT){NH2(CH2)6O(PO3H)d(T3CTC2TC)-3´-OH}]+
24 trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)dT4-3´-OH}Cl]+
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25 trans-[Pt(NH2CH3)2{NH2(CH2)6O(PO3H)d(T3CTC2TC)-3´-OH}Cl] +
26* MMTrHN(CH2)6OP{(OCH2CH2CN)(N(iPr)2}
27* 5´-OH-d(T2CTC2TC)-3´-CPG
28* 5´-NH2(CH2)6O-d(T2CTC2TC)-3´-CPG
29 trans-[Pt(NH2CH3)2(CHMT){(NH2CH2CONH(CH2)6O(PO3H)d(T2CTC2TC)-3´-OH}]+
30* NH2-c5-gly-HMBA-PS
31 trans-[Pt(NH2CH3)2(CHMT)(NH2CH2CONH-c5-gly)]+
32* N-[(N2-benzhydryloxycarbonylguanin-9-yl)acetyl]-
N-[2-{(9-fluorenylmethyloxycarbonyl)amino}ethyl]glycine
(Fmoc/N-Bhoc protected guanine PNA monomer)
33 trans-[Pt(NH3)2(Fmoc/N-Bhoc G)Cl]+BF4-
34 trans-[Pt(NH3)2(CHMT)(Fmoc/N-Bhoc G)]+BF4-
35 Ac-gattcgc-Rink-PEG-PS;
36 Ac-gattcgc-NH2
37 Fmoc-attcgc-Rink-PEG-PS
38 Fmoc-attcgc-lys-Rink-PEG-PS
39 Fmoc-atctcagc-Rink-PEG-PS
40 trans-[Pt(NH3)2Cl(Fmoc-g-N7-attcgc-Rink-PEG-PS)]+
41 trans-[Pt(NH3)2Cl(Fmoc-g-N7-attcgc-lys-Rink-PEG-PS)]+
42 trans-[Pt(NH3)2Cl(Fmoc-g-N7-atctcagc-Rink-PEG-PS)]+
43 trans-[Pt(NH3)2Cl(Ac-g-N7-attcgc-NH2)]+
44 trans-[Pt(NH3)2Cl(Ac-g-N7-attcgc-lys-NH2)]+
45 trans-[Pt(NH3)2Cl(Ac-g-N7-atctcagc-NH2)]+
46* 5´d(GCGAATG)
47 trans-[Pt(NH3)2(Ac-g-N7-attcgc-NH2){3´d(G-N7-TAAGCG}]2+
48 9-N-cyclohexylmethyladenine
49* 2´,3´,5´-tris-(tert-butyldimethylsilyl)-adenosine
50 trans-[Pt(NH2CH3)2(CHMA)(CHMT)]+NO3-
51 trans-[Pt(NH2CH3)2(CHMT)(TBS-ado)]+BF4-
52§ 3´,5´-diacetyl-2´-deoxyuridine
* not described for the first time
** not isolated
§ provided by Dr. K. Weisz, FU Berlin
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